Jaguar Health (JAGX) 10-Q 17 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 06, 2021
Document Information [Line Items]
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Entity Registrant Name	JAGUAR HEALTH, INC.
Title of 12(b) Security	Common Stock, Par Value $0.0001 Per Share
Trading Symbol	JAGX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001585608
Amendment Flag	false
Common stock - voting
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		137,318,263
Common stock - non-voting
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		2,120,786

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 32,250	$ 8,090
Accounts receivable	5,897	2,098
Accounts receivable - pledged		2,434
Other receivable	30	28
Inventory	2,821	2,782
Prepaid expenses and other current assets	3,106	2,360
Total current assets	44,104	17,792
Property and equipment, net	674	677
Intangible assets, net	23,916	24,337
Other assets	19	37
Total assets	68,713	42,843
Current liabilities:
Accounts payable	4,740	4,759
Accrued liabilities	6,409	4,493
Warrant liability	12	179
Notes payable, net of discount, current	1,431	3,789
Total current liabilities	12,592	13,220
Notes payable, net of current portion (includes hybrid instrument designated at FVO amounting to $6.5 million and zero as of March 31, 2021 and December 31, 2020, respectively)	24,230	12,421
Total liabilities	36,822	25,641
Commitments and contingencies (See Note 6)
Stockholders' equity
Additional paid-in capital	210,786	184,090
Accumulated deficit	(178,908)	(166,899)
Total stockholders' equity	31,891	17,202
Total liabilities, convertible preferred stock and stockholders' equity	68,713	42,843
Series D perpetual preferred stock
Current liabilities:
Series D perpetual preferred stock: $0.0001 par value; 977,300 shares authorized at March 31, 2021 and December 31, 2020; zero shares issued and outstanding at March 31, 2021 and December 31, 2020
Series B-2 convertible preferred stock
Stockholders' equity
Preferred stock value
Series C perpetual preferred stock
Stockholders' equity
Preferred stock value
Common stock - voting
Stockholders' equity
Common stock value	$ 13	11
Common stock - non-voting
Stockholders' equity
Common stock value

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Notes payable, net of current portion (includes hybrid instrument designated at FVO )	$ 6,452	$ 0
Preferred stock, shares authorized	1,021,165
Series D perpetual preferred stock
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	977,300	977,300
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Preferred stock, shares outstanding	0	0
Series B-2 convertible preferred stock
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	10,165	10,165
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Preferred stock, shares authorized	10,165
Preferred stock, shares outstanding	0	0
Series C perpetual preferred stock
Preferred stock, shares authorized	1,011,000	1,011,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock
Common stock, shares authorized	204,475,074
Common Stock | Common stock - voting
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	127,906,558	114,022,368
Common stock, shares outstanding	127,906,558	114,022,368
Common Stock | Common stock - non-voting
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	2,120,786	2,120,786
Common stock, shares outstanding	2,120,786	2,120,786

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses
Cost of product revenue	$ 583,000	$ 676,000
Research and development	2,414,000	1,582,000
Sales and marketing	2,139,000	1,469,000
General and administrative	3,409,000	3,149,000
Series 3 warrants inducement expense	1,462,000
Series B convertible preferred stock inducement expense		1,647,000
Total operating expenses	10,007,000	8,523,000
Loss from operations	(8,766,000)	(7,654,000)
Interest expense	(1,901,000)	(199,000)
Loss on extinguishment of debt	(753,000)
Change in fair value of financial instruments and hybrid instrument designated at FVO	(599,000)	(1,000)
Other income (expense), net	10,000	(82,000)
Loss before income tax	(12,009,000)	(7,936,000)
Net loss	(12,009,000)	(7,936,000)
Net loss attributable to common shareholders	$ (12,009,000)	$ (8,416,000)
Net loss per share, basic and diluted	$ (0.10)	$ (0.56)
Weighted-average common shares outstanding, basic and diluted	125,416,228	15,141,906
Series A convertible preferred stock
Operating expenses
Deemed dividend		$ (480,000)
Product revenue
Revenue
Total revenue	$ 1,241,000	$ 869,000

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Series 3 warrantsCommon StockCommon stock - voting	Series 3 warrantsAdditional paid-in capital	Series 3 warrants	Series 1, Series 2, and 2019 Bridge Note warrantsCommon StockCommon stock - voting	Series 1, Series 2, and 2019 Bridge Note warrantsAdditional paid-in capital	Series 1, Series 2, and 2019 Bridge Note warrants	Series 2 warrants and inducement offer conversion of Series B-1 convertible preferred stockCommon StockCommon stock - voting	Series 2 warrants and inducement offer conversion of Series B-1 convertible preferred stockAdditional paid-in capital	Series 2 warrants and inducement offer conversion of Series B-1 convertible preferred stock	Series B-2 convertible preferred stockCommon StockCommon stock - voting	Series B-2 convertible preferred stockAdditional paid-in capital	Series B-2 convertible preferred stockSeries B-2 convertible preferred stock	PIPE Financing Warrants, Dec 2019	Private Investment in Public EntitiesCommon StockCommon stock - voting	Private Investment in Public EntitiesAdditional paid-in capital	Private Investment in Public Entities	At The Market OfferingCommon StockCommon stock - voting	At The Market OfferingAdditional paid-in capital	At The Market Offering	Registered public offeringCommon StockCommon stock - voting	Registered public offeringAdditional paid-in capital	Registered public offering	Common StockCommon stock - voting	Common StockCommon stock - non-voting	Additional paid-in capital	Accumulated deficit	Series A convertible preferred stock	Series B convertible preferred stock	Series B-2 convertible preferred stock	Series D perpetual preferred stock	Total
Beginning Balance at Dec. 31, 2019																											$ 9,895,000
Beginning Balance (in shares) at Dec. 31, 2019																											5,524,926
Increase (decrease) in temporary equity
Accretion to redemption value of redeemable preferred stock																											$ 480,000
Ending Balance at Mar. 31, 2020																											$ 10,375,000
Ending Balance (in shares) at Mar. 31, 2020																											5,524,926
Beginning Balance at Dec. 31, 2019																							$ 1,000	$ 4,000	$ 142,046,000	$ (133,090,000)		$ 476,000	$ 1,236,000		$ 10,673,000
Beginning Balance (in shares) at Dec. 31, 2019																							14,273,061	40,301,237				1,971	10,165
Increase (decrease) in Stockholders' Equity (Deficit)
Shares issued on conversion of Series B-2 convertible preferred stock											$ 320,000	$ (320,000)
Shares issued on conversion of Series B-2 convertible preferred stock (in shares)										499,890		(2,631)
Value of shares issued on exercise of warrants					$ 392,000	$ 392,000	$ 1,000	$ 2,340,000	$ 2,341,000
Shares issued on exercise of warrants				548,962			1,250,000
Issuance of common stock															$ 668,000	$ 668,000
Issuance of common stock (In shares)														1,714,283
Underwriter settlement offering cost																									185,000						185,000
Conversion of Series B convertible preferred stock into common stock																													$ (320,000)
Accretion to redemption value of Series A contingently redeemable convertible preferred stock																									(480,000)		$ 480,000				(480,000)
Stock-based compensation																									760,000						760,000
Net loss																										(7,936,000)					(7,936,000)
Ending Balance at Mar. 31, 2020																							$ 2,000	$ 4,000	145,861,000	(141,026,000)		$ 476,000	$ 916,000		6,233,000
Ending Balance (in shares) at Mar. 31, 2020																							18,286,196	40,301,237				1,971	7,534
Beginning Balance at Dec. 31, 2019																											$ 9,895,000
Beginning Balance (in shares) at Dec. 31, 2019																											5,524,926
Ending Balance (in shares) at Dec. 31, 2020																													0	0
Beginning Balance at Dec. 31, 2019																							$ 1,000	$ 4,000	142,046,000	(133,090,000)		$ 476,000	$ 1,236,000		$ 10,673,000
Beginning Balance (in shares) at Dec. 31, 2019																							14,273,061	40,301,237				1,971	10,165
Increase (decrease) in Stockholders' Equity (Deficit)
Issuance of warrants													$ 465,000
Issuance of common stock													$ 1,000,000
Shares issued upon exercise of stock options (in shares)																															0
Ending Balance at Dec. 31, 2020																							$ 11,000		184,090,000	(166,899,000)					$ 17,202,000
Ending Balance (in shares) at Dec. 31, 2020																							114,022,368	2,120,786
Ending Balance (in shares) at Mar. 31, 2021																													0	0
Increase (decrease) in Stockholders' Equity (Deficit)
Issuance of warrants																				$ 1,000	$ 13,397,000	$ 13,398,000
Value of shares issued on exercise of warrants		$ 1,776,000	$ 1,776,000	$ 1,000	$ 2,033,000	$ 2,034,000
Shares issued on exercise of warrants	620,750			4,150,600
Issuance of common stock															$ 975,000	$ 975,000		$ 5,365,000	$ 5,365,000
Issuance of common stock (In shares)														1,250,000			2,009,554			4,437,870
Shares issued on conversion of Napo merger common shares (in shares)																							1,810
Shares issued in extinguishment of Exchange Note 2																									2,516,000						$ 2,516,000
Shares issued in extinguishment of Exchange Note 2 (in shares)																							1,413,606
Shares issued upon exercise of stock options (in shares)																															0
Stock-based compensation																									634,000						$ 634,000
Net loss																										(12,009,000)					(12,009,000)
Ending Balance at Mar. 31, 2021																							$ 13,000		$ 210,786,000	$ (178,908,000)					$ 31,891,000
Ending Balance (in shares) at Mar. 31, 2021																							127,906,558	2,120,786

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)	3 Months Ended
	Mar. 31, 2021USD ($)
At The Market Offering
Stock Transactions, Parenthetical Disclosures
Issuance costs	$ 311,000
Registered public offering
Stock Transactions, Parenthetical Disclosures
Issuance costs	$ 1,602,000

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss	$ (12,009,000)	$ (7,936,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Series 3 warrants inducement expense	1,462,000
Amortization of debt issuance costs and debt discount and non-cash interest expense	1,198,000	14,000
Loss on extinguishment of debt	753,000
Stock-based compensation	634,000	760,000
Change in fair value of financial instruments and hybrid instrument designated at FVO	599,000	1,000
Change in fair value of financial instruments and hybrid instrument designated at FVO		(1,000)
Depreciation and amortization expense	431,000	432,000
Derecognition of debt discount on settlement of receivables secured borrowing	49,000
Amortization of operating lease right-of-use-assets		191,000
Expense on modification of warrants		85,000
Series B convertible preferred stock inducement expense		1,647,000
Changes in assets and liabilities
Accounts receivable	(1,365,000)	609,000
Other receivable	(2,000)	(1,000)
Inventory	(39,000)	(575,000)
Prepaid expenses and other current assets	(649,000)	189,000
Other non-current assets	18,000	27,000
Operating lease liabilities		(119,000)
Accounts payable	(113,000)	191,000
Accrued expenses	2,325,000	191,000
Total cash used in operating activities	(6,708,000)	(4,296,000)
Cash flows from investing activities
Purchase of equipment		(7,000)
Total cash used in investing activity		(7,000)
Cash flows from financing activities
Proceeds from issuance of notes payable, net of issuance costs of $50	10,975,000	350,000
Repayment of receivables secured borrowing	(1,822,000)
Repayment of insurance premium financing	(95,000)
Repayment of notes payable	(50,000)	(50,000)
Total cash provided by financing activities	30,868,000	2,023,000
Net increase (decrease) in cash and restricted cash	24,160,000	(2,280,000)
Cash and restricted cash at beginning of period	8,090,000	3,883,000
Cash and restricted cash at end of period	32,250,000	1,603,000
Supplemental schedule of cash flow information
Cash paid for interest	6,000	6,000
Supplemental schedule of non-cash financing and investing activities
Shares issued in extinguishment of Exchange Note 2	2,516,000
Umbrella insurance financing	98,000
Purchase of equipment	6,000
Accretion to redemption value of Series A contingently redeemable convertible preferred stock		(480,000)
Cash	32,250,000	1,215,000
Restricted cash		388,000
Cash and restricted cash at end of period	32,250,000	1,603,000
Private Investment in Public Entities
Cash flows from financing activities
Proceeds from issuance of shares in PIPE financing, net of $51 issuance costs in 2020	975,000	698,000
2019 Bridge Note Warrants
Cash flows from financing activities
Proceeds from issuance of shares on conversion of Series 1, Series 2, and 2019 Bridge Note warrants	2,034,000	1,025,000
At The Market Offering
Cash flows from financing activities
Proceeds from issuance of shares in At the Market offering, net of issuance and offering costs of $311	5,365,000
Registered public offering
Cash flows from financing activities
Proceeds from issuance of shares in registered public offering, net of issuance and offering costs of $1,514	13,486,000
Accounts payable and accrued expenses
Supplemental schedule of non-cash financing and investing activities
Offering costs included in accounts payable and accrued expenses	88,000	240,000
Series 3 warrants
Supplemental schedule of non-cash financing and investing activities
Shares Issued	$ 1,776,000
Series A convertible preferred stock
Supplemental schedule of non-cash financing and investing activities
Accretion to redemption value of Series A contingently redeemable convertible preferred stock		480,000
Series B-2 convertible preferred stock
Supplemental schedule of non-cash financing and investing activities
Conversion of Series B-2 convertible preferred stock into common stock		$ 320,000

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net of debt discount and issuance costs	$ 1,514
Private Investment in Public Entities
Issuance costs		$ 51
Notes payable
Issuance costs	50
At The Market Offering
Net of debt discount and issuance costs	$ 311

Organization and Business

Organization and Business	3 Months Ended
	Mar. 31, 2021
Organization and Business
Organization and Business	1. Organization and Business Jaguar Health, Inc. (“Jaguar” or the “Company”), formerly known as Jaguar Animal Health, Inc., was incorporated on June 6, 2013 (inception) in Delaware. The Company was a majority-owned subsidiary of Napo until the close of the Company's initial public offering on May 18, 2015. The Company was formed to develop and commercialize first-in-class gastrointestinal products for companion and production animals and horses. The Company's first commercial product, Neonorm Calf, was launched in 2014 and Neonorm Foal was launched in the first quarter of 2016. The Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding in order to timely complete the development and commercialization of products. On July 31, 2017, Jaguar completed a merger with Napo pursuant to the Agreement and Plan of Merger dated March 31, 2017 by and among Jaguar, Napo, Napo Acquisition Corporation (“Merger Sub”), and Napo's representative (the “Merger Agreement”). In accordance with the terms of the Merger Agreement, upon the completion of the merger, Merger Sub merged with and into Napo, with Napo surviving as the wholly-owned subsidiary (the “Merger” or “Napo Merger”). Immediately following the Merger, Jaguar changed its name from “Jaguar Animal Health, Inc.” to “Jaguar Health, Inc.” Napo now operates as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of Mytesi, a Napo drug product approved by the U.S. Food and Drug Administration (“FDA”) for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. On March 15, 2021, the Company established Napo EU S.p.A (“Napo EU”) in Italy as a subsidiary of Napo. Napo EU will serve as the foundation of the Company’s efforts to address the growing burden particularly in Europe – of the inflammatory diarrhea associated with long-hauler syndrome in the post COVID-19 patient population. Napo EU is located in Milan, which is also the headquarters of the Company’s secondary supplier of Crofelemer, Indena S.p.A. The Company manages its operations through two segments – human health and animal health and is headquartered in San Francisco, California. Nasdaq Communication and Compliance Minimum Stockholders’ Equity Requirement On August 17, 2020, the Company received a letter from the Staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) due to the Company’s failure to maintain a minimum of $2.5 million in stockholders’ equity (or meet the alternatives of market value of listed securities of $35 million or net income from continuing operations). On September 9, 2020, the Company received a letter from Nasdaq stating that, based on the Company’s Current Report on Form 8-K filed on September 2, 2020, the Staff has determined that the Company complied with Nasdaq Listing Rule 5550(b)(1). However, if the Company failed to evidence compliance with Nasdaq Listing Rule 5550(b)(1) upon filing its next periodic report, the Company may be subject to delisting. Minimum Bid Price Requirement On September 11, 2020, the Company received written notice from Nasdaq indicating that, based upon the Company’s continued non-compliance with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market (the “Rule”), as set forth in Nasdaq Listing Rule 5550(a)(2), as of September 11, 2020, and notwithstanding the Company’s compliance with the quantitative criteria necessary to obtain a second 180-day period within which to evidence compliance with the Rule, as set forth in Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Hearings Panel”). On October 22, 2020, the hearing was held with the Hearings Panel. On October 28, 2020, the Company received formal notice that the Hearings Panel granted the Company an extension through December 23, 2020 to evidence compliance with the Rule. In order to comply with the Rule, the Company must have a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days by December 23, 2020. As the Company consistently reached a closing bid price of above $1.00 in 2021, on January 21, 2021, the Company received a letter from the Nasdaq Office of General Counsel that the Company has regained compliance with the bid price and warrant concerns, as required by the Hearings Panel decision dated October 28, 2020. Accordingly, the Hearings Panel has determined to continue the listing of the Company’s securities on Nasdaq and is closing this matter. Liquidity The Company, since its inception, has incurred recurring operating losses and negative cash flows from operations and has an accumulated deficit of $178.9 million as of March 31, 2021. The Company expects to incur substantial losses and negative cash flows in future periods. Further, the Company’s future operations, which include the satisfaction of current obligations, are dependent on the success of the Company’s ongoing development and commercialization efforts, as well as securing of additional financing and generating positive cash flows from operations. As of the issuance date of the unaudited condensed consolidated financial statements, the Company has cash of $35.0 million. Based on the Company’s current operating plan and forecasted operations, management believes that existing cash will be sufficient to fund the Company’s obligations for at least 12 months after these unaudited condensed consolidated financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and on a basis consistent with the annual consolidated financial statements, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of the results to be expected for the year ending There has been no material change to the Company's significant accounting policies during the three months ended March 31, 2021, as compared to the significant accounting policies described in Note 2 of the “Notes to Consolidated Financial Statements” in the Company's Annual Report on Form 10-K as of and for the year ended December 31, 2020 which was filed to SEC on March 31, 2021. Except as noted above, the unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly the financial position as of March 31, 2021, results of operations for the three months ended March 31, 2021 and 2020, changes in convertible preferred stock and stockholders' equity for the three months ended March 31, 2021 and 2020, and cash flows for the three months ended March 31, 2021 and 2020. The interim results are not necessarily indicative of the results for any future interim periods or for the entire year. Principles of Consolidation The unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and include the accounts of the Company and its wholly-owned subsidiary. All inter-company transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its unaudited condensed consolidated financial statements and the accompanying notes. The accounting policies that reflect the Company’s more significant estimates and judgments and that the Company believes are the most critical to aid in fully understanding and evaluating its reported financial results are the valuation of stock options, valuation of hybrid instruments designated at fair value option (“FVO”), valuation of warrant liabilities, acquired in-process research and development (“IPR&D”), and useful lives assigned to long-lived assets; valuation adjustments for excess and obsolete inventory; allowance for doubtful accounts; deferred taxes and valuation allowances on deferred tax assets; evaluation and measurement of contingencies; and recognition of revenue, including estimates for product returns. Those estimates could change, and as a result, actual results could differ materially from those estimates. In March 2020, the World Health Organization declared the COVID-19 outbreak to be a pandemic. During the period ended March 31, 2021, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it. Cash and Restricted Cash Our cash on deposit may exceed United States federally insured limits at certain times during the year. We maintain cash accounts with certain major financial institutions in the United States. Restricted cash represents cash not available to us for immediate and general use. Amounts included in restricted cash primarily relate to security deposits and a letter of credit with a financial institution, both in connection with office space lease agreements. Accounts Receivable Accounts receivable is recorded net of allowances for discounts for prompt payment and credit losses. Accounts receivable is written off when it has been outstanding for two years or earlier when collection efforts have ceased. Prior to that, the Company estimates an allowance for credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The corresponding expense for the credit loss allowance is reflected in general and administrative expenses. The credit loss allowance was immaterial as of March 31, 2021 and 2020. Concentrations Cash is the financial instrument that potentially subjects the Company to a concentration of credit risk as cash is deposited with a bank and cash balances are generally in excess of Federal Deposit Insurance Corporation insurance limits. For the three months ended March 31, 2021 and 2020, substantially all of the Company’s revenue was derived from the sale of Mytesi. In looking at sales by the Company to distributors whose net revenue percentage of total net revenue was equal to or greater than 10%, for the three months ended March 31, 2021, the Company earned Mytesi revenue primarily from two pharmaceutical distributors located in the United States. For the three months ended Three Months Ended March 31, (unaudited) 2021 2020 Customer 1 86 % 96 % Customer 2 10 % — % The Company is subject to credit risk from its accounts receivable related to its sales. The Company generally does not perform evaluations of customers' financial condition and generally does not require collateral. As of The Company is subject to concentration risk from its suppliers. The Company sources raw material used to produce the active pharmaceutical ingredient in Mytesi from two suppliers and is dependent on a single third-party contract manufacturer, both for the supply of the active pharmaceutical ingredient in Mytesi, as well as for the supply of finished products for commercialization. Fair Value The Company’s financial instruments include accounts receivable, accounts payable, accrued liabilities, warrant liabilities, equity-linked financial instruments and debt. The recorded carrying amounts of accounts receivable, accounts payable and accrued liabilities reflect their fair value due to their short-term nature. Other financial liabilities are initially recorded at fair value, and subsequently measured at either fair value or amortized cost using the effective interest method. See Note 3 for the fair value measurements. Fair Value Option ASC 825-10, Financial Instruments , provides FVO election that allows companies an irrevocable election to use fair value as the initial and subsequent accounting measurement attribute for certain financial assets and liabilities. ASC 825-10 permits entities to elect to measure eligible financial assets and liabilities at fair value on an ongoing basis. Unrealized gains and losses on items for which the FVO has been elected are reported in earnings. The decision to elect the FVO is determined on an instrument-by-instrument basis, must be applied to an entire instrument and is irrevocable once elected. Assets and liabilities measured at fair value pursuant to ASC 825-10 are required to be reported separately from those instruments measured using another accounting method. In accordance with the options presented in ASC 825-10, the Company elected to present the aggregate of fair value and non-fair-value amounts in the same line item in the condensed consolidated balance sheets and parenthetically disclose the amount measured at fair value in the aggregate amount. Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. Cost is initially recorded at the invoiced amount of raw materials or active pharmaceutical ingredient, including the sum of qualified expenditures and charges in bringing the inventory to its existing condition and location. The Company calculates inventory valuation adjustments when conditions indicate that net realizable value is less than cost due to physical deterioration, usage, obsolescence, reductions in estimated future demand or reduction in selling price. Inventory write-downs are measured as the difference between the cost of inventory and net realizable value. Property and Equipment Land is stated at cost, reflecting the fair value of the property at July 31, 2017, the date of the Napo merger. Equipment is stated at cost, net of accumulated depreciation. Equipment begins to be depreciated when it is placed into service. Depreciation is calculated using the straight-line method over estimated useful lives ranging between 3 to 10 years. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Costs of major additions and betterments are capitalized and depreciated on a straight-line basis over their estimated useful lives. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in the unaudited condensed consolidated statements of operations. Long-lived Assets The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist that warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives. Definite-lived intangible assets are amortized on a straight-line basis over the estimated periods benefited, and are reviewed when impairment indicators are identified. Indefinite-lived Intangible Assets Acquired IPR&D are intangible assets acquired in the July 2017 Napo merger. Under ASC 805, IPR&D are initially recognized at fair value and classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. During the development period, these assets will not be amortized as charges to earnings; instead, these assets will be tested for impairment on an annual basis or more frequently if impairment indicators are identified. An impairment loss is measured based on the excess of the carrying amount over the asset’s fair value. The Company recorded no impairment in the three months ended March 31, 2021 and 2020. Leases The Company accounts for its leases in accordance with ASC 842, Leases . The Company elected not to separate nonlease components from lease components and instead accounts for each separate lease component and the nonlease components associated with that lease component as a single lease component. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. Because the interest rate implicit in lease contracts is typically not readily determinable, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Operating Lease The Company had a non-cancelable operating lease with CA-Mission Street Limited Partnership for its offices in San Francisco, California, through September 30, 2020. The lease agreement called for monthly base rents between $38,000 and $41,000 over the term of the lease. The lease agreement was not renewed upon expiration. The Company entered into a sublease agreement with Peacock Construction Inc., a California corporation, for office space located in San Francisco, California. The term of the sublease began on August 31, 2020 and will expire on May 31, 2021, unless earlier terminated in accordance with the contract. The rent under the sublease is $15,000 per month beginning October 1, 2020, which includes operating expenses and taxes. On October 1, 2020, the Company transitioned its operations from its existing premises to the sublease premises, which the Company expects will serve as its principal administrative headquarters. In April 2021, The Company entered into a new office lease agreement (see Note 14). The Company elected not to apply the recognition requirements to short-term leases, and instead recognize the lease payments in profit or loss on a straight-line basis over the lease term. As a result, there was no right-of-use asset and lease liability recognized related to the sublease. Research and Development Expense Research and development expense consist of expenses incurred in performing research and development activities including related salaries, clinical trials and related drug and non-drug product costs, contract services and other outside service expenses. Research and development expense is charged to operating expense in the period incurred. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company’s policy typically permits returns if the product is damaged, defective, or otherwise cannot be used when received by the customer if the product has expired. Returns are accepted for product that will expire within six months or that have expired up to one year after their expiration dates. Estimates for expected returns of expired products are based primarily on an ongoing analysis of our historical return patterns. The Company recognizes revenue in accordance with the core principle of ASC 606 or when there is a transfer of control of promised goods or services to customers in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those goods or services. The Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. The Company does not adjust the amount of consideration for the effects of a significant financing component if, at contract inception, the expected period between the transfer of promised goods or services and customer payment is one year or less. The Company has elected to treat shipping and handling activities as fulfillment costs. Additionally, the Company elected to record revenue net of sales and other similar taxes. Contracts – Cardinal Health Effective January 16, 2019, the Company engaged Cardinal Health as its exclusive third-party logistics distribution agent for commercial sales of the Company’s Mytesi product and to perform certain other services which include, without limitation, storage, distribution, returns, customer support, financial support, Electronic Data Interchange (“EDI”) and system access support (the “Exclusive Distribution Agreement”). In addition to the terms and conditions of the Exclusive Distribution Agreement, Cardinal Health’s purchase of products, and assumption of title therein, is set forth in the Title Model Addendum. The Title Model Addendum states that upon receipt of product at the 3PL Facility (Cardinal Health in La Vergne, Tennessee) from the Company, title and risk of loss for the Mytesi product purchased by Cardinal Health (excluding consigned inventory) shall pass to Cardinal Health, and title and risk of loss for consigned inventory shall remain with the Company until purchased by Cardinal Health in accordance with the Title Model Addendum. The Company considers Cardinal Health the Company’s exclusive customer for Mytesi products per the Exclusive Distribution Agreement. The Company's Neonorm and botanical extract products are primarily sold to distributors, who then sell the products to the end customers. Since 2014, the Company has entered into several distribution agreements with established distributors such as Animart, Vedco, VPI, RJ Matthews, Covetrus, and Stockmen Supply to distribute the Company's products in the United States, Japan, and China. The distribution agreements and the related purchase order together meet the contract existence criteria under ASC 606‑10‑25‑1. The Company sells directly to its customers without the use of an agent. Performance obligations For animal products sold by the Company, the single performance obligation identified above is the Company’s promise to transfer the Company’s animal products to distributors based on specified payment and shipping terms in the arrangement. Product warranties are assurance type warranties that do not represent a performance obligation. For the Company’s human product, Mytesi, the single performance obligation identified above is the Company’s promise to transfer Mytesi to Cardinal Health, the Company’s exclusive distributor for the product, based on specified payment and shipping terms as outlined in the Exclusive Distribution Agreement. Transaction price For contracts with Cardinal Health, for the Company, the transaction price is the amount of consideration to which the Company expects to collect in exchange for transferring the promised goods or services. The transaction price of Mytesi and Neonorm is the Wholesaler Acquisition Cost (“WAC”), net of discounts, returns, and price adjustments. Allocate transaction price For contracts with Cardinal Health, for the Company, the entire transaction price is allocated to the single performance obligation contained in each contract. Revenue recognition For contracts with Cardinal Health, for the Company, a single performance obligation is satisfied at a point in time, upon the free on board (“FOB”) terms of each contract when control, including title and all risks, has transferred to the customer. Disaggregation of Product Revenue Human Sales of Mytesi are recognized as revenue at a point in time when the products are delivered to the wholesaler. Net revenues from the sale of Mytesi were $729,000 and $835,000 for the three months ended March 31, 2021 and 2020, respectively. Animal The Company recognized Neonorm revenues of $ Contracts – Specialty Pharmacies Effective October 1, 2020, the Company engaged a private company as its third-party logistics distribution agent for commercial sales of the Company’s Mytesi product. Under the Specialty Product Distribution Agreement, the Company shall supply the products to the private company’s specialty pharmacies, through a designated wholesaler, in such amounts as may be ordered. There is no minimum purchase or inventory requirement. The specialty pharmacies were authorized distributors of record for all National Drug Codes (“NDCs”) of Mytesi. Performance obligations The single performance obligation identified above is the Company’s promise to transfer Mytesi to specialty pharmacies, based on specified payment and shipping terms as outlined in the Specialty Product Distribution Agreement. Transaction price For contracts with the private company, for the Company, the transaction price is the amount of consideration to which the Company expects to collect in exchange for transferring the promised goods or services. The transaction price of Mytesi is the WAC, net of estimated discounts, returns, and price adjustments. Allocate transaction price For contracts with the private company, for the Company, the entire transaction price is allocated to the single performance obligation contained in each contract. Revenue recognition For contracts with the private company, for the Company, a single performance obligation is satisfied at a point in time, upon the free on board (“FOB”) terms of each contract when control, including title and all risks, has transferred to the customer. Disaggregation of Product Revenue Sales of Mytesi are recognized as revenue at a point in time when the products are delivered to the specialty pharmacies. Net revenue from the sale of Mytesi to the specialty pharmacies were $479,000 and zero for the three months ended March 31, 2021 and 2020, respectively. Collaboration Revenue Revenue recognition for collaboration agreements requires significant judgment. The Company’s assessments and estimates are based on contractual terms, historical experience and general industry practice. Revisions in these values or estimations have the effect of increasing or decreasing collaboration revenue in the period of revision. On September 24, 2018, the Company entered into a Distribution, License and Supply Agreement (“License Agreement”) with Knight Therapeutics ("Knight"). The License Agreement has a term of 15 years (with automatic renewals) and provides Knight with an exclusive right to commercialize current and future Jaguar human health products (including crofelemer, Lechlemer, and any product containing a proanthocyanidin or with an anti-secretory mechanism) in Canada and Israel. Knight forfeited its right of first negotiation for expansion to Latin America. Under the License Agreement, Knight is responsible for applying for and obtaining necessary regulatory approvals in the territory of Canada and Israel, as well as marketing, sales and distribution of the licensed products. Knight will pay a transfer price for all licensed products, and upon achievement of certain regulatory and sales milestones, the Company may receive payments from Knight in an aggregate amount of up to approximately $18 million payable throughout the initial 15-year term of the agreement. The Company did not have any license revenues for the three months ended March 31, 2021 and 2020. Modifications to Liability-classified Instruments In the three months ended March 31, 2021, the Company amended the terms of its Exchange Note 2 (see Note 7). In accounting for debt modifications and exchange transactions, it is the Company’s policy to first determine whether it qualifies as a troubled debt restructuring (“TDR”) pursuant to the guidance provided in ASC 470-60. A debt modification or exchange transaction that is not within the scope of the ASC 470-60 is accounted for under ASC 470-50 to determine if the transaction is a mere modification or an extinguishment. The Company did not modify any liability-classified instrument for the three months ended March 31, 2020. Modifications to Equity-classified Instruments In the three months ended March 31, 2020, the Company modified certain equity-classified warrants (see Note 8). It is the Company’s policy to determine the impact of modifications to equity-classified warrants by analogy to the share-based compensation guidance of ASC 718, Compensation - Stock Compensation (“ASC 718”). The model for a modified share-based payment award that is classified as equity and remains classified in equity after the modification is addressed in ASC 718-20-35-3. Pursuant to that guidance, the incremental fair value from the modification is recognized as an expense in the statements of operations to the extent the modified instrument has a higher fair value; however, in certain circumstances, such as when an entire class of warrants are modified, the measured increase in fair value may be more appropriately recorded as a deemed dividend, depending upon the nature of the warrant modification. In the three months ended March 31, 2020, the Company modified the terms of its Series B convertible preferred stock (see Note 9). For amendments to preferred stock, it is the Company’s policy to measure the impact by analogy to ASC 470-50 in determining if such an amendment is an extinguishment or a modification. If the amendment results in an extinguishment, the Company follows the SEC staff guidance in ASC 260-10-S99-2 and ASC 470-20. If the amendment results in a modification, the Company follows the model in either ASC 718 or ASC 470-50, depending on the nature of the amendment. The Company did not modify any equity-classified instrument for the three months ended March 31, 2021. Stock-based Compensation The Company's stock incentive plans (see Note 11) provide for the grant of stock options, restricted stock and restricted stock unit awards. The Company measures stock awards granted to employees, non-employees and directors at fair value on the date of grant and recognizes the corresponding compensation expense of the awards, net of estimated forfeiture over the requisite service periods, which correspond to the vesting periods of the awards. The Company issues stock awards with only service-based vesting conditions, and records compensation expense for these awards using the straight-line method. The Company uses the grant date fair market value of its common stock to determine the grant date fair value of options granted to employees, non-employees and directors. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company has adopted the provisions of ASC 740, Income Taxes Related to Uncertain Tax Positions . Under these principals, tax positions are evaluated in a two-step process. The Company first determines whether it is more-likely-than-not that a tax position will be sustained upon examination. If a tax position meets the more-likely-than-not recognition threshold, it is then measured to determine the amount of benefit to be recognized in the financial statements. The tax position is measured as the largest amount of benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement. Comprehensive Loss For all periods presented, the comprehensive loss was equal to the net loss; therefore, a separate statement of comprehensive loss is not included in the accompanying unaudited condensed consolidated financial statements. Basic and Diluted Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the year by the weighted-average number of common shares outstanding during the year. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the year by the weighted-average number of common shares, including potential dilutive shares of common stock assuming the dilutive effect of potential dilutive securities. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, because the impact of the potential dilutive shares of common stock would be anti-dilutive to the calculation of net loss per common share. Diluted net loss per common share is the same as basic net loss per common share for the three months ended March 31, 2021 and 2020. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which is intended to simplify various aspects related to accounting for income taxes. The standard also removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. The Company adopted the standard on January 1, 2021. The adoption of this standard did not have a material effect on the Company’s unaudited condensed consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The main objective of the standard is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in this standard replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The update is effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is still evaluating the impact of the adoption of this standard. In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The pronouncement is effective for the Company beginning January 1, 2022 with early adoption permitted. The Company is still evaluating the impact of the adoption of this standard. In May 2021, the FASB issued ASU 2021-04, Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options – a consensus of the FASB Emerging Issues Task Force. The ASU provides a “principles-based framework to determine whether an issue should recognize the modification or exchange as an adjustment to equity or an expense. The amendments in the update is effective for all entities for fiscal years beginning January 1, 2022, including interim periods within those fiscal years with early adoption permitted. The Company is still evaluating the impact of the adoption of this standard. Reclassification of Prior Period Presentation Certain prior period amounts of cash flows from financing activities in the unaudited condensed consolidated statements of cash flows have been reclassified within the same category of cash flow activity to be consistent with the current period presentation. There were no reclassifications to other categories of cash flow activity and that the reclassification did not impact the profit or loss during the prior period.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Measurements
Fair Value Measurements	3. Fair Value Measurements ASC 820, Fair Value Measurements , defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: · Level 1 – Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets. · Level 2 – Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model derived valuations whose significant inputs are observable. · Level 3 – Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables set forth the fair value of the Company’s financial instruments that were measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020. March 31, 2021 (unaudited) (in thousands) Level 1 Level 2 Level 3 Total Warrant liability $ — $ — $ 12 $ 12 Streeterville note — — 6,452 6,452 Total fair value $ — $ — $ 6,464 $ 6,464 December 31, 2020 (in thousands) Level 1 Level 2 Level 3 Total Warrant liability $ — $ — $ 179 $ 179 Total fair value $ — $ — $ 179 $ 179 The change in the estimated fair value of Level 3 liabilities is summarized below: Three Months Ended March 31, 2021 (unaudited) (in thousands) Warrant liability Streeterville note Beginning fair value of Level 3 liability $ 179 $ — Additions 1,462 6,000 Exercises (1,776) — Change in fair value 147 452 Ending fair value of Level 3 liability $ 12 $ 6,452 Warrant Liability The warrants associated with the Level 3 warrant liability were the November 2016 Series A Warrants, the October 2018 Underwriter Warrants and the May 2020 Series 3 Warrants, which, at March 31, 2021, were valued at zero, $12,000 and zero respectively, in the Company’s unaudited condensed consolidated balance sheet. The warrants associated with the Level 3 warrant liability activity for the year ended December 31, 2020 were the November 2016 Series A Warrants, the October 2018 Underwriter Warrants and the May 2020 Series 3 Warrants, which, at The November 2016 Series A Warrants The Series A warrant valuation of zero at March 31, 2021 was computed using the Black-Scholes-Merton pricing model using a stock price of $1.80, a strike price of $787.50 per share, an expected term of 1.16 years, volatility of 184% and a risk-free discount rate of 0.16%. The Series A warrant valuation of zero at December 31, 2020 was computed using the Black-Scholes-Merton pricing model using a stock price of $0.82, a strike price of $787.50 per share, an expected term of 1.41 years, volatility of 148% and a risk-free discount rate of 0.13%. The change in fair value of the warrants for the three months ended March 31, 2021 was zero. The October 2018 Underwriter Warrants The October 2018 Underwriter Warrants valuation of $12,000 at March 31, 2021 was computed using the Black-Scholes-Merton pricing model using a stock price of $1.80, a strike price of $52.50 per share, an expected term of 2.50 years, volatility of 169% and a risk-free discount rate of 0.35%. The October 2018 Underwriter Warrants valuation of $4,000 at December 31, 2020 was computed using the Black-Scholes-Merton pricing model using a stock price of $0.82, a strike price of $52.50 per share, an expected term of 2.76 years, volatility of 156% and a risk-free discount rate of 0.17%. The net increase in the fair value of the warrants of $8,000 for the three months ended March 31, 2021, was recorded as a loss in the change in fair value of financial instruments in the unaudited condensed consolidated statements of operations. The May 2020 Series 3 Warrants There were no outstanding May 2020 Series 3 Warrants as of March 31, 2021. The May 2020 Series 3 Warrants valuation of $175,000 at December 31, 2020 was computed using the Black-Scholes-Merton pricing model using a stock price of $0.82, a strike price of $0.00 per share, an expected term of 4.89 years, volatility of 142% and a risk-free discount rate of 0.36%. In January 2021, an investor received 406,250 Series 3 Warrants for the exercise of 406,250 2019 Bridge Note Warrants in accordance with the May 2020 Modification of the 2019 Bridge Note Warrants and Inducement Offer. The fair value of these Series 3 Warrants was $1.5 million on the issuance date. For the three months ended March 31, 2021, certain holders of the Series 3 Warrants agreed to exercise total of 620,750 shares for a 1-for-1 exchange of common shares in an Alternate Cashless Exercise. The aggregate fair value of the common stock issued upon the exercise of the Series 3 Warrants as of the exercise date was $1.8 million . The net increase in the fair value of the warrants of $139,000 for the three months ended March 31, 2021 was recorded as a loss in the change in fair value of financial instruments in the unaudited condensed consolidated statements of operations. Streeterville Note The fair value of the Streeterville Note at January 13, 2021, date of issuance and as of March 31, 2021 amounting to $6.0 million and $6.5 million, respectively, were based on the weighted average discounted expected future cash flows representing the terms of the note, discounting them to their present value equivalents. This was classified as Level 3 fair values in the fair value hierarchy due to the use of unobservable inputs, including the Company’s own credit risk. The Company determined and performed the valuations of the Streeterville Note with the assistance of an independent valuation service provider. On a quarterly basis, the Company considers the main Level 3 inputs used derived as follows: · Discount rate for the Streeterville note were determined using comparison of various effective yields on bonds as of the valuation date. · Market indications for vouchers, which affects the Return Bonus from the sale of Tropical Disease Priority Review Voucher (“TDPRV”). · Weighted probability of cash outflows was estimated based on the entity's knowledge of the business and how the current economic environment is likely to impact the timing of the cash outflows, attributed to the different repayment features of the note. The following table summarizes the quantitative information about the significant unobservable inputs used in Level 3 fair value measurement: Range of Inputs (probability-weighted average) Relationship of unobservable inputs Unobservable Inputs 2021 2020 to fair value Risk Adjusted Discount Rate 6.56% - 22% N/A Lower and higher discount rate (+/- 100 basis points) would insignificantly affect the amount of FV. Sales Proceeds: Amount of comparable TDPRV $67.5 million to $350.0 million ($100.0 million) N/A If expected cash flows by management considered the lowest amount of market indications for vouchers, FV would have decreased by $954,000. Range of Probability for Timing of Cash Flows: 0.39% - 39.78% N/A If expected cash flows by management considered the scenario with the least amount of indicated value, FV would have decreased by $211,000. Fair Value Option Beginning January 1, 2021, the Company elected to apply the FVO accounting to selected financial instruments to align the measurement attributes of those instruments under U.S. GAAP and to simplify the accounting model applied to those financial instruments. The Company elected to apply FVO accounting to the entire class of hybrid instruments, including structured notes, of which there are assessed embedded derivatives that would be eligible for bifurcation. Changes in the fair value of FVO assets and liabilities as well as the mark-to-market adjustment on the entire class of hybrid instruments, including derivatives and the net realized gains or losses on these instruments are reported in change in fair value of financial instruments in the unaudited condensed consolidated statements of operations. As of March 31, 2021, the Company did not note any fair value movement on FVO liabilities attributable to any instrument-specific credit risk, which is recorded in other comprehensive income (loss). Hybrid Instruments The Company elected to apply FVO accounting to all of the hybrid instruments issued, including structured notes. The valuation of the hybrid instruments is predominantly driven by the derivative features embedded within the instruments. The Company determined and performed the valuations of the hybrid instruments with the assistance of an independent valuation service provider. The valuation methodology utilized is consistent with the income approach for estimating the fair value of the interest-bearing portion of the instrument and the related derivatives. Cash flows of the hybrid instruments in their entirety, including the embedded derivatives, are discounted at an appropriate rate for the applicable duration of the instrument. Interest on the interest-bearing portion of the instrument that is held to maturity is aggregated as gain (loss) on instruments designated at fair value and related derivatives in the change in fair value of financial instruments and hybrid instruments designated at FVO of the unaudited condensed consolidated statements of operations. The following table summarizes the fair value and unpaid principal balance for items the Company accounts for under FVO: (in thousands) Fair value Unpaid Principal Balance Fair Value Over (Under) Unpaid Prepaid Balance At March 31, 2021 Hybrid Instrument: Structured note (Streeterville note) $ 6,452 $ 6,000 $ 452

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2021
Balance Sheet Components
Balance Sheet Components	4. Balance Sheet Components Inventory Inventory at March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, (in thousands) 2021 2020 (unaudited) Raw Material $ 790 $ 1,321 Work in Process 1,478 1,026 Finished Goods 553 435 Inventory $ 2,821 $ 2,782 Property and Equipment, net Property and equipment at March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, (in thousands) 2021 2020 (unaudited) Land $ 396 $ 396 Lab equipment 424 418 Clinical equipment 65 65 Software 63 63 Total property and equipment at cost 948 942 Accumulated depreciation (274) (265) Property and equipment, net $ 674 $ 677 Depreciation and amortization expense was $9,000 and $10,000 in the three months ended March 31, 2021 and 2020, respectively. Intangible Assets, net Intangible assets at March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, (in thousands) 2021 2020 (unaudited) Developed technology $ 25,000 $ 25,000 Accumulated developed technology amortization (6,111) (5,694) Developed technology, net 18,889 19,306 In-process research and development 4,800 4,800 In process research and development, net 4,800 4,800 Trademarks 300 300 Accumulated trademark amortization (73) (69) Trademarks, net 227 231 Total intangible assets, net $ 23,916 $ 24,337 Amortization expense was $422,000 for the three months ended March 31, 2021 and 2020. There were no IPR&D impairment charges for the three months ended March 31, 2021 and 2020. The following table summarized the Company’s estimated future amortization expense of intangible assets with finite lives as of March 31, 2021: (in thousands) Amounts 2021 $ 1,265 2022 1,687 2023 1,687 2024 1,687 2025 1,687 Thereafter 11,103 $ 19,116

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions
Related Party Transactions	5. Related Party Transactions Management Services Agreement In March 2018, concurrent with the issuance of the Company’s Series A Convertible Preferred Stock to Sagard Capital Partners, L.P. (“Sagard Capital”), the Company entered into a Management Services Agreement with Sagard Capital. Under the agreement, Sagard Capital was to provide consulting and management advisory service to the Company from March 2018 through March 2021. These services include assistance with strategic planning regarding the Company’s commercial strategy, research and due diligence regarding human resource activities, and strategic advice in financial matters. In consideration for such services, the Company paid Sagard Capital an annual fee of $450,000, with total fees over the term of the agreement not to exceed $1.4 million. On September 1, 2020, in concurrence with other transactions by and between the Company, Chicago Venture Partners, L.P. (“CVP” or “Chicago Venture Partners”) and its affiliates, and Sagard Capital, the Company and Iliad Research and Trading, L.P. (“Iliad”), a Utah limited partnership affiliated with CVP , agreed to issue 2,289,474 shares of the Company’s Common Stock to Sagard Capital pursuant to the Stock Plan Agreement for termination of the Management Services Agreement in lieu of payment of $1.1 million in accrued consulting and management fees . For the three months ended March 31, 2021 and 2020, total fees incurred were zero and $112,500, respectively. As of March 31, 2021 and December 31, 2020, the Company had a balance of zero due to Sagard Capital. Letter of Credit On March 24, 2020, the Company entered into a letter of credit agreement with Dr. Charles Conte, the brother of Lisa Conte, the Company’s President, CEO and member of the Company’s board of directors, pursuant to which the Company will, subject to CA-Mission Street Partnership’s consent, replace the existing letter of credit in the amount of $475,000 entered into on August 28, 2018 by the Company with CA-Mission Street Partnership to satisfy the letter of credit requirement in the Company’s office lease agreement with a new letter of credit in the amount of $475,000. In consideration of the new letter of credit, the Company paid Dr. Conte an amount equal to $10,000 per month and reimburse up to $7,500 for reasonable out-of-pocket expenses incurred.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies
Commitments and Contingencies	6. Commitments and Contingencies Commitments Leases On August 28, 2018, the Company entered into an office lease extension agreement for approximately 6,311 square feet of office space in San Francisco, CA. The term of the lease began on September 1, 2018 and expired on September 30, 2020. The monthly base rent under the lease was as follows: $38,000 for the first twelve months, $40,000 for the subsequent twelve months, and $41,000 for the final month. The Company also paid an additional monthly amount for the Company’s proportionate share of the building’s operating charges. An existing shareholder provided a standby letter of credit in the amount of $475,000 to the lessor as collateral for the full performance by the Company of all of its obligations under the lease. In consideration of the Letter of Credit, the Company issued the shareholder a five-year warrant (see Note 8) to purchase 9,580 shares of the Company’s voting common stock. The $494,000 fair value of the Warrant was classified in stockholders’ equity with an offset to deferred rent. On August 31, 2020, the Company entered into an office sublease of approximately 5,263 square feet of office space in San Francisco. The term of the sublease will expire on May 31, 2021. The rent sublease is $15,000 per month beginning on October 1, 2020, which includes operating expenses and taxes. The Company recognizes rent expense on a straight-line basis over the non-cancelable lease period. Rent expense was $45,000 and $191,000 for the three months ended March 31, 2021 and 2020, respectively. Rent expense is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. As of March 31, 2021, the remaining commitment under the lease is $30,000 Purchase Commitment On September 3, 2020, the Company entered into a manufacturing and supply agreement (the “Agreement”) with Glenmark Life Sciences Limited (“Glenmark”), pursuant to which Glenmark will continue to serve as the Company’s manufacturer of crofelemer for use in Mytesi, the Company’s human prescription drug product approved by the U.S. Food and Drug Administration, and for other crofelemer-based products manufactured by the Company or its affiliates for human or animal use. The term of the Agreement is approximately 2.5 years (i.e., until March 31, 2023) and may be extended for successive two-year renewal terms upon mutual agreement between the parties thereto. Pursuant to the terms of the Agreement, Glenmark will supply crofelemer to the Company. The Agreement contains provisions regarding the rights and responsibilities of the parties with respect to manufacturing specifications, forecasting and ordering, delivery arrangements, payment terms, confidentiality and indemnification, as well as other customary provisions. The Agreement includes a commitment for the purchase from Glenmark of a minimum quantity of 300 kilograms of crofelemer per year, pro-rated for partial years, where the Company may be obligated to pay any shortfall. Either party may terminate the Agreement for any reason with 12 months prior written notice to the other party. In addition, either party may terminate the Agreement upon written notice as a result of a material breach of the Agreement that remains uncured for a period of 90 days. If the Company terminates the Agreement as a result of a material breach caused by Glenmark, the Company will not be obligated to pay for any minimum quantity shortfall. Master Services Agreement (“MSA”) On June 24, 2019, the Company entered into an MSA for clinical research organization services (the “2019 MSA”) and a service order under such 2019 MSA with Integrium, LLC (“Integrium”). The service order supports the Company’s study to evaluate the effect of Mytesi on gastrointestinal microbiome in people living with HIV. The 2019 MSA will terminate upon the satisfactory performance of all services to be provided thereunder unless earlier terminated by the parties. As of March 31, 2021, the remaining commitment under the 2019 MSA is $86,000. On October 5, 2020, the Company entered into another MSA for clinical research organization services (the “2020 MSA”) and a service order under such 2020 MSA with Integrium. The service order covers the Company’s planned upcoming pivotal Phase 3 clinical trial for cancer-therapy related diarrhea. As consideration for its services, the Company will pay Integrium a total amount of up to approximately $12.4 million that will be paid over the term of the engagement and based on the achievement of certain milestones. The 2020 MSA will terminate upon the satisfactory performance of all services to be provided thereunder unless earlier terminated by the parties . As of March 31, 2021, the remaining commitment under the 2020 MSA is $11.8 million. Asset Transfer and Transition Commitment On September 25, 2017, the Company entered into the Termination, Asset Transfer and Transition Agreement dated September 22, 2017 with Glenmark. As a result of the agreement, the Company now controls commercial rights for Mytesi for all indications, territories and patient populations globally, and also holds commercial rights to the existing regulatory approvals for crofelemer in Brazil, Ecuador, Zimbabwe and Botswana. In exchange, the Company agrees to pay Glenmark 25% of any payment it receives from a third party to whom the Company grants a license or sublicense or with whom the Company partners in respect of, or sells or otherwise transfers any of the transferred assets, subject to certain exclusions, until Glenmark has received a total of $7.0 million. No payments have been made to date. Revenue Sharing Commitment Update On December 14, 2017, the Company announced its entry into a collaboration agreement with Seed Mena Businessmen Services LLC (“SEED”) for Equilevia™, the Company's non-prescription, personalized, premium product for total gut health in equine athletes. According to the terms of the Agreement, the Company will pay SEED 15% of total revenue generated from any clients or partners introduced to the Company by SEED in the form of fees, commissions, payments or revenue received by the Company or its business associates or partners, and the agreed-upon revenue percentage increases to 20% after the first million dollars of revenue. In return, SEED will provide the Company access to its existing United Arab Emirates (“UAE”) network and contacts and assist the Company with any legal or financial requirements. The agreement became effective on December 13, 2017 and will continue indefinitely until terminated by either party pursuant to the terms of the Agreement. No payments have been made to date. Legal Proceedings On July 20, 2017, a putative class action complaint was filed in the United States District Court, Northern District of California, Civil Action No. 3:17‑cv‑04102, by Tony Plant (the “Plaintiff”) on behalf of shareholders of the Company who held shares on April 12, 2017 and were entitled to vote at the 2017 Special Shareholders Meeting, against the Company and certain individuals who were directors as of the date of the vote (collectively, the “Defendants”), in a matter captioned Tony Plant v. Jaguar Animal Health, Inc., et al. (Jaguar Health, Inc. was formerly known as Jaguar Animal Health, Inc.), making claims arising under Section 14(a) and Section 20(a) of the Exchange Act and Rule 14a‑9, 17 C.F.R. § 240.14a‑9, promulgated thereunder by the SEC. The claims alleged false and misleading information provided to investors in the Joint Proxy Statement/Prospectus on Form S‑4 (File No. 333‑217364) declared effective by the Commission on July 6, 2017 related to the solicitation of votes from shareholders to approve the merger and certain transactions related thereto. The Company accepted service of the complaint and summons on behalf of itself and the United States‑based director Defendants on November 1, 2017. The Company has not accepted service on behalf of, and Plaintiff has not yet served, the non‑U.S.‑based director Defendants. By order dated September 20, 2018, the court dismissed the lawsuit for failure to state a claim. Plaintiff was entitled to amend that complaint within 20 days from the date of dismissal. On October 10, 2018, Plaintiff filed a second amended complaint to focus on the Company’s commercial strategy in support of Equilevia and the related disclosure statements in the Form S-4 described above. On November 6, 2018, the Defendants moved to dismiss the second amended complaint. The court denied the Defendants’ motion to dismiss on June 28, 2019. The Company answered the second amended complaint on August 2, 2019; the answer denied the material allegations of the second amended complaint. Following the completion of document discovery, the parties engaged in a mediation that resulted in an agreement in principle to settle the litigation on a class-wide basis for $2.6 million, subject to court approval. Plaintiff filed a motion for preliminary approval of the proposed settlement on December 30, 2020. The court preliminarily approved the proposed settlement, and authorized Plaintiff to provide settlement class members with notice of the proposed settlement, in an order dated February 2, 2021. The final settlement approval hearing is currently scheduled for May 27, 2021. Assuming that the court gives final approval to the proposed settlement following the final settlement approval hearing, the entire settlement consideration will be provided by the Company’s director and officer liability insurance carrier. Under the loss recovery model in ASC 450 and in reference to ASC 410, the ultimate net income effect of the recognized loss and the insurance proceeds directly related to the recognized loss is zero. As of March 31, 2021 and December 31, 2020, the Company concluded not to record any loss contingency and insurance recovery. Settlement of Underwriter Fee In August 2018, the Company entered into an agreement with an underwriter pursuant to which the underwriter would aid the Company in identifying certain financing transactions, in exchange for a percentage fee of any such financing and warrants. In the first quarter of 2020, the Company and the underwriter agreed on a final settlement for the underwriter services comprised of a cash payment, warrants and common stock. The cash payment amount totalled $387,000, of which $202,000 had been paid in 2019, and $185,000 was paid in 2020. The total warrant issuance payment consisted of the Company issuing 1,096 equity-classified warrants to the underwriter in 2018 and, in 2020, issuing an additional 100,780 equity-classified warrants (see Note 8) to the underwriter to purchase shares of common stock at an exercise price of $2.50 per share. The common stock issuance payment consisted of the Company issuing 100,000 shares of the Company’s common stock to the underwriter with a value of $45,000 in 2020. The Company classified the cash payments, warrant and common stock issuance payments as issuance costs in the unaudited condensed consolidated statements of changes in convertible preferred stock and stockholders’ equity. Severance Agreements In June 2020, the Company entered into certain agreements relating to the payment of severance and other benefits to executive officers of the Company, the severance agreements provide for compensation and benefits if the executive officer is subject to (a) a termination of employment by the Company without cause or (b) a good reason termination, within three months following a change in control. Contingencies From time to time, the Company may be involved in legal proceedings (other than those noted above) arising in the ordinary course of business. The Company believes there is no litigation pending that could have, individually or in the aggregate, a material adverse effect on the financial position, results of operations or cash flows.

Debt

Debt	3 Months Ended
	Mar. 31, 2021
Debt
Debt	7. Debt Notes payable at March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, (in thousands) 2021 2020 (unaudited) Royalty Interest $ 40,000 $ 30,000 Streeterville Note 6,452 — Tempesta Note 400 450 Umbrella Insurance Financing 98 — Oasis Secured Borrowing — 1,822 Exchange Note 2 — 1,525 Insurance Premium Financing — 95 46,950 33,892 Less: unamortized discount and debt issuance costs (21,289) (17,682) Note payable, net of discount $ 25,661 $ 16,210 Notes payable - non-current, net $ 24,230 $ 12,421 Notes payable - current, net $ 1,431 $ 3,789 Future maturities of the notes payable not designated at FVO as of March 31, 2021 are as follows: (in thousands) Amounts As of March 31, 2022 $ 1,431 2023 6,398 2024 15,851 2025 7,080 2026 8,150 2027 1,588 40,498 Less: unamortized discount and debt issuance costs (21,289) Total $ 19,209 Future maturities are based on contractual minimum payments. Timing of maturities may fluctuate based on future revenue. Sale of Future Royalty Interest March 2020 Purchase Agreement In March 2020, the Company entered into a royalty interest purchase agreement (the “March 2020 Purchase Agreement”) with Iliad, pursuant to which the Company sold to Iliad a royalty interest entitling Iliad to receive $500,000 of future royalties on sales of Mytesi and certain up-front license fees and milestone payments from licensees and/or distributors (the “Royalty Repayment Amount”) for an aggregate purchase price of $350,000. Until such time as the Royalty Repayment Amount has been paid in full, the Company will pay Iliad ten percent (10%) of the Company’s Net Sales on Included Products and ten percent (10%) of worldwide revenues related to upfront licensing fees and milestone payments from licensees and/or distributors, but specifically excluding licensing fees and/or milestone payments that are reimbursements of clinical trial expenses (the “Royalty Payments”). Beginning on the six-month anniversary of the Purchase Price Date and continuing until the 12-month anniversary of the Purchase Price Date, the monthly Royalty Payment shall be the greater of (a) $25,000, and (b) the actual Royalty Payment amount Iliad is entitled to for such month. Beginning on the 12-month anniversary of the Purchase Price Date and continuing until the Revenue Repayment Amount has been paid in full, the monthly Royalty Payment shall be the greater of (a) $44,000 and (b) the actual Royalty Payment amount Iliad is entitled to for such month. The Royalty Interest amount of $500,000 is classified as debt, net of a $150,000 discount, at initial recognition. Under ASC 470-10-35-3, royalty payments to Iliad will be amortized under the interest method per ASC 835-30. Because there is no set interest rate, and because the royalty payments are variable, the discount rate is variable. After each royalty payment, the Company will use a prospective method to determine a new discount rate based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. At issuance, based on projected cash outflows from future revenue streams, the discount rate was 105%. On July 10, 2020, the Company and Iliad entered into an amendment to the March 2020 Purchase Agreement to which the parties agreed that no royalty payments or other payment will be due prior to December 10, 2020. The Royalty Payments shall resume as of December 10, 2020, which Royalty Payment will cover Net Sales on Included Products and licensing fees and milestone payments for the month of November. In consideration of the amendment, the balance of the Royalty Repayment Amount as of July 10, 2020 was increased by 10%. All other terms remain unchanged. This amendment resulted in the Company accounting for the transaction as a TDR, under which the carrying amount of the debt remained unchanged but interest expense is computed using a new effective rate that equates the present value of future cash payments specified by the new terms with the carrying amount of the debt. Subsequent to March 2020, the Company had paid $283,000 of the $500,000 Royalty Interest Amount. In November 2020, the Company and Iliad entered into an exchange agreement pursuant to which the Company issued 1,314,974 shares of common stock in exchange for the outstanding balance of the debt as of November 16, 2020. The exchange agreement was accounted for as a TDR. As of December 31, 2020, the carrying amount of the debt was zero. October 2020 Purchase Agreement On October 8, 2020, the Company entered into another royalty interest purchase agreement (the “October 2020 Purchase Agreement”) with Iliad, pursuant to which the Company sold to Iliad a royalty interest entitling Iliad to receive $12.0 million of future royalties on sales of Mytesi and certain up-front license fees and milestone payments from licensees and/or distributors (the “Royalty Repayment Amount”) for an aggregate purchase price of $6.0 million. Until such time as the Royalty Repayment Amount has been paid in full, the Company will pay Iliad 10% of the Company’s net sales on included products and 10% of worldwide revenues related to upfront licensing fees and milestone payments from licensees and/or distributors, but specifically excluding licensing fees and/or milestone payments that are reimbursements of clinical trial expenses (the “Royalty Payments”). Beginning on the six-month anniversary of the delivery of the October 2020 Purchase Agreement to the Company (the “Purchase Price Date”) and continuing until the 12-month anniversary of the Purchase Price Date, the monthly Royalty Payment shall be the greater of (a) $250,000, and (b) the actual Royalty Payment amount Iliad is entitled to for such month. Beginning on the 12-month anniversary of the Purchase Price Date and continuing until 18-month anniversary of the Purchase Price Date, the monthly Royalty Payment shall be the greater of (a) $400,000 and (b) the actual Royalty Payment amount Iliad is entitled to for such month. Beginning on the 18-month anniversary of the Purchase Price Date and continuing until 24-month anniversary of the Purchase Price Date, the monthly Royalty Payment shall be the greater of (a) $600,000 and (b) the actual Royalty Payment amount Iliad is entitled to for such month. Beginning on the 24-month anniversary of the Purchase Price Date and continuing until the Royalty Repayment Amount has been paid in full, the monthly Royalty Payment shall be the greater of (a) $750,000, and (b) the actual Royalty Payment amount Iliad is entitled to for such month. The Royalty Interest amount of $12.0 million is classified as debt, net of a $6.0 million discount, at initial recognition. Under ASC 470-10-35-3, royalty payments to Iliad will be amortized under the interest method per ASC 835-30. Because there is no set interest rate, and because the royalty payments are variable, the discount rate is variable. After each royalty payment, the Company will use a prospective method to determine a new discount rate based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. At issuance, based on projected cash outflows from future revenue streams, the discount rate was 34.51%. Pursuant to the October 2020 Purchase Agreement, if the weekly volume weighted average price (“VWAP”) of the Company’s common stock is not equal or greater than the minimum VWAP of $0.3035 at least twice during each calendar month during the six-month period beginning on November 1, 2020, then the Royalty Repayment Amount will be automatically be increased by $6.0 million at the end of such six-month period. During the observation period starting November 1, 2020, the Company’s weekly VWAP failed to reach the minimum VWAP of $0.3035 and on November 13, 2020, the Company concluded that the contingent clause has been met, warranting an additional $6.0 million Royalty Repayment Amount, to be added to the outstanding balance commencing on May 10, 2021 for the purpose of cash interest calculation. The change in the Royalty Repayment Amount was accounted for as a debt modification and resulted in a new discount rate of 45.42%. As of March 31, 2021, the forecasted future revenues remained the same based on management assessment, thus, the discount rate remained at 45.42%. Interest expense for the three months ended March 31, 2021 was $1.1 million. As of March 31, 2021 and December 31, 2020, the carrying value of the debt is $7.3 million and $6.3 million, respectively. December 2020 Purchase Agreement On December 22, 2020, the Company entered into a royalty interest purchase agreement (the “December 2020 Purchase Agreement”) with Irving Park Capital, LLC (“Irving”), a company affiliated with CVP, pursuant to which the Company sold to Irving a royalty interest entitling Irving to receive $12.0 million of future royalties on sales of Mytesi and certain up-front license fees and milestone payments from licensees and/or distributors (the “Royalty Repayment Amount”) for an aggregate purchase price of $6.0 million. Until such time as the Royalty Repayment Amount has been paid in full, the Company will pay Irving 10% of the Company’s Net Sales on Included Products and 10% of worldwide revenues related to upfront licensing fees and milestone payments from licensees and/or distributors, but specifically excluding licensing fees and/or milestone payments that are reimbursements of clinical trial expenses (the “Royalty Payments”). Beginning on the payment start date of March 8, 2024 and continuing until the 12-month anniversary of the Purchase Price Date, the monthly Royalty Payment shall be the greater of (a) $750,000, and (b) the actual Royalty Payment amount Irving is entitled to for such month. The Royalty Interest amount of $12.0 million is classified as debt, net of a $6.0 million discount, at initial recognition. Under ASC 470-10-35-3, royalty payments to Irving will be amortized under the interest method per ASC 835-30. Because there is no set interest rate, and because the royalty payments are variable, the discount rate is variable. After each royalty payment, the Company will use a prospective method to determine a new discount rate based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. At issuance, based on projected cash outflows from future revenue streams, the discount rate was 23.70%. As of March 31, 2021, the forecasted future revenues remained the same based on management assessment, thus, the discount rate remained at 23.70%. Interest expense for the three months ended March 31, 2021 was $664,000. As of March 31, 2021 and December 31, 2020, the carrying value of the debt is $6.3 million and $6.0 million, respectively. March 2021 Purchase Agreement On March 8, 2021, the Company entered into a purchase agreement (the “March 2021 Purchase Agreement”) with Streeterville Capital, LLC (“Streeterville”), a company affiliated with CVP, pursuant to which the Company sold a royalty interest entitling Streeterville to $10.0 million and any interest, fees, and charges as royalty repayment amount for an aggregate purchase price of $5.0 million. Interest will accrue on the royalty repayment amount at a rate of 5% per annum, compounding quarterly, and will increase to 10% per annum, compounding quarterly on the 12-month anniversary of the closing date. The Company will be obligated to make minimum royalty payments on a monthly basis beginning at the earlier of (a) 36 months following the closing date or (b) 30 days following the satisfaction of all existing royalties to Streeterville, and its affiliates namely Iliad and Irving, but not earlier than 18 months following the closing date in an amount equal to the greater of (i) $250,000 beginning on the royalty payment start date and continuing until either the royalty repayment amount has been paid in full or the 6-month anniversary of the royalty payment start date, $400,000 beginning on the 6-month anniversary of the royalty payment start date and continuing until either the royalty repayment amount has been paid in full or the 12-month anniversary of the royalty payment start date, $600,000 beginning on the 12-month anniversary of the royalty payment start date and continuing until either the royalty repayment amount has been paid in full or the 18-month anniversary of the royalty payment start date, $750,000 beginning on the 18-month anniversary of the royalty payment start date and continuing until the royalty repayment amount has been paid in full, and (ii) 10% of the Company’s net sales on included products, 10% of worldwide revenues related to upfront licensing fees and milestone payments from licensees and/or distributors but specifically excluding licensing fees and/or milestone payments that are reimbursements of clinical trial expenses or associated with the license of Included Products from the Company to Napo EU, including but not limited to the upfront fee payable by Napo EU to Napo for included products and Crofelemer for other indications; and 50% of royalties collected from licenses of the included products to third parties. The Royalty Interest amount of $10.0 million is classified as debt, net of a $5.0 million discount, at initial recognition. Under ASC 470-10-35-3, royalty payments to Streeterville will be amortized under the interest method per ASC 835-30. Because there is no set interest rate, and because the royalty payments are variable, the discount rate is variable. After each royalty payment, the Company will use a prospective method to determine a new discount rate based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. At issuance, based on projected cash outflows from future revenue streams, the discount rate was 19.36%. As of March 31, 2021, the forecasted future revenues remained the same based on management assessment, thus, the discount rate remained at 19.36%. Interest expense for the three months ended March 31, 2021 was $62,000. As of March 31, 2021, the carrying value of the debt is $5.0 million. Streeterville Note On January 13, 2021, the Company issued a secured promissory note to Streeterville in the original principal amount of $6.2 million for an aggregate purchase price of $6.0 million. The Company will use the proceeds to fund development of the Company’s NP-300 (lechlemer) drug product candidate for the indication of the symptomatic relief of diarrhea from cholera and general corporate purposes, including the Company’s product pipeline activities. The note is due after four years and bears interest at 3.25% per annum. Interest on the note is payable annually in advance by adding the interest charge for each upcoming year to the outstanding balance on the date each such interest charge is accrued. The Company also paid $25,000 to cover legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the issuance of the note. The first year of prepaid interest and the transaction expenses are included in the original principal amount. At any time following the occurrence of a trial failure which refers to any of the following: (i) the Company abandons the clinical trial with lechlemer for an indication for the symptomatic relief of infectious diarrhea for cholera; (ii) the Company fails to start the Phase 1 clinical trial of lechlemer for the symptomatic relief of infectious diarrhea for cholera by July 1, 2022; or (iii) the Company fails to meet all primary endpoints in the pivotal trials of Lechlemer for the symptomatic relief if infectious diarrhea for cholera with statistical significance, Streeterville may elect to increase the outstanding balance as of the date of the trial failure by 25% without acceleration (the “Trial Failure Effect”). If Streeterville elects to apply the Trial Failure Effect, it reserves the right to declare the outstanding balance immediately due and payable at any time. As of March 31, 2021, no trial failure occurred. Streeterville is entitled to a maximum of 18% and a minimum of 1% of the gross proceeds received by the Company from the sale of TDPRV (the “Return Bonus”). The Return Bonus percentage is reduced pro rata based on the percentage of the original principal balance of the note that has been repaid as of the date of the sale of the TDPRV. Even if the note has been paid in full at the time of the sale of the TDPRV, the Company is still obliged to pay Streeterville a Return Bonus of 1%. If Streeterville applies the Trial Failure Effect, the Return Bonus will automatically be reduced to 1%. If the TDPRV has not been sold as of the day immediately preceding the maturity date of the note, the Return Bonus percentage will be fixed as of such date. As of March 31, 2021, the Company has not sold any TDPRV. Beginning on the earlier of (a) 6 months after January 2021, and (b) initiation of human trials with lechlemer for symptomatic relief of infectious diarrhea for cholera, the Company may pay all or any portion of the outstanding balance earlier than it is due. In the event the Company elects to prepay all or any portion of the outstanding balance, it shall pay to Streeterville 112.5% of the portion of the outstanding balance the Company elects to prepay. The Company may not prepay the note without the Streeterville’s consent on the date the last patient is enrolled in a pivotal trial. After Streeterville becomes aware of the occurrence of any default, Streeterville may accelerate the note, with the outstanding balance becoming immediately due and payable in cash at the Mandatory Default Amount (i.e., the outstanding balance following the application of the Default Effect). Streeterville reserves the right to declare the outstanding balance immediately due and payable at any time following the default. Default Effect means multiplying the outstanding balance as of the date of default by 5% or 15% for each occurrence of default, capped at an aggregate of 25%, and then adding the resulting product to the outstanding balance. The percentage to be used depends on whether the default is viewed as minor or major as defined in the agreement. Furthermore, interest accrues on the outstanding balance beginning on the date of default at an interest rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law. As of March 31, 2021, no default has occurred. In connection with the note issuance, the Company has entered into a security agreement with Streeterville, pursuant to which Streeterville will receive a first priority security interest in all existing and future lechlemer technology, and any TDPRV and the sale proceeds therefrom that may be granted to the Company by the FDA in connection with the development of lechlemer for the cholera indication. The Company also agreed, with certain exceptions, not to grant any lien on any of the collateral securing the note and not to grant any license under any of the intellectual property relating to such collateral. The grant of security interest has become effective upon the receipt of the Salix Waiver on April 6, 2021 in observance to the requirement of the settlement agreement previously entered by the Company with Salix Pharmaceuticals, Inc. The Company irrevocably elected to initially and subsequently apply the FVO accounting to the entire note. The fair value at transaction date was equal to the cash proceeds received of $6.0 million. The transaction expense of $25,000 was recognized in profit and loss as incurred. The Company used the valuation report from an independent valuation service provided to measure the reporting date fair value of the note. At March 31, 2021, the fair value was determined to be $6.5 million. For the three months ended March 31, 2021, the net increase in the fair value of $452,000 was recorded as a loss included in the change in fair value of financial instruments in the unaudited condensed consolidated statements of operations. 2019 Tempesta Note In October 2019, the Company entered into a License Termination and Settlement Agreement with Dr. Michael Tempesta, pursuant to which certain royalty payment disputes between the Company and Tempesta were settled. Per the terms of the Agreement, Tempesta received $50,000 in cash, an unsecured promissory note issued by the Company in the aggregate principal amount of $550,000 and 40,000 shares of the Company’s common stock in exchange for the cessation of all royalty payments by the Company to Dr. Tempesta under the License Agreements. The $550,000 promissory note bears interest at the rate of 2.5% per annum and matures on March 1, 2025. The promissory note provides for the Company to make semi-annual payments equal to $50,000 plus accrued interest beginning on March 1, 2020 until the Note is paid in full. At March 31, 2021 and December 31, 2020, the net carrying value of the note was $400,000 and $450,000, respectively. Umbrella Insurance Financing In March 2021, the Company entered into a premium finance agreement for $98,000 with First Insurance Funding (“First Insurance”) representing the unpaid balance of the total premiums, taxes, and fees of $115,000 with an annual interest rate of 4.6%. The total finance charge was $2,000. Payment of principal and interest is due in equal monthly installments over ten months. The Company granted and assigned First Insurance a first priority lien on and security interest in the financed policies and any additional premium required under the financed policies. The financing balance was $98,000 as of March 31, 2021. Insurance Premium Financing In May 2020, the Company entered into a financing agreement for $873,000 for a portion of the Company’s annual insurance premiums. The balance is due in monthly installments over nine months with an annual interest rate of 4.15%. The financing balance was zero and $95,000 as of March 31, 2021 and December 31, 2020, respectively. Oasis Secured Borrowing The Purchase Agreement In May 2020, the Company, entered into a one-year Accounts Receivable Purchase Agreement (the “Purchase Agreement”) with Oasis Capital (“Oasis”), pursuant to which Oasis may from time to time at its discretion purchase accounts receivable of the Company on a recourse basis, at a purchase price equal to 37.5% of the face amount of the first purchase, and at a purchase price equal to 42.5% for subsequent purchased accounts (“Purchase Price”). With respect to purchased accounts, in the event that Oasis receives more than an amount equal to the sum of (i) the face amount of such purchased account multiplied by 0.0545 and (ii) the Purchase Price (such amount, the “Threshold Price”) from collection on such purchased accounts, then Oasis will return any such excess overage amount (the “Overage”) to the Company, as applicable, within five days after Oasis’s receipt thereof. In the event Oasis does not receive at least the Threshold Price for a purchased account on or before such account becomes due and payable, the Company will, at Oasis’s election, be obligated to either (i) pay the difference between the Threshold Price and the amount received by Oasis for such account (the “Shortfall”) within 30 days thereof, or (ii) assign or transfer to Oasis additional accounts receivable with a Purchase Price equal to (A) the Shortfall plus (B) an amount equal to 25% of the Shortfall (the “Additional Amount”). The initial term of the Purchase Agreement is one year, which will automatically renew for successive one-year periods unless notice of non-renewal is provided by the Company at least 30 days prior to the expiration of a term. Notwithstanding the foregoing, either Oasis or the Company may terminate the Purchase Agreement on 60 days prior written notice. Under the Purchase Agreement, Oasis is entitled to a transaction fee of $25,000 and may be entitled to additional transaction fees to the extent Oasis acquires additional accounts receivable under the Purchase Agreement, which fees will not exceed $5,000 per transaction. Per the Purchase Agreement, the Company will service and administer the purchased accounts receivable for Oasis. Oasis appointed the Company to be its agent and servicer for monitoring and collecting the accounts receivable subject to the terms of the Purchase Agreement. The Company will perform its duties in a commercially reasonable manner and agrees that Company will not commence any legal action with respect to such servicing and collection efforts and shall not terminate, discharge, discount or write off any accounts receivable without Oasis's prior written consent. The Company, having determined that it did not meet the criteria per ASC 860-10-40-5 to account for the transactions under the Purchase Agreement as sales, accounts for such transactions as secured borrowings in accordance with ASC 860-30, “Transfers – Secured Borrowings and Collateral.” May 2020 Oasis Secured Note - Tranche #1 In May 2020, for the first sale under the terms of the Purchase Agreement, the Company received cash proceeds of $1.0 million from Oasis less a $25,000 transaction fee (the “Tranche #1 Secured Note”). Oasis purchased accounts receivable with a carrying value of $1.7 million, or gross accounts receivable of $2.8 million net of chargebacks and discounts of $1.1 million. The Company recorded the sale as a short-term secured borrowing with a principal amount of $1.0 million, or $1.2 million net of a $175,000 discount. Though there was no stated interest rate, the effective interest rate was 147.9%. In June 2020, the Company made its final required payment to Oasis under the Tranche #1 Secured Note, with total payments equalling the $1.2 million Threshold amount, and the Tranche #1 Secured Note was extinguished. June 2020 Oasis Secured Note - Tranche #2 In June 2020, for its second sale under the terms of the Purchase Agreement, the Company received cash proceeds of $1.2 million from Oasis (the “Tranche #2 Secured Note”). Oasis purchased accounts receivable with a carrying value of $1.7 million, or gross accounts receivable of $2.8 million net of chargebacks and discounts of $1.1 million. The Company recorded the sale to Oasis as a short-term secured borrowing with a principal amount of $1.2 million, or $1.4 million net of a $156,000 discount. Though there was no stated interest rate, the effective interest rate at issuance was 77.7%. In September 2020, the Company made its final required payment to Oasis under the Tranche #2 Secured Note, with total payments equaling the $1.4 million Threshold amount plus the transaction fee, and the Tranche #2 Secured Note was extinguished. August 2020 Oasis Secured Note - Tranche #3 In August 2020, for its third sale under the terms of the Purchase Agreement, the Company received cash proceeds of $1.3 million from Oasis (the “Tranche #3 Secured Note”). Oasis purchased accounts receivable with a carrying value of $1.9 million, or gross accounts receivable of $3.1 million net of chargebacks and discounts of $1.2 million. The Company recorded the sale to Oasis as a short-term secured borrowing with a principal amount of $1.3 million, or $1.5 million net of a $177,000 discount. Though there was no stated interest rate, the effective interest rate at issuance was 125.6%. In October 2020, the Company made its final required payment to Oasis under the Tranche #3 Secured Note, with total payments equaling the $1.5 million Threshold amount plus the transaction fee, and the Tranche #3 Secured Note was extinguished. September 2020 Oasis Secured Note - Tranche #4 In September 2020, for its fourth sale under the terms of the Purchase Agreement, the Company received cash proceeds of $985,000 from Oasis (the “Tranche #4 Secured Note”). Oasis purchased accounts receivable with a carrying value of $1.4 million, or gross accounts receivable of $2.3 million net of chargebacks and discounts of $920,000. The Company recorded the sale to Oasis as a short-term secured borrowing with a principal amount of $985,000, or $1.1 million net of a $132,000 discount. Though there was no stated interest rate, the effective interest rate at issuance was 98.4%. In November 2020, the Company made its final required payment to Oasis under the Tranche #4 Secured Note, with total payments equaling the $1.1 million Threshold amount plus the transaction fee, and the Tranche #4 Secured Note was extinguished. October 2020 Oasis Secured Note – Tranche #5 In October 2020, for its fifth sale under the terms of the Purchase Agreement, the Company received cash proceeds of $895,000 from Oasis (the “Tranche #5 Secured Note”). Oasis purchased accounts receivable with a carrying value of $1.2 million, or gross accounts receivable of $2.1 million net of chargebacks and discounts of $955,000. The Company recorded the sale to Oasis as a short-term secured borrowing with a principal amount of $895,000, or $1.0 million net of a $120,000 discount. Though there was no stated interest rate, the effective interest rate at issuance was 90.2%. In December 2020, the Company made its final required payment to Oasis under the Tranche #5 Secured Note, with total payments equaling the $1.0 million Threshold amount plus the transaction fee, and the Tranche #5 Secured Note was extinguished. December 2020 Oasis Secured Note – Tranche #6 In December 2020, for its sixth sale under the terms of the Purchase Agreement, the Company received cash proceeds of $1.6 million from Oasis (the “Tranche #6 Secured Note”). Oasis purchased accounts receivable with a carrying value of $2.2 million, or gross accounts receivable of $3.8 million net of chargebacks and discounts of $1.6 million. The purchase was effectuated pursuant to an amended Assignment Agreement, effective December 3, 2020, between the Company and Oasis. The Maturity Date, by which date Oasis must collect the $1.8 million Threshold Price, was February 10, 2021. The Company recorded the sale to Oasis as a short-term secured borrowing with a principal amount of $1.6 million, or $1.8 million net of a $213,000 discount. Though there was no stated interest rate, the effective interest rate at issuance was 128.4%. The Tranche #6 Secured Note had a maturity date of February 10, 2021, or earlier if the Threshold amount was received by Oasis prior to that date (payment of the Threshold amount is the maturity date). Accordingly, during the term of the Tranche #6 Secured Note, the effective interest rate is variable, dependent on the amount of any principal payment and payment dates. The secured borrowing gross balance remaining to be paid is $1.8 million as of December 31, 2020. In February 2021, the Company made its final required payment to Oasis under Tranche #6 Secured Note, with total payments equaling the $1.8 million Threshold amount plus the transaction fee, and the Tranche #6 Secured Note was extinguished . Exchange Note 2 In May 2019, the Company and CVP entered into an exchange agreement whereby CVP purchased the two outstanding Napo convertible notes and all rights thereof from the current debt holders. Subject to the terms of the exchange agreement, CVP and the Company agreed to exchange the two Napo convertible notes for a single CVP Note (“Exchange Note 1”). The maturity date of Exchange Note 1 was December 31, 2020, with an interest rate of 10%. Per the terms of the exchange agreement, CVP agreed to extend the maturity date from December 31, 2019 (the same maturity date carried over from the two Napo convertible notes) to December 31, 2020; in consideration of this extension, the Company issued a note (“Exchange Note 2”) with a principal balance of $2.3 million. The maturity date of Exchange Note 2 is December 31, 2020, with an interest rate of 10%. Between September 2020 and November 2020, the Company and CVP entered into a series of note exchange agreements pursuant to which the Company made prepayments of principal and related accrued interest of an aggregate amount of $5.0 mi

Warrants

Warrants	3 Months Ended
	Mar. 31, 2021
Warrants
Warrants	8. Warrants The following table summarizes information about warrants outstanding and exercisable into shares of the Company’s common stock as of March 31, 2021 and December 31, 2020: March 31, December 31, 2021 2020 (unaudited) Warrants outstanding, beginning balance 7,205,454 19,421,892 Issuances 406,250 22,048,278 Exercises (6,021,350) (34,264,393) Expirations and cancelations — (323) Warrants outstanding, ending balance 1,590,354 7,205,454 May 2020 Series 3 Warrants In May 2020, concurrent with the May 2020 modification of the exercise price of the Series 1, Series 2 and Bridge Note Warrants and inducement offer, the Company issued unregistered Series 3 Warrants to purchase 8,670,852 shares of common stock. The Series 3 Warrants had an exercise price of $0.53 per share and are exercisable beginning the earlier of (i) six months from their May 22, 2020 issuance date and (ii) receipt of the requisite Stockholder Approval (defined below), and expire five years thereafter. In addition to the fixed settlement method at $0.53 per warrant share, the Series 3 Warrants had two contingent settlement methods: (i) if at the time of exercise there is no effective registration statement, then the holders of the 8,670,852 warrants may exercise the warrants in a “cashless exercise,” under which the holders will receive the aggregate warrants less the number of warrants equal to the exercise price; or (ii) a cashless exercise feature wherein, regardless if there is an effective registration agreement, following the requisite Stockholder Approval, each such Series 3 Warrant will be exercisable into one share of common stock for no consideration (the “Alternate Cashless Exercise”). The Series 3 Warrants were initially valued at $3.7 million using the Black-Scholes-Merton option pricing model as follows: probability-weighted exercise price of $0.05 per share, stock price of $0.44 per share, expected life of 5.50 years, volatility of 141%, and a risk-free rate of 0.34%. The Series 3 Warrants were classified as liabilities in the Company’s A Special Meeting of Stockholders was held on July 21, 2020, whereupon a proposal to approve the “Alternate Cashless Exercise” settlement method for the Series 3 Warrants was approved. In 2020, certain holders of the Series 3 Warrants agreed to exercise a total of 8,456,352 shares for a 1-for-1 exchange of common shares in an Alternate Cashless Exercise. The aggregate fair value of the common stock issued upon the exercise of the Series 3 Warrants as of the exercise date was $6.1 million. On January 8, 2021, in accordance with the May 2020 Modification of the 2019 Bridge Note Warrants and Inducement Offer, an investor received 406,250 Series 3 Warrants for the exercise of 406,250 2019 Bridge Note Warrants on the same date. During the three months ended March 31, 2021, certain holders of the Series 3 Warrants agreed to exercise a total of 620,750 shares for a 1-for-1 exchange of common shares in an Alternate Cashless Exercise. The aggregate fair value of the common stock issued upon the exercise of the Series 3 Warrants as of the exercise date was $1.8 million. A total of zero and 214,500 Series 3 Warrants were outstanding as of March 31, 2021 and December 31, 2020, respectively. October 2018 Underwriter Warrants In October 2018, in consideration of services provided leading up to the Company’s October 2018 public offering, the Company issued warrants to various service providers to purchase an aggregate of 17,142 shares of common stock at an exercise price of $52.50 per common share. The warrants were classified as liabilities pursuant to ASC 815-40 as there was potential cash settlement. April 2020 Underwriter Warrants In April 2020, in consideration of the settlement of a dispute regarding underwriting fees (see Note 6), the Company issued warrants to purchase 100,780 shares of common stock at an exercise price of $2.50 per common share. The warrants were valued at $32,000 using the Black-Scholes-Merton option pricing model as follows: exercise price of $2.50 per share, stock price of $0.45 per share, expected life of 4.25 years, volatility of 141%, and a risk-free rate of 0.29%. The warrants were equity classified in the unaudited condensed consolidated statements of changes in convertible preferred stock and stockholders’ equity. March 2019 Ladenburg Warrants In March 2019, in consideration of services provided in the Company’s March 2019 public offering of 19,019 common shares, the Company issued to Ladenburg Thalmann & Co. warrants to purchase an aggregate of 761 shares of common stock at an exercise price of $17.50 per common share. The warrants were valued at $13,000 using the Black-Scholes-Merton option pricing model as follows: exercise price of $17.50 per share, stock price of $18.90 per share, expected life of 5 years, volatility of 146%, and a risk-free rate of 2.21%. The warrants were equity classified in the unaudited condensed consolidated statements of changes in convertible preferred stock and stockholders’ equity. March 2019 LOC Warrant In March 2019, in consideration of a letter of credit cancellation related to the Company’s office lease, the Company issued a warrant to purchase warrant shares equal to a fixed principal amount divided by a variable exercise price. The warrants were initially classified as liabilities pursuant to ASC 480-10 due to their debt-like nature. On 2019 Bridge Note Warrants Between March 18, 2019 and June 26, 2019, concurrent to the Company entering into Promissory Notes of $5.1 million, the Company issued twenty-one warrants to purchase warrant shares equal to a fixed principal amount divided by a variable exercise price. The warrants for all twenty-one Bridge Notes Warrants were initially liability classified pursuant to ASC 480-10 due to their debt-like nature. On July 23, 2019, upon the exercise price of the warrants becoming fixed, the warrants became exercisable into 2,781,250 shares of the Company’s common stock and were reclassified to additional paid-in-capital with a fair value of $4.3 million, calculated using the Black-Scholes-Merton pricing model using a stock price of $1.73, a strike price of $2.00 per share, an average expected term of 4.80 years, volatility of 145.84% and a risk-free discount rate of 1.76%. February 2020 Modification of Certain 2019 Bridge Note Warrants In February 2020, the Company entered into a warrant exercise agreement with a holder of its Bridge Note Warrants, pursuant to which the holder agreed to exercise 250,000 Bridge Notes Warrants in consideration of the Company lowering the exercise price of the 250,000 warrants from $2.00 to $0.692. Upon exercise of the warrants, the Company received cash proceeds of $173,000 and, in turn, issued 250,000 common shares. It is the Company’s policy to determine the impact of modifications to equity-classified warrants by analogy to the share-based compensation guidance per ASC 718, Compensation – Stock Compensation . Pursuant to that guidance, and due to the modification being applicable only to a single holder of the Bridge Note Warrants, the incremental increase of $7,000 in fair value of the modified warrants was recorded as an expense in the unaudited condensed consolidated statements of operations for the three months ended March 31, 2020. May 2020 Modification of the 2019 Bridge Note Warrants and Inducement Offer In May 2020, the Company reduced the exercise price of all outstanding 2019 Bridge Note Warrants from $2.00 per share to $0.49 per share. The Company determined the impact of this modification to be an increase in the fair value of the warrants of $166,000. Because the modification applied to the entire class of Bridge Warrant holders, the increase in fair value represented a deemed dividend to the entire class of Bridge Warrant holders. The modification did not result in the reclassification of the equity-classified Bridge Note Warrants from additional paid-in-capital to liability classification. In May 2020, concurrent with the reduction of the exercise price of the Bridge Note Warrants, the Company entered into a warrant exercise inducement offer with certain holders of the Bridge Note Warrants, pursuant to which such holders agreed to exercise for cash Bridge Notes Warrants to purchase 93,750 shares of common stock, in exchange for the Company’s issuing to the exercising holders new unregistered Series 3 Warrants to purchase 93,750 shares of common stock. During the three months ended March 31, 2021, an aggregate of 1,331,250 shares of common stock were issued upon the exercise of the Bridge Note Warrants for total proceeds of $652,000. A total of 571,875 and 1,903,125, 2019 Bridge Notes Warrants were outstanding as of March 31, 2021 and December 31, 2020, respectively. July 2019 Series 1 Warrants In July 2019, the Company entered into an underwriting agreement, relating to a public offering, which was comprised of (1) 2,886,500 Class A Units, priced at $2.00 per unit, with each unit consisting of (i) one share of the Company’s voting common stock, (ii) one Series 1 warrant to purchase one share of common stock, and (iii) one Series 2 warrant to purchase one share of common stock, and (2) 10,787 Class B Units, priced at a price of $1,000 per unit, with each unit consisting of (i) one share of Series B convertible preferred stock, convertible into 500 shares of common stock, (ii) 500 Series 1 Warrants and (iii) 500 Series 2 Warrants. The Series 1 Warrants had an exercise price of $2.00 and expire on the earlier of (a) 5 years from the date of issuance and (b) 30 calendar days following the public announcement of Positive Interim Results related to the diarrhea results from the HALT-D investigator-initiated trial, if and only if certain trading benchmarks are achieved during such 30 calendar day period. In the offering, the Company sold (i) 2,886,500 Class A Units, which included Series 1 warrants to purchase 2,886,500 shares of the Company’s common stock and (ii) 10,787 Class B Units, which included Series 1 warrants to purchase 5,393,500 shares of the Company’s common stock. In total, 8,280,000 Series 1 warrants were issued, with an initial valuation of $5.0 million computed using the Black-Scholes-Merton pricing model using a stock price of $1.73, a strike price of $2.00, an expected term of 5.0 years, volatility of 109.25% and a risk-free discount rate of 1.83%. Upon issuance, the Series 1 warrants were classified in additional paid-in-capital. September 2019 Modification of the July 2019 Series 1 Warrants In September 2019, the Company reduced the exercise price of all 8,280,000 Series 1 Warrants from $2.00 to $1.40. The Company determined the impact of this modification to be an increase in the fair value of the warrants of $522,000. Because the modification applied to the entire class of Series 1 Warrant holders, the increase in fair value represented a deemed dividend to the entire class of Series 1 Warrant holders. The modification did not result in the reclassification of the equity-classified Series 1 warrants from additional paid-in-capital to liability classification. February 2020 Modification of the July 2019 Series 1 Warrants In February 2020, the Company entered into a warrant exercise agreement with a holder of its Series 1 Warrants, pursuant to which the holder agreed to exercise 208,022 Series 1 Warrants in consideration of the Company lowering the exercise price of the 208,022 warrants from $2.00 to $0.6920. Upon exercise of the warrants, the Company received cash proceeds of $144,000 and, in turn, issued 208,022 common shares. It is the Company’s policy to determine the impact of modifications to equity-classified warrants by analogy to share-based compensation guidance per ASC 718, Compensation – Stock Compensation . Pursuant to that guidance, and due to the modification being applicable only to a single holder of the Series 1 Warrants, the incremental increase of $6,000 in fair value of the modified warrants was recorded as an expense in the unaudited condensed consolidated statements of operations for the three months ended March 31, 2020. May 2020 Modification of the July 2019 Series 1 Warrants and Inducement Offer In May 2020, the Company reduced the exercise price of all outstanding Series 1 Warrants from $1.40 per share to $0.49 per share. The Company determined the impact of this modification to be an increase in the fair value of the warrants of $284,000. Because the modification applied to the entire class of Series 1 Warrant holders, the increase in fair value represented a deemed dividend to the entire class of Series 1 Warrant holders. The modification did not result in the reclassification of the equity-classified Series 1 Warrants from additional paid-in-capital to liability classification. In May 2020, concurrent with the reduction of the exercise price of the Series 1 Warrants, the Company entered into a warrant exercise inducement offer with certain holders of the Series 1 Warrants, pursuant to which such holders agreed to exercise for cash Series 1 Warrants to purchase 4,572,040 shares of common stock, in exchange for the Company’s issuing to the exercising holders new unregistered Series 3 Warrants to purchase 4,572,040 shares of common stock. During the three months ended March 31, 2021, an aggregate of 1,392,175 shares of common stock were issued upon the exercise of the Series 1 Warrants for total proceeds of $682,000. A total of 436,190 and 1,078,365 Series 1 Warrants were outstanding as of March 31, 2021 and July 2019 Series 2 Warrants The Series 2 Warrants have an exercise price of $2.00 and expire on the first date on the earlier of (a) 5 years from the date of issuance and (b) 30 calendar days following the public announcement by the Company that a pivotal phase 3 clinical trial using crofelemer (Mytesi, or the same or similar product with a different name) for the treatment of cancer therapy-related diarrhea in humans has met its primary endpoint in accordance with the protocol, if and only if certain trading benchmarks are achieved during such 30 calendar day period. In addition, each Series 2 Warrant has an embedded call option that allows the Company to redeem any unexercised warrants if certain contingencies are met. In the July 2019 offering, the Company sold (i) 2,886,500 Class A Units, which included Series 2 warrants to purchase 2,886,500 shares of the Company’s common stock and (ii) 10,787 Class B Units, which included Series 2 warrants to purchase 5,393,500 shares of the Company’s common stock. In total, 8,280,000 Series 2 warrants were issued, with an initial valuation of $5.0 million computed using the Black-Scholes-Merton pricing model using a stock price of $1.73, a strike price of $2.00, an expected term of 5.0 years, volatility of 109.25% and a risk-free discount rate of 1.83%. Upon issuance, the Series 2 Warrants were classified in additional paid-in-capital. March 5, 2020 Modification of the July 2019 Series 2 Warrants On March 5, 2020, the Company entered into a warrant exercise agreement with a holder of its Series 2 Warrants, pursuant to which the holder agreed to exercise 90,940 Series 2 Warrants in consideration of the Company lowering the exercise price of the 90,940 warrants from $2.00 to $0.6050. Upon exercise of the warrants, the Company received cash proceeds of $55,000 and, in turn, issued 90,940 common shares. It is the Company’s policy to determine the impact of modifications to equity-classified warrants by analogy to share-based compensation guidance per ASC 718, Compensation – Stock Compensation . Pursuant to that guidance, and due to the modification being applicable only to a single holder of the Series 2 Warrants, the incremental increase of $6,000 in fair value of the modified warrants was recorded as an expense in the unaudited condensed consolidated statements of operations for the three months ended March 31, 2020. March 23, 2020 Modification of the July 2019 Series 2 Warrants On March 23, 2020, the Company entered into a Warrant Exercise and Preferred Stock Amendment Agreement (see Note 9) with a holder of its Series 2 Warrants, pursuant to which the holder agreed to exercise in cash its Series 2 Warrants to purchase an aggregate of 1,250,000 shares of common stock, in consideration of the Company reducing the Series 2 Warrant exercise price from $2.00 to $0.5227 per share, for gross proceeds to the Company of approximately $653,000, or $628,000 net of $25,000 of issuance costs. The Company determined the impact of this modification to be an increase in the fair value of the warrants of $65,000. Because the modification applied to a sole holder of Series 2 Warrants, the $65,000 increase in fair value was recorded as an expense in the unaudited condensed consolidated statements of operations for the three months ended March 31, 2020. The modification did not result in the reclassification of the equity-classified Series 2 Warrants from additional paid-in-capital to liability classification, and as of March 31, 2020, all 8,280,000 Series 2 Warrants have been exercised. May 2020 Modification of the July 2019 Series 2 Warrants and Inducement Offer In May 2020, the Company reduced the exercise price of all outstanding Series 2 Warrants from $2.00 per share to $0.49 per share. The Company determined the impact of this modification to be an increase in the fair value of the warrants of $406,000. Because the modification applied to the entire class of Series 2 Warrant holders, the increase in fair value represented a deemed dividend to the entire class of Series 2 Warrant holders. The modification did not result in the reclassification of the equity-classified Series 2 Warrants from additional paid-in-capital to liability classification. In May 2020, concurrent with the reduction of the exercise price of the Series 2 Warrants, the Company entered into a warrant exercise inducement offer with certain holders of the Series 2 Warrants, pursuant to which such holders agreed to exercise for cash Series 2 Warrants to purchase 4,033,562 shares of common stock, in exchange for the Company’s issuing to the exercising holders new unregistered Series 3 Warrants to purchase 4,005,062 shares of common stock. During the three months ended March 31, 2021, an aggregate of 1,427,175 shares of common stock were issued upon the exercise of the Series 2 Warrants for total proceeds of $700,000. A total of 401,190 and 878,365 Series 2 Warrants were outstanding as of March 31, 2021 and December 2019 PIPE Financing Warrants In December 2019, the Company entered into a securities purchase agreement with certain investors pursuant to which the Company, in a Private Placement, sold (i) an aggregate of 2,500,000 unregistered shares of the Company’s common stock, and (ii) warrants to purchase up to an aggregate of approximately 1,250,000 shares of common stock, for an aggregate purchase price of $1.5 million (see Note 10). The warrants have an exercise price of $0.78 per share and became exercisable on June 24, 2020 (6 months after their issuance date) and have a five-year term. The warrants were valued at $686,000 using the Black-Scholes option pricing model as follows: exercise price of $0.78 per share, stock price of $0.62 per share, expected life of five years, volatility of 143%, and a risk-free rate of 2.42%. As the common stock and warrants were issued in a unit structure, the aggregate proceeds of $1,500,000 were allocated to the two securities using the relative fair value method, resulting in the common stock and warrants being allocated $1.0 million and $465,000, respectively. The warrants were classified in additional paid-in-capital. During January 2021, an aggregate of 1,250,000 shares of common stock were issued upon the exercise of the December 2019 PIPE Financing Warrants for total proceeds of $975,000. As of March 31, 2021, all December 2019 PIPE Financing Warrants have been exercised .

Preferred Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2021
Preferred Stock
Preferred Stock	9. Preferred Stock At March 31, 2021 and December 31, 2020, preferred stock consisted of the following: Liquidation ( in thousands, except share and per share data) Shares Issued and Carrying Preference Series Authorized Outstanding Value per Share B-2 10,165 — $ — $ — C 1,011,000 — — 8.00 Total 1,021,165 — $ — Series A Convertible Preferred Stock In March 2018, the Company entered into a stock purchase agreement with Sagard Capital pursuant to which the Company, in a private placement, agreed to issue and sell to Sagard Capital 5,524,926 shares of the Company's Series A Convertible Preferred Stock, $0.0001 par value per share, for gross proceeds of $9.2 million, or $9.0 million net of issuance costs. The preferred stock was convertible into approximately 473,565 shares of common stock at the option of the holder at an effective conversion price of $194.25 per share. Subject to certain limited exceptions, the shares of preferred stock could not be offered, pledged or sold by Sagard Capital for one year from the date of issuance. The conversion price was subject to certain adjustments in the event of any stock dividend, stock split, reverse stock split, combination or other similar recapitalization. The preferred stock was classified outside of stockholders' equity in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. In September 2020, the Company and Sagard Capital entered into an exchange agreement, by which the remaining Series A Convertible Preferred shares were exchanged for (i) 842,500 shares of the Company’s Series C Perpetual Preferred shares, and (ii) 842,500 shares of the Company’s Series D Perpetual Preferred shares, all issued to Iliad. The exchange agreement was entered into to effect a share-for-share exchange transaction. The Series A Convertible Preferred shares were cancelled upon surrender, and the Company issued Iliad the Series C and Series D Perpetual Preferred shares. The exchange agreement was treated as an extinguishment of the Series A Convertible Preferred Stock. As of the exchange date, the related extinguishment required recording derecognition of the Series A accreted value and recording Series C and Series D at fair value. In September 2020, the Company filed a certificate with the Secretary of State of Delaware effecting the retirement and cancellation of the Series A Convertible Preferred Stock. As of December 31, 2020, there were no Series A Convertible Preferred shares authorized or outstanding. Series B Convertible Preferred Stock In July 2019, the Company entered into an underwriting agreement relating to the public offering comprised of (1) 2,886,500 Class A Units, priced at a public offering price of $2.00 per unit, with each unit consisting of (i) one share of the Company’s voting common stock, (ii) one Series 1 warrant to purchase one share of Common Stock and (2) 10,787 Class B Units, priced at a public offering price of $1,000 per unit, with each Class B unit consisting of (i) one share of Series B Convertible Preferred Stock with a stated value of $1,000 and convertible into 500 shares of Common Stock, (ii) 500 Series 1 Warrants and (iii) 500 Series 2 Warrants, at a public offering price of $1,000 per Class B Unit. The Company sold 10,787 Class B Units, comprised of 10,787 shares of Series B Convertible Preferred Stock, Series 1 warrants to purchase 5,393,500 shares of common stock and Series 2 warrants to purchase 5,393,500 shares of common stock. The total gross proceeds to the Company from the offering of the Class B Units were $10.8 million of which $4.2 million was allocated to the Series B Convertible Preferred Stock, $3.3 million to the Series 1 Warrants and $3.3 million to the Series 2 Warrants. Issuance costs of $1.6 million were allocated to the Class B Units. Holders of the Series B shares were entitled to participate equally and ratably with the holders of shares of common stock in all dividends paid and distributions made to the holders of the common stock as if, immediately prior to each record date of the common stock, the shares of Series B then outstanding were converted into shares of common stock. With certain exceptions, the shares of Series B Convertible Preferred Stock had no voting rights. However, as long as any shares of Series B Convertible Preferred Stock remain outstanding, the Company shall not, without the affirmative vote of holders of a majority of the then outstanding shares of Series B Convertible Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Convertible Preferred Stock or alter or amend the Series B Certificate of Designation or (b) enter into any agreement with respect to any of the foregoing. Each share of Series B Convertible Preferred Stock is convertible at any time at the holder’s option into 500 shares of Common Stock, which conversion ratio will be subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations and other similar transactions. In July 2019, the effective conversion price per share was less than the fair value of the underlying common stock. As a result, the Company determined that there was a Beneficial Conversion Feature of $4.2 million. Because the Company's Series B Convertible Preferred Stock does not have a stated conversion date and was immediately convertible at the issuance date, the Company recorded a deemed dividend charge of $4.2 million for the accretion of the discount on the Series B Convertible Preferred Stock. During 2019, certain investors converted 8,816 Series B Convertible Preferred shares into 4,408,000 shares of the Company’s common shares at the stated conversion ratio. The preferred stock has been classified in stockholders' equity in accordance with authoritative guidance. In March 2020, the Company entered into a Warrant Exercise and Preferred Stock Amendment Agreement (“Amendment Agreement”) with a Ionic Ventures of its Series 2 Warrants, pursuant to which the holder agreed to exercise in cash its Series 2 Warrants to purchase an aggregate of 1,250,000 shares of common stock, in consideration of the Company reducing the warrant exercise price from $2.00 to $0.5227 per share, for gross proceeds to the Company of approximately $653,000 (see Note 8). As a further inducement to enter into the Amendment Agreement, the Company agreed to reduce the conversion price of the Company’s Series B Convertible Preferred Stock from $2.00 to $0.4456, resulting in the application of accounting for modification of preferred stock instruments under ASC 260-10-S99-2 where the difference between the fair value of the consideration transferred and the net carrying amount of the convertible preferred stock is treated as a dividend and must be deducted from net income in arriving at income available to common stockholders. Because the reduction to the conversion price was an inducement, the Company applied the guidance in ASC 470-20, resulting in the recording of an inducement charge of $1.6 million in the unaudited condensed consolidated statement of operations for the three months ended March 31, 2020. In September 2020, the Company filed a certificate with the Secretary of State of Delaware effecting the retirement and cancellation of the Series B Convertible Preferred Stock. As of December 31, 2020, there were no Series B Convertible Preferred shares authorized or outstanding. Series B-2 Convertible Preferred Stock In December 2019, the Company entered into an exchange agreement with Oasis Capital, pursuant to which Oasis Capital gave up (i) its remaining unexercised Prepaid Forward contracts exercisable for 1,236,223 shares of the Company’s common stock and (ii) 695,127 common shares held as an investment by Oasis Capital, in exchange for 10,165 shares of the Company’s newly authorized Series B-2 Convertible Preferred Stock. Holders of the Series B-2 Convertible Preferred Stock are entitled to receive dividends on shares of Series B-2 Convertible Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends shall be paid on shares of the Series B-2 Convertible Preferred Stock. The shares of Series B-2 Convertible Preferred Stock have no voting rights. However, as long as any shares of Series B-2 Convertible Preferred Stock remain outstanding, the Company shall not, without the affirmative vote of holders of a majority of the then outstanding shares of Series B-2 Convertible Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B-2 Convertible Preferred Stock or alter or amend the Series B-2 Certificate of Designation or (b) enter into any agreement with respect to any of the foregoing. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the Holders of the Series B-2 Convertible Preferred Stock were entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Series B-2 Convertible Preferred Stock were fully converted to Common Stock which amounts shall be paid pari passu with all holders of common stock. Each share of Series B-2 Convertible Preferred Stock is convertible at any time at the holder’s option into 190 shares of Common Stock, as determined by dividing the $153.90 stated value of each Series B-2 Convertible Preferred Share by the $0.81 conversion price ($153.90 divided by 0.81 = 190 conversion ratio), and which conversion ratio is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations and other similar transactions as specified in the Series B-2 Certificate of Designation. The Series B-2 Convertible Preferred Stock was classified in stockholders' equity in accordance with authoritative guidance. In January 2020, a holder of the Series B-2 Convertible Preferred Stock converted 2,631 preferred shares into 499,890 shares of common stock. In October 2020, the Company entered into an exchange agreement with Oasis Capital pursuant to which the Company agreed to issue 500,186 shares of common stock in exchange for 975 shares of the Series B-2 Convertible Preferred Stock. The exchange agreement was accounted for as a modification. In December 2020, an investor converted the remaining 6,559 Series B-2 Convertible Preferred Stock into a total of 1,246,210 shares of the Company’s common stock. As of March 31, 2021 and December 31, 2020, there were no Series B-2 Convertible Preferred shares outstanding. Series C Perpetual Preferred Stock In September 2020, the Company entered into an exchange agreement with Iliad to issue 842,500 shares of the Company's Series C Perpetual Preferred Stock at $0.0001 par value per share, for a non-cash exchange of equity instruments. The exchange agreement was contemporaneously entered with the issuance of Series D Perpetual Preferred shares, in exchange of remaining Series A Convertible Preferred shares totaling 5,524,926 shares, and accreted value of $11.2 million as of the exchange date. An amendment agreement of the Exchange Note 2 was also entered into, with issuance value of $2.3 million and carrying value of $2.6 million as of the exchange date, to extend maturity from December 31, 2020 to December 31, 2021, in consideration of 5% increase in the outstanding balance. Holders of the Series C Perpetual Preferred Stock were not entitled to voting rights. However, as long as any Series C Perpetual Preferred share is outstanding, the Company is restricted to alter, change, or enter into an agreement to alter or change adversely the powers, preferences, or rights given to the shareholders. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or deemed liquidation event, the holders of Series C Perpetual Preferred shares then outstanding would be entitled to be paid in cash out of the assets of the Company before any payment shall be made to the holders of common stock or shares of any series or class of preferred or other capital stock then outstanding that by its terms is junior to the Series C Perpetual Preferred shares in respect of the preferences as to distributions and payments upon such liquidation event by reason of their ownership, an amount per share of Series C equal to one times the Series C original issue price. The Series C Perpetual Preferred shares were redeemable upon the option or discretion of the Company. The Series C Perpetual Preferred shares were entitled to receive 10% cumulative stock dividends, to be payable in arrears on a monthly basis for 24 consecutive months. Dividends payable on the Series C Perpetual Preferred shares shall be payable through the Company’s issuance of Series C Perpetual Preferred share by delivering to each record holder the calculated number of PIK dividend shares. The Series C Perpetual Preferred shares were initially measured at fair value using the income approach, which considered the weighted probability of discounted cash flows at various scenarios of redemption by the Company or liquidation event and perpetual holding of the shares. As of the date of exchange, total fair value of the Series C Perpetual Preferred shares amounted to $4.7 million. Subsequently, the carrying amount of Series C Perpetual Preferred shares increased as the PIK dividend shares were recognized. The preferred stock has been classified as permanent stockholders' equity in accordance with authoritative guidance for the classification and measurement of perpetual shares without mandatory redemption period because the redemption option was ultimately in the control of the Company. In October 2020, the Company entered into an exchange agreement with Iliad pursuant to which the Company agreed to issue a total of 250,000 shares of common stock and pre-funded warrants to purchase 7,057,692 shares of common stock in exchange for 285,000 shares of Series C Perpetual Preferred Stock. The pre-funded warrants were exercisable immediately and could be exercised at any time until all of the pre-funded warrants were exercised in full. The nominal exercise price of each pre-funded warrant was $0.0001 . In December 2020, the Company also entered into a series of exchange agreements with Iliad pursuant to which the Company agreed to issue a total of 8,203,880 shares of common stock in exchange for 573,810 shares of Series C Perpetual Preferred Stock. The series of exchanges were viewed as singular transaction, hence combined for purposes of accounting for the subsequent amendments. The series of exchanges was accounted for as an extinguishment which resulted in a $2.5 million deemed dividend, recorded against additional paid-in capital, for the difference between the fair value of the shares of common stock and pre-funded warrants transferred and the carrying amount of the Series C Perpetual Preferred Stock. As of December 31, 2020, Iliad had exercised all pre-funded warrants for $1,000. As of March 31, 2021 and December 31, 2020, there were no Series C Perpetual Preferred shares outstanding.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity
Stockholders' Equity	10. Stockholders' Equity As of March 31, 2021 and December 31, 2020, the Company had reserved shares of common stock, on an as-if converted basis, for issuance as follows: March 31, December 31, 2021 2020 (unaudited) Options issued and outstanding 4,449,398 4,456,748 Inducement options issued and outstanding 170,892 114,892 Options available for grant under stock option plans 6,355,104 596,597 Restricted stock unit awards issued and outstanding 5,613 5,613 Warrants issued and outstanding 1,590,354 7,205,454 Total 12,571,361 12,379,304 Common Stock The holders of common stock are entitled to one vote for each share of common stock held. The common stockholders are also entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors. The holders of non-voting common stock are not entitled to vote, except on an as converted basis with respect to any change of control of the Company that is submitted to the stockholders of the Company for approval. Shares of the Company's non-voting common stock have the same rights to dividends and other distributions and are convertible into shares of the Company's common stock on a one-for-one basis. The Company is authorized to issue a total number of 204,475,074 shares, of which 150,000,000 shares are common stock, 50,000,000 are non-voting common stock and 4,475,074 are preferred stock. Reverse Stock-splits On December 22, 2020, the Company obtained approval through a special shareholders meeting held on December 9, 2020 to effect a reverse split of the Company’s issued and outstanding voting common stock at a ratio not less than 1-for-2 and not greater than 1-for-20. As of March 31, 2021, the reverse stock split has not yet been effectuated. March 2020 ELOC (Equity Line of Credit) In March 2020, the Company entered into an equity purchase agreement (the “March 2020 ELOC”) with Oasis Capital, which provides that Oasis Capital is committed to purchase up to an aggregate of $2.0 million shares of the Company’s common stock over the 36-month term of the March 2020 ELOC. Pursuant to the terms and conditions of the March 2020 ELOC, on any trading day selected by the Company (such date the “Put Date”), after the SEC has declared effective the registration statement registering the sale of the shares of common stock that may be issued to Oasis Capital under the March 2020 ELOC, the Company has the right, in its sole discretion, to present to Oasis Capital with a purchase notice (each a “Put Notice”), directing Oasis Capital to purchase up to the lesser of (i) 200,000 shares of common stock or (ii) 20% of the average trading volume of common stock in the 10 trading days immediately preceding the date of such Put Notice, at a per share price equal to $0.436 (each an “Option 1 Put”), provided that the aggregate of all Option 1 Puts and Option 2 Puts (described below) does not exceed $2.0 million. In addition, on any date on which Oasis Capital receives shares of common stock in connection with a Put Notice (the “Clearing Date”), the Company also has the right, in its sole discretion, to present to Oasis Capital with a Put Notice (each an “Option 2 Put”) directing Oasis Capital to purchase an amount of common stock equal to the lesser of (i) such amount that equals 10% of the daily trading volume of the common stock on the date of such Put Notice and (ii) $200,000, provided that the aggregate amount of the Option 1 Put and Option 2 Put on any Put Date or Clearing Date does not exceed $500,000 and the aggregate amount of all Option 1 Puts and Option 2 Puts does not exceed $2.0 million. The purchase price per share pursuant to such Option 2 Put is equal to $0.436. The threshold price and the purchase price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring during the period used to compute the threshold price or the purchase price. On April 15, 2020, the SEC declared effective the registration statement registering the sale of the shares of common stock issued to Oasis Capital under the March 2020 ELOC. The Company will control the timing and amount of sales of common stock to Oasis Capital. Oasis Capital has no right to require any sales by the Company but is obligated to make purchases from the Company as directed by the Company in accordance with the March 2020 ELOC. In connection with the equity line, the Company agreed to pay Oasis Capital a commitment fee and in April 2020, in settlement of the commitment fee, the Company issued to Oasis Capital 68,807 shares of common stock. At issuance, the 68,807 shares of common stock had a fair value of $33,027, and were expensed as an issuance cost in the Company’s unaudited condensed consolidated statements of operations. Per the terms of the equity purchase agreement, the Option Put 1 and Option Put 2 may be exercised only at a price that is always above the trading price of the underlying common stock at the exercise date, thereby rendering any exercise by the Company being out-of-the-money. At inception of the equity line on March 24, 2020, the Put Options were classified as derivative assets with a fair value of zero, and upon an effective registration statement on In April 2020, the Company exercised a single Put Option Put 1 under which the Company sold 52,000 common shares to Oasis for gross proceeds of $22,627. As of March 31, 2021 and December 31, 2020, the Company had not exercised any further put options to require Oasis Capital to purchase common stock under the equity purchase agreement. On April 7, 2021, the Company and Oasis Capital entered into a First Amendment to the March 2020 ELOC (see Note 14). March 2020 PIPE Financing In March 2020, Company entered into a securities purchase agreement (the “PIPE Purchase Agreement”) with certain investors, pursuant to which the Company agreed to issue and sell to the investors in a private placement an aggregate of 1,714,283 shares of the Company’s common stock, for an aggregate purchase price of approximately $720,000, or $668,000 net of $52,000 of issuance costs. At the Market Offering (“ATM”) On October 5, 2020, the Company entered into an ATM Agreement with Ladenburg, pursuant to which the Company may offer and sell, from time to time through Ladenburg, shares of common stock, subject to the terms and conditions of the ATM Agreement. The ATM Agreement will terminate upon the earlier of (i) October 5, 2022 and (ii) termination of the ATM Agreement as permitted therein. In 2020, the Company sold 3,814,925 shares of common stock under the ATM Agreement resulting in net proceeds of approximately $1.3 million after commissions and expenses of approximately $40,000. During January and February 2021, the Company issued an aggregate of 2,009,554 shares under the ATM Agreement for total net proceeds of $5.4 million after commissions and expenses of approximately $311,000. As of March 31, 2021, all shares under the ATM Agreement have been issued. PoC Capital Registered Direct Offering On October 6, 2020, the Company entered into a Stock Plan Agreement for payment of contracted research fees (the “SPA”) with PoC Capital, LLC (“PoC”), pursuant to which the Company issued to PoC an aggregate of 1,333,333 shares of the Company’s common stock, par value $0.0001 per share, as consideration for PoC’s assumption of $400,000 in payment obligations of the Company under the service order with Integrium for the Company’s planned upcoming pivotal Phase 3 clinical trial for cancer-therapy related diarrhea, for an effective offering price of $0.30 per share. Securities Purchase Agreement On January 13, 2021, the Company entered into a securities purchase agreement, pursuant to which the Company agreed to issue and sell, in a registered public offering an aggregate of 4,437,870 shares of common stock, par value $0.0001 per share, at an offering price of $3.38 per share for gross proceeds of approximately $15.0 million before deducting $1.6 million placement agent fee and related offering expenses. The offering closed on January 15, 2021.

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2021
Stock Based Compensation
Stock Based Compensation	11. Stock-based Compensation 2013 Equity Incentive Plan Effective November 1, 2013, the Company's board of directors and sole stockholder adopted the Jaguar Health, Inc. 2013 Equity Incentive Plan (the “2013 Plan”). The 2013 Plan allows the Company's board of directors to grant stock options, restricted stock awards and restricted stock unit awards to employees, officers, directors and consultants of the Company. Following the effective date of the IPO and after effectiveness of any grants under the 2013 Plan that were contingent on the IPO, no additional stock awards will be granted under the 2013 Plan. Outstanding grants continue to be exercisable; however, any unissued shares under the plan and any forfeitures of outstanding options do not rollover to the 2014 Stock Incentive Plan. There were 384 option shares outstanding at March 31, 2021 and December 31, 2020. 2014 Stock Incentive Plan Effective May 12, 2015, the Company adopted the Jaguar Health, Inc. 2014 Stock Incentive Plan (“2014 Plan”). The 2014 Plan provides for the grant of options, restricted stock and restricted stock units to eligible employees, directors and consultants to purchase the Company's common stock. The term of an incentive stock option may not exceed 10 years, except that with respect to any participant who owns more than 10% of the voting power of all classes or our outstanding stock, the term must not exceed 5 years. The 2014 Plan that provides for automatic share increases on the first day of each fiscal year in the amount of 2% of the outstanding number of shares of the Company's common stock on the last day of the preceding calendar year. The 2014 Plan replaced the 2013 Plan except that all outstanding options under the 2013 Plan remain outstanding until exercised, canceled or expired. As of March 31, 2021, there were 4,449,014 options outstanding and 6,025,922 options available for grant. As of December 31, 2020, there were 4,456,364 options outstanding and 211,415 options available for grant. 2020 New Employee Inducement Award Plan Effective June 16, 2020, the Company adopted the Jaguar Health, Inc. New Employee Inducement Award Plan (“2020 Inducement Award Plan”) and, subject to the adjustment provisions of the Inducement Award Plan, reserved 500,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Award Plan. The term of an incentive stock option may not exceed 10 years, except that with respect to any participant who owns more than 10% of the voting power of all classes or our outstanding stock, the term must not exceed 5 years. The 2020 Inducement Award Plan provides for the grant of nonstatutory stock options, restricted stock units, restricted stock, and performance shares. The 2020 Inducement Award Plan was adopted without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the 2020 Inducement Award Plan are substantially similar to the Company’s 2014 Stock Incentive Plan, but with such other terms and conditions intended to comply with the Nasdaq inducement award rules. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, the only persons eligible to receive grants of equity awards under the Inducement Award Plan are individuals who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company. As of March 31, 2021, there were 170,818 options outstanding and 329,182 options available for grant. Stock Options and Restricted Stock Units (“RSUs”) The following table summarizes incentive plan activity for the three months ended March 31, 2021 ( unaudited ): Weighted Weighted Average Shares Stock Average Remaining Aggregate Available Options RSUs Stock Option Contractual Life Intrinsic (in thousands, except share and per share data) for Grant Outstanding Outstanding Exercise Price (Years) Value* Outstanding at December 31, 2020 596,597 4,571,566 5,613 $ 4.23 8.71 $ 364 Additional shares authorized 5,807,157 — — — — Options granted (70,000) 70,000 — 1.92 — Options exercised — — — — — Options canceled 21,350 (21,350) — 10.68 — Outstanding at March 31, 2021 6,355,104 4,620,216 5,613 $ 4.16 8.51 $ 1,808 Exercisable at March 31, 2021 2,623,013 $ 6.35 8.39 $ 686 Vested and expected to vest at 4,400,382 $ 4.31 8.49 $ 1,655 *Fair market value of JAGX common stock on March 31, 2021 was $1.80 per share. The intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair market value of the Company's common stock for options that were in-the-money. No options were exercised in the three months ended March 31, 2021 and 2020. The weighted average grant date fair value of stock options granted was $1.76 and $0.41 per share during the three months ended March 31, 2021 and 2020, respectively. The number of options that vested in the three months ended March 31, 2021 and 2020 was 383,419 and 333,926, respectively. The grant date weighted average fair value of options that vested in the three months ended Stock-Based Compensation The following table summarizes stock-based compensation expense related to stock options, inducement stock options and RSUs for the three months ended March 31, 2021 and 2020, and are included in the unaudited condensed consolidated statements of operations as follows: Three Months Ended March 31, (in thousands) 2021 2020 (unaudited) Research and development expense $ 164 $ 202 Sales and marketing expense 52 56 General and administrative expense 418 502 Total $ 634 $ 760 As of March 31, 2021, the Company had $2.2 million of unrecognized stock-based compensation expense for options, inducement options and restricted stock units outstanding, which is expected to be recognized over a weighted-average period of 1.13 years. The fair value of options granted during the three months ended March 31, 2021 and 2020, respectively, were calculated using the range of assumptions set forth below: Three Months Ended March 31, 2021 2020 (unaudited) Volatility 163.8 - 164.0 % 150.1 % Expected term (years) 5.0 5.0 Risk-free interest rate 0.5 - 0.9 % 0.5 % Expected dividend yield — — 401(k) Plan The Company sponsors a 401(k) defined contribution plan covering all employees. There were no employer contributions to the plan from plan inception through March 31, 2021 .

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2021
Net Loss Per Share
Net Loss Per Share	12. Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share of common stock for the periods indicated: Three Months Ended March 31, (In thousands, except share and per share data) 2021 2020 (unaudited) Net loss attributable to common shareholders (basic and diluted) $ (12,009) $ (8,416) Shares used to compute net loss per common share, basic and diluted 125,416,228 15,141,906 Net loss per share attributable to common shareholders, basic and diluted $ (0.10) $ (0.56) Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company's potentially dilutive securities which include stock options, convertible preferred stock, RSUs and common stock warrants have been excluded from the computation of diluted net loss per share as they would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares outstanding due to the Company's net loss position. The following outstanding common stock equivalents have been excluded from diluted net loss per common share for the three months ended March 31, 2021 and 2020 because their inclusion would be anti-dilutive. Three Months Ended March 31, 2021 2020 (unaudited) Options issued and outstanding 4,449,398 4,508,021 Inducement options issued and outstanding 170,892 74 Restricted stock units issued and outstanding 5,613 5,613 Warrants issued and outstanding 1,590,354 17,622,930 Series A convertible preferred stock — 473,565 Series B convertible preferred stock — 4,423,250 Series B-2 convertible preferred stock — 1,431,460 Total 6,216,257 28,464,913 As of May 6, 2021, there were 9,411,705 shares of common stock issued after the balance sheet date. Including these shares will have a material effect on the diluted net loss per common share in future periods.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2021
Segment Information
Segment Information	13. Segment Information The Company has two reportable segments-human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is approved by the U.S. FDA for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Company's reportable segments net revenues and net loss for the three months ended March 31, 2021 and 2020 consisted of the following: Three Months Ended March 31, (in thousands) 2021 2020 (unaudited) Revenue from external customers Human Health $ 1,208 $ 835 Animal Health 33 34 Consolidated Totals $ 1,241 $ 869 Segment net loss Human Health $ (3,941) $ (3,200) Animal Health (8,068) (4,736) Consolidated Totals $ (12,009) $ (7,936) The Company's reportable segments assets consisted of the following: March 31, December 31, (in thousands) 2021 2020 (unaudited) Segment assets Human Health $ 37,064 $ 34,201 Animal Health 110,052 79,760 Total $ 147,116 $ 113,961 The reconciliation of segments assets to the consolidated assets is as follows: March 31, December 31, (in thousands) 2021 2020 (unaudited) Total assets for reportable segments $ 147,116 $ 113,961 Less: Investment in subsidiary (29,241) (29,241) Less: Intercompany loan (49,162) (41,877) Consolidated Totals $ 68,713 $ 42,843

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events
Subsequent Events	14. Subsequent Events Lease Agreement On April 6, 2021, the Company entered into an office lease agreement with M & E, LLC, a California Limited Liability Company, to lease approximately 10,526 square feet of office space located in San Francisco, California, inclusive of office space currently covered under the sublease agreement with Peacock Construction, Inc. The term of the lease will begin on September 1, 2021 and expires on August 31, 2024, unless earlier terminated. The base rent under the lease will be $42,000 monthly for the first 12 months, $43,000 monthly for the next 12 months and $45,000 for the last twelve months. Amendment to March 2020 ELOC On April 7, 2021, the Company entered into an amendment to the March 2020 ELOC with Oasis Capital, pursuant to which the parties agreed to increase (i) the purchase price from $0.436 to $3.00 and (ii) the threshold price from $0.5014 to $3.45. In consideration for Oasis Capital’s entry into the amendment, the Company issued Oasis Capital a common stock purchase warrant exercisable for 100,000 shares of Common Stock (“ELOC Warrant”) with an exercise price per share equal to $1.87 on the date of the amendment. Royalty Interest Exchange Agreement On April 13, 2021, the Company entered into an exchange agreement with Iliad, pursuant to which the parties agreed to partition a new royalty interest in the royalty repayment amount of $3.0 million from the October 2020 Purchase Agreement and then cause the outstanding balance of the royalty interest to be reduced by an amount equal to the initial outstanding balance of the partitioned royalty. The parties further agreed to exchange the partitioned royalty for 1,764,705 shares of the Company’s common stock. The exchange will consist of Iliad surrendering the partitioned royalty in exchange for the exchange shares. Other than the surrender of the partitioned royalty, no consideration of any kind whatsoever shall be given by Iliad to the Company in connection with the exchange agreement. Securities Purchase Agreement On April 29, 2021, the Company entered into a securities purchase agreement, pursuant to which the Company agreed to issue and sell, in a registered public offering through Ladenburg as the placement agent, an aggregate of 7,647,000 shares of common stock, par value $0.0001 per share, at an offering price of $1.41 per share for gross proceeds of approximately $10.8 million before deducting placement agent fees and related offering expenses of $995,000.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and on a basis consistent with the annual consolidated financial statements, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of the results to be expected for the year ending There has been no material change to the Company's significant accounting policies during the three months ended March 31, 2021, as compared to the significant accounting policies described in Note 2 of the “Notes to Consolidated Financial Statements” in the Company's Annual Report on Form 10-K as of and for the year ended December 31, 2020 which was filed to SEC on March 31, 2021. Except as noted above, the unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly the financial position as of March 31, 2021, results of operations for the three months ended March 31, 2021 and 2020, changes in convertible preferred stock and stockholders' equity for the three months ended March 31, 2021 and 2020, and cash flows for the three months ended March 31, 2021 and 2020. The interim results are not necessarily indicative of the results for any future interim periods or for the entire year.
Principles of Consolidation	Principles of Consolidation The unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and include the accounts of the Company and its wholly-owned subsidiary. All inter-company transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its unaudited condensed consolidated financial statements and the accompanying notes. The accounting policies that reflect the Company’s more significant estimates and judgments and that the Company believes are the most critical to aid in fully understanding and evaluating its reported financial results are the valuation of stock options, valuation of hybrid instruments designated at fair value option (“FVO”), valuation of warrant liabilities, acquired in-process research and development (“IPR&D”), and useful lives assigned to long-lived assets; valuation adjustments for excess and obsolete inventory; allowance for doubtful accounts; deferred taxes and valuation allowances on deferred tax assets; evaluation and measurement of contingencies; and recognition of revenue, including estimates for product returns. Those estimates could change, and as a result, actual results could differ materially from those estimates. In March 2020, the World Health Organization declared the COVID-19 outbreak to be a pandemic. During the period ended March 31, 2021, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it.
Cash and Restricted Cash	Cash and Restricted Cash Our cash on deposit may exceed United States federally insured limits at certain times during the year. We maintain cash accounts with certain major financial institutions in the United States. Restricted cash represents cash not available to us for immediate and general use. Amounts included in restricted cash primarily relate to security deposits and a letter of credit with a financial institution, both in connection with office space lease agreements.
Accounts Receivable	Accounts Receivable Accounts receivable is recorded net of allowances for discounts for prompt payment and credit losses. Accounts receivable is written off when it has been outstanding for two years or earlier when collection efforts have ceased. Prior to that, the Company estimates an allowance for credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The corresponding expense for the credit loss allowance is reflected in general and administrative expenses. The credit loss allowance was immaterial as of March 31, 2021 and 2020.
Concentrations	Concentrations Cash is the financial instrument that potentially subjects the Company to a concentration of credit risk as cash is deposited with a bank and cash balances are generally in excess of Federal Deposit Insurance Corporation insurance limits. For the three months ended March 31, 2021 and 2020, substantially all of the Company’s revenue was derived from the sale of Mytesi. In looking at sales by the Company to distributors whose net revenue percentage of total net revenue was equal to or greater than 10%, for the three months ended March 31, 2021, the Company earned Mytesi revenue primarily from two pharmaceutical distributors located in the United States. For the three months ended Three Months Ended March 31, (unaudited) 2021 2020 Customer 1 86 % 96 % Customer 2 10 % — % The Company is subject to credit risk from its accounts receivable related to its sales. The Company generally does not perform evaluations of customers' financial condition and generally does not require collateral. As of The Company is subject to concentration risk from its suppliers. The Company sources raw material used to produce the active pharmaceutical ingredient in Mytesi from two suppliers and is dependent on a single third-party contract manufacturer, both for the supply of the active pharmaceutical ingredient in Mytesi, as well as for the supply of finished products for commercialization.
Fair Value	Fair Value The Company’s financial instruments include accounts receivable, accounts payable, accrued liabilities, warrant liabilities, equity-linked financial instruments and debt. The recorded carrying amounts of accounts receivable, accounts payable and accrued liabilities reflect their fair value due to their short-term nature. Other financial liabilities are initially recorded at fair value, and subsequently measured at either fair value or amortized cost using the effective interest method. See Note 3 for the fair value measurements.
Fair Value Option	Fair Value Option ASC 825-10, Financial Instruments , provides FVO election that allows companies an irrevocable election to use fair value as the initial and subsequent accounting measurement attribute for certain financial assets and liabilities. ASC 825-10 permits entities to elect to measure eligible financial assets and liabilities at fair value on an ongoing basis. Unrealized gains and losses on items for which the FVO has been elected are reported in earnings. The decision to elect the FVO is determined on an instrument-by-instrument basis, must be applied to an entire instrument and is irrevocable once elected. Assets and liabilities measured at fair value pursuant to ASC 825-10 are required to be reported separately from those instruments measured using another accounting method. In accordance with the options presented in ASC 825-10, the Company elected to present the aggregate of fair value and non-fair-value amounts in the same line item in the condensed consolidated balance sheets and parenthetically disclose the amount measured at fair value in the aggregate amount.
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. Cost is initially recorded at the invoiced amount of raw materials or active pharmaceutical ingredient, including the sum of qualified expenditures and charges in bringing the inventory to its existing condition and location. The Company calculates inventory valuation adjustments when conditions indicate that net realizable value is less than cost due to physical deterioration, usage, obsolescence, reductions in estimated future demand or reduction in selling price. Inventory write-downs are measured as the difference between the cost of inventory and net realizable value.
Property and Equipment	Property and Equipment Land is stated at cost, reflecting the fair value of the property at July 31, 2017, the date of the Napo merger. Equipment is stated at cost, net of accumulated depreciation. Equipment begins to be depreciated when it is placed into service. Depreciation is calculated using the straight-line method over estimated useful lives ranging between 3 to 10 years. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Costs of major additions and betterments are capitalized and depreciated on a straight-line basis over their estimated useful lives. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in the unaudited condensed consolidated statements of operations.
Long-Lived Assets	Long-lived Assets The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist that warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives. Definite-lived intangible assets are amortized on a straight-line basis over the estimated periods benefited, and are reviewed when impairment indicators are identified.
Indefinite-lived Intangible Assets	Indefinite-lived Intangible Assets Acquired IPR&D are intangible assets acquired in the July 2017 Napo merger. Under ASC 805, IPR&D are initially recognized at fair value and classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. During the development period, these assets will not be amortized as charges to earnings; instead, these assets will be tested for impairment on an annual basis or more frequently if impairment indicators are identified. An impairment loss is measured based on the excess of the carrying amount over the asset’s fair value. The Company recorded no impairment in the three months ended March 31, 2021 and 2020.
Leases	Leases The Company accounts for its leases in accordance with ASC 842, Leases . The Company elected not to separate nonlease components from lease components and instead accounts for each separate lease component and the nonlease components associated with that lease component as a single lease component. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. Because the interest rate implicit in lease contracts is typically not readily determinable, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Operating Lease The Company had a non-cancelable operating lease with CA-Mission Street Limited Partnership for its offices in San Francisco, California, through September 30, 2020. The lease agreement called for monthly base rents between $38,000 and $41,000 over the term of the lease. The lease agreement was not renewed upon expiration. The Company entered into a sublease agreement with Peacock Construction Inc., a California corporation, for office space located in San Francisco, California. The term of the sublease began on August 31, 2020 and will expire on May 31, 2021, unless earlier terminated in accordance with the contract. The rent under the sublease is $15,000 per month beginning October 1, 2020, which includes operating expenses and taxes. On October 1, 2020, the Company transitioned its operations from its existing premises to the sublease premises, which the Company expects will serve as its principal administrative headquarters. In April 2021, The Company entered into a new office lease agreement (see Note 14). The Company elected not to apply the recognition requirements to short-term leases, and instead recognize the lease payments in profit or loss on a straight-line basis over the lease term. As a result, there was no right-of-use asset and lease liability recognized related to the sublease.
Research and Development Expense	Research and Development Expense Research and development expense consist of expenses incurred in performing research and development activities including related salaries, clinical trials and related drug and non-drug product costs, contract services and other outside service expenses. Research and development expense is charged to operating expense in the period incurred.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company’s policy typically permits returns if the product is damaged, defective, or otherwise cannot be used when received by the customer if the product has expired. Returns are accepted for product that will expire within six months or that have expired up to one year after their expiration dates. Estimates for expected returns of expired products are based primarily on an ongoing analysis of our historical return patterns. The Company recognizes revenue in accordance with the core principle of ASC 606 or when there is a transfer of control of promised goods or services to customers in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those goods or services. The Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. The Company does not adjust the amount of consideration for the effects of a significant financing component if, at contract inception, the expected period between the transfer of promised goods or services and customer payment is one year or less. The Company has elected to treat shipping and handling activities as fulfillment costs. Additionally, the Company elected to record revenue net of sales and other similar taxes. Contracts – Cardinal Health Effective January 16, 2019, the Company engaged Cardinal Health as its exclusive third-party logistics distribution agent for commercial sales of the Company’s Mytesi product and to perform certain other services which include, without limitation, storage, distribution, returns, customer support, financial support, Electronic Data Interchange (“EDI”) and system access support (the “Exclusive Distribution Agreement”). In addition to the terms and conditions of the Exclusive Distribution Agreement, Cardinal Health’s purchase of products, and assumption of title therein, is set forth in the Title Model Addendum. The Title Model Addendum states that upon receipt of product at the 3PL Facility (Cardinal Health in La Vergne, Tennessee) from the Company, title and risk of loss for the Mytesi product purchased by Cardinal Health (excluding consigned inventory) shall pass to Cardinal Health, and title and risk of loss for consigned inventory shall remain with the Company until purchased by Cardinal Health in accordance with the Title Model Addendum. The Company considers Cardinal Health the Company’s exclusive customer for Mytesi products per the Exclusive Distribution Agreement. The Company's Neonorm and botanical extract products are primarily sold to distributors, who then sell the products to the end customers. Since 2014, the Company has entered into several distribution agreements with established distributors such as Animart, Vedco, VPI, RJ Matthews, Covetrus, and Stockmen Supply to distribute the Company's products in the United States, Japan, and China. The distribution agreements and the related purchase order together meet the contract existence criteria under ASC 606‑10‑25‑1. The Company sells directly to its customers without the use of an agent. Performance obligations For animal products sold by the Company, the single performance obligation identified above is the Company’s promise to transfer the Company’s animal products to distributors based on specified payment and shipping terms in the arrangement. Product warranties are assurance type warranties that do not represent a performance obligation. For the Company’s human product, Mytesi, the single performance obligation identified above is the Company’s promise to transfer Mytesi to Cardinal Health, the Company’s exclusive distributor for the product, based on specified payment and shipping terms as outlined in the Exclusive Distribution Agreement. Transaction price For contracts with Cardinal Health, for the Company, the transaction price is the amount of consideration to which the Company expects to collect in exchange for transferring the promised goods or services. The transaction price of Mytesi and Neonorm is the Wholesaler Acquisition Cost (“WAC”), net of discounts, returns, and price adjustments. Allocate transaction price For contracts with Cardinal Health, for the Company, the entire transaction price is allocated to the single performance obligation contained in each contract. Revenue recognition For contracts with Cardinal Health, for the Company, a single performance obligation is satisfied at a point in time, upon the free on board (“FOB”) terms of each contract when control, including title and all risks, has transferred to the customer. Disaggregation of Product Revenue Human Sales of Mytesi are recognized as revenue at a point in time when the products are delivered to the wholesaler. Net revenues from the sale of Mytesi were $729,000 and $835,000 for the three months ended March 31, 2021 and 2020, respectively. Animal The Company recognized Neonorm revenues of $ Contracts – Specialty Pharmacies Effective October 1, 2020, the Company engaged a private company as its third-party logistics distribution agent for commercial sales of the Company’s Mytesi product. Under the Specialty Product Distribution Agreement, the Company shall supply the products to the private company’s specialty pharmacies, through a designated wholesaler, in such amounts as may be ordered. There is no minimum purchase or inventory requirement. The specialty pharmacies were authorized distributors of record for all National Drug Codes (“NDCs”) of Mytesi. Performance obligations The single performance obligation identified above is the Company’s promise to transfer Mytesi to specialty pharmacies, based on specified payment and shipping terms as outlined in the Specialty Product Distribution Agreement. Transaction price For contracts with the private company, for the Company, the transaction price is the amount of consideration to which the Company expects to collect in exchange for transferring the promised goods or services. The transaction price of Mytesi is the WAC, net of estimated discounts, returns, and price adjustments. Allocate transaction price For contracts with the private company, for the Company, the entire transaction price is allocated to the single performance obligation contained in each contract. Revenue recognition For contracts with the private company, for the Company, a single performance obligation is satisfied at a point in time, upon the free on board (“FOB”) terms of each contract when control, including title and all risks, has transferred to the customer. Disaggregation of Product Revenue Sales of Mytesi are recognized as revenue at a point in time when the products are delivered to the specialty pharmacies. Net revenue from the sale of Mytesi to the specialty pharmacies were $479,000 and zero for the three months ended March 31, 2021 and 2020, respectively.
Collaboration Revenue	Collaboration Revenue Revenue recognition for collaboration agreements requires significant judgment. The Company’s assessments and estimates are based on contractual terms, historical experience and general industry practice. Revisions in these values or estimations have the effect of increasing or decreasing collaboration revenue in the period of revision. On September 24, 2018, the Company entered into a Distribution, License and Supply Agreement (“License Agreement”) with Knight Therapeutics ("Knight"). The License Agreement has a term of 15 years (with automatic renewals) and provides Knight with an exclusive right to commercialize current and future Jaguar human health products (including crofelemer, Lechlemer, and any product containing a proanthocyanidin or with an anti-secretory mechanism) in Canada and Israel. Knight forfeited its right of first negotiation for expansion to Latin America. Under the License Agreement, Knight is responsible for applying for and obtaining necessary regulatory approvals in the territory of Canada and Israel, as well as marketing, sales and distribution of the licensed products. Knight will pay a transfer price for all licensed products, and upon achievement of certain regulatory and sales milestones, the Company may receive payments from Knight in an aggregate amount of up to approximately $18 million payable throughout the initial 15-year term of the agreement. The Company did not have any license revenues for the three months ended March 31, 2021 and 2020.
Modifications to Liability-classified Instruments	Modifications to Liability-classified Instruments In the three months ended March 31, 2021, the Company amended the terms of its Exchange Note 2 (see Note 7). In accounting for debt modifications and exchange transactions, it is the Company’s policy to first determine whether it qualifies as a troubled debt restructuring (“TDR”) pursuant to the guidance provided in ASC 470-60. A debt modification or exchange transaction that is not within the scope of the ASC 470-60 is accounted for under ASC 470-50 to determine if the transaction is a mere modification or an extinguishment. The Company did not modify any liability-classified instrument for the three months ended March 31, 2020.
Modifications to Equity-classified Instruments	Modifications to Equity-classified Instruments In the three months ended March 31, 2020, the Company modified certain equity-classified warrants (see Note 8). It is the Company’s policy to determine the impact of modifications to equity-classified warrants by analogy to the share-based compensation guidance of ASC 718, Compensation - Stock Compensation (“ASC 718”). The model for a modified share-based payment award that is classified as equity and remains classified in equity after the modification is addressed in ASC 718-20-35-3. Pursuant to that guidance, the incremental fair value from the modification is recognized as an expense in the statements of operations to the extent the modified instrument has a higher fair value; however, in certain circumstances, such as when an entire class of warrants are modified, the measured increase in fair value may be more appropriately recorded as a deemed dividend, depending upon the nature of the warrant modification. In the three months ended March 31, 2020, the Company modified the terms of its Series B convertible preferred stock (see Note 9). For amendments to preferred stock, it is the Company’s policy to measure the impact by analogy to ASC 470-50 in determining if such an amendment is an extinguishment or a modification. If the amendment results in an extinguishment, the Company follows the SEC staff guidance in ASC 260-10-S99-2 and ASC 470-20. If the amendment results in a modification, the Company follows the model in either ASC 718 or ASC 470-50, depending on the nature of the amendment. The Company did not modify any equity-classified instrument for the three months ended March 31, 2021.
Stock-Based Compensation	Stock-based Compensation The Company's stock incentive plans (see Note 11) provide for the grant of stock options, restricted stock and restricted stock unit awards. The Company measures stock awards granted to employees, non-employees and directors at fair value on the date of grant and recognizes the corresponding compensation expense of the awards, net of estimated forfeiture over the requisite service periods, which correspond to the vesting periods of the awards. The Company issues stock awards with only service-based vesting conditions, and records compensation expense for these awards using the straight-line method. The Company uses the grant date fair market value of its common stock to determine the grant date fair value of options granted to employees, non-employees and directors.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company has adopted the provisions of ASC 740, Income Taxes Related to Uncertain Tax Positions . Under these principals, tax positions are evaluated in a two-step process. The Company first determines whether it is more-likely-than-not that a tax position will be sustained upon examination. If a tax position meets the more-likely-than-not recognition threshold, it is then measured to determine the amount of benefit to be recognized in the financial statements. The tax position is measured as the largest amount of benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement.
Comprehensive Loss	Comprehensive Loss For all periods presented, the comprehensive loss was equal to the net loss; therefore, a separate statement of comprehensive loss is not included in the accompanying unaudited condensed consolidated financial statements.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the year by the weighted-average number of common shares outstanding during the year. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the year by the weighted-average number of common shares, including potential dilutive shares of common stock assuming the dilutive effect of potential dilutive securities. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, because the impact of the potential dilutive shares of common stock would be anti-dilutive to the calculation of net loss per common share. Diluted net loss per common share is the same as basic net loss per common share for the three months ended March 31, 2021 and 2020.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which is intended to simplify various aspects related to accounting for income taxes. The standard also removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. The Company adopted the standard on January 1, 2021. The adoption of this standard did not have a material effect on the Company’s unaudited condensed consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The main objective of the standard is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in this standard replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The update is effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is still evaluating the impact of the adoption of this standard. In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The pronouncement is effective for the Company beginning January 1, 2022 with early adoption permitted. The Company is still evaluating the impact of the adoption of this standard. In May 2021, the FASB issued ASU 2021-04, Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options – a consensus of the FASB Emerging Issues Task Force. The ASU provides a “principles-based framework to determine whether an issue should recognize the modification or exchange as an adjustment to equity or an expense. The amendments in the update is effective for all entities for fiscal years beginning January 1, 2022, including interim periods within those fiscal years with early adoption permitted. The Company is still evaluating the impact of the adoption of this standard.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Customer risk | Total net revenue
Schedule of concentration risk	Three Months Ended March 31, (unaudited) 2021 2020 Customer 1 86 % 96 % Customer 2 10 % — %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Measurements
Summary of information about the company's financial instruments that were measured at fair value on a recurring basis	March 31, 2021 (unaudited) (in thousands) Level 1 Level 2 Level 3 Total Warrant liability $ — $ — $ 12 $ 12 Streeterville note — — 6,452 6,452 Total fair value $ — $ — $ 6,464 $ 6,464 December 31, 2020 (in thousands) Level 1 Level 2 Level 3 Total Warrant liability $ — $ — $ 179 $ 179 Total fair value $ — $ — $ 179 $ 179
Summary of change in the estimated fair value of level 3 liabilities	Three Months Ended March 31, 2021 (unaudited) (in thousands) Warrant liability Streeterville note Beginning fair value of Level 3 liability $ 179 $ — Additions 1,462 6,000 Exercises (1,776) — Change in fair value 147 452 Ending fair value of Level 3 liability $ 12 $ 6,452
Summary of information about the significant unobservable inputs used in level 3 fair value measurements	Range of Inputs (probability-weighted average) Relationship of unobservable inputs Unobservable Inputs 2021 2020 to fair value Risk Adjusted Discount Rate 6.56% - 22% N/A Lower and higher discount rate (+/- 100 basis points) would insignificantly affect the amount of FV. Sales Proceeds: Amount of comparable TDPRV $67.5 million to $350.0 million ($100.0 million) N/A If expected cash flows by management considered the lowest amount of market indications for vouchers, FV would have decreased by $954,000. Range of Probability for Timing of Cash Flows: 0.39% - 39.78% N/A If expected cash flows by management considered the scenario with the least amount of indicated value, FV would have decreased by $211,000.
Summary of the fair value and unpaid principal balance for items the Company accounts for under FVO	(in thousands) Fair value Unpaid Principal Balance Fair Value Over (Under) Unpaid Prepaid Balance At March 31, 2021 Hybrid Instrument: Structured note (Streeterville note) $ 6,452 $ 6,000 $ 452

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2021
Balance Sheet Components
Schedule of inventory	March 31, December 31, (in thousands) 2021 2020 (unaudited) Raw Material $ 790 $ 1,321 Work in Process 1,478 1,026 Finished Goods 553 435 Inventory $ 2,821 $ 2,782
Schedule of property and equipment	March 31, December 31, (in thousands) 2021 2020 (unaudited) Land $ 396 $ 396 Lab equipment 424 418 Clinical equipment 65 65 Software 63 63 Total property and equipment at cost 948 942 Accumulated depreciation (274) (265) Property and equipment, net $ 674 $ 677
Schedule of intangible assets	March 31, December 31, (in thousands) 2021 2020 (unaudited) Developed technology $ 25,000 $ 25,000 Accumulated developed technology amortization (6,111) (5,694) Developed technology, net 18,889 19,306 In-process research and development 4,800 4,800 In process research and development, net 4,800 4,800 Trademarks 300 300 Accumulated trademark amortization (73) (69) Trademarks, net 227 231 Total intangible assets, net $ 23,916 $ 24,337
Schedule of estimated future amortization expense of intangible assets with finite lives	(in thousands) Amounts 2021 $ 1,265 2022 1,687 2023 1,687 2024 1,687 2025 1,687 Thereafter 11,103 $ 19,116

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Debt
Schedule of notes payable	March 31, December 31, (in thousands) 2021 2020 (unaudited) Royalty Interest $ 40,000 $ 30,000 Streeterville Note 6,452 — Tempesta Note 400 450 Umbrella Insurance Financing 98 — Oasis Secured Borrowing — 1,822 Exchange Note 2 — 1,525 Insurance Premium Financing — 95 46,950 33,892 Less: unamortized discount and debt issuance costs (21,289) (17,682) Note payable, net of discount $ 25,661 $ 16,210 Notes payable - non-current, net $ 24,230 $ 12,421 Notes payable - current, net $ 1,431 $ 3,789
Schedule of future maturities of notes payable	(in thousands) Amounts As of March 31, 2022 $ 1,431 2023 6,398 2024 15,851 2025 7,080 2026 8,150 2027 1,588 40,498 Less: unamortized discount and debt issuance costs (21,289) Total $ 19,209

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Warrants
Summary of warrant activity	March 31, December 31, 2021 2020 (unaudited) Warrants outstanding, beginning balance 7,205,454 19,421,892 Issuances 406,250 22,048,278 Exercises (6,021,350) (34,264,393) Expirations and cancelations — (323) Warrants outstanding, ending balance 1,590,354 7,205,454

Preferred Stock (Tables)

Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2021
Preferred Stock
Schedule of convertible preferred stock	At March 31, 2021 and December 31, 2020, preferred stock consisted of the following: Liquidation ( in thousands, except share and per share data) Shares Issued and Carrying Preference Series Authorized Outstanding Value per Share B-2 10,165 — $ — $ — C 1,011,000 — — 8.00 Total 1,021,165 — $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity
Schedule of common reserved shares of common stock for issuance	March 31, December 31, 2021 2020 (unaudited) Options issued and outstanding 4,449,398 4,456,748 Inducement options issued and outstanding 170,892 114,892 Options available for grant under stock option plans 6,355,104 596,597 Restricted stock unit awards issued and outstanding 5,613 5,613 Warrants issued and outstanding 1,590,354 7,205,454 Total 12,571,361 12,379,304

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Stock Based Compensation
Summary of incentive plan activity	Weighted Weighted Average Shares Stock Average Remaining Aggregate Available Options RSUs Stock Option Contractual Life Intrinsic (in thousands, except share and per share data) for Grant Outstanding Outstanding Exercise Price (Years) Value* Outstanding at December 31, 2020 596,597 4,571,566 5,613 $ 4.23 8.71 $ 364 Additional shares authorized 5,807,157 — — — — Options granted (70,000) 70,000 — 1.92 — Options exercised — — — — — Options canceled 21,350 (21,350) — 10.68 — Outstanding at March 31, 2021 6,355,104 4,620,216 5,613 $ 4.16 8.51 $ 1,808 Exercisable at March 31, 2021 2,623,013 $ 6.35 8.39 $ 686 Vested and expected to vest at 4,400,382 $ 4.31 8.49 $ 1,655 *Fair market value of JAGX common stock on March 31, 2021 was $1.80 per share.
Summary of stock-based compensation expense	Three Months Ended March 31, (in thousands) 2021 2020 (unaudited) Research and development expense $ 164 $ 202 Sales and marketing expense 52 56 General and administrative expense 418 502 Total $ 634 $ 760
Employee stock options
Stock Based Compensation
Schedule of estimated grant-date fair value of stock options calculated using the Black-Scholes option-pricing model	Three Months Ended March 31, 2021 2020 (unaudited) Volatility 163.8 - 164.0 % 150.1 % Expected term (years) 5.0 5.0 Risk-free interest rate 0.5 - 0.9 % 0.5 % Expected dividend yield — —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Net Loss Per Share
Schedule of calculation of basic and diluted net income (loss) per common share	Three Months Ended March 31, (In thousands, except share and per share data) 2021 2020 (unaudited) Net loss attributable to common shareholders (basic and diluted) $ (12,009) $ (8,416) Shares used to compute net loss per common share, basic and diluted 125,416,228 15,141,906 Net loss per share attributable to common shareholders, basic and diluted $ (0.10) $ (0.56)
Schedule of common stock equivalents excluded from the calculation of diluted net loss per common share	Three Months Ended March 31, 2021 2020 (unaudited) Options issued and outstanding 4,449,398 4,508,021 Inducement options issued and outstanding 170,892 74 Restricted stock units issued and outstanding 5,613 5,613 Warrants issued and outstanding 1,590,354 17,622,930 Series A convertible preferred stock — 473,565 Series B convertible preferred stock — 4,423,250 Series B-2 convertible preferred stock — 1,431,460 Total 6,216,257 28,464,913

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Information
Schedule of reportable segments net revenue and net loss	Three Months Ended March 31, (in thousands) 2021 2020 (unaudited) Revenue from external customers Human Health $ 1,208 $ 835 Animal Health 33 34 Consolidated Totals $ 1,241 $ 869 Segment net loss Human Health $ (3,941) $ (3,200) Animal Health (8,068) (4,736) Consolidated Totals $ (12,009) $ (7,936)
Schedule of reportable segments assets	March 31, December 31, (in thousands) 2021 2020 (unaudited) Segment assets Human Health $ 37,064 $ 34,201 Animal Health 110,052 79,760 Total $ 147,116 $ 113,961
Schedule of reconciliation of segments assets to the consolidated assets	March 31, December 31, (in thousands) 2021 2020 (unaudited) Total assets for reportable segments $ 147,116 $ 113,961 Less: Investment in subsidiary (29,241) (29,241) Less: Intercompany loan (49,162) (41,877) Consolidated Totals $ 68,713 $ 42,843

Organization and Business - (De

Organization and Business - (Details)	3 Months Ended
	Mar. 31, 2021segment
Organization and Business
Number of operations segments	2

Organization and Business - Liq

Organization and Business - Liquidity and Going Concern (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Organization and Business
Accumulated deficit	$ (178,908)	$ (166,899)
Cash	$ 35,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Accounts receivable and Concentrations (Details) - item	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Concentrations
Period of outstanding accounts receivable for write off	2 years
Supplier risk
Concentrations
Number of suppliers	2
Total net revenue | Customer risk | Major pharmaceutical distributors
Concentrations
Number of major distributors	2	1
Total net revenue | Customer risk | Customer 1
Concentrations
Concentration risk (as a percentage)	86.00%	96.00%
Total net revenue | Customer risk | Customer 2
Concentrations
Concentration risk (as a percentage)	10.00%
Total net revenue | Customer risk | Minimum | Customer 1
Concentrations
Concentration risk (as a percentage)	10.00%	10.00%
Total accounts receivable | Credit risk | Customer 1
Concentrations
Concentration risk (as a percentage)	92.00%	95.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Property and Equipment and Indefinite-lived Intangible Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Goodwill impairment charges
Impairment of indefinite-lived intangible assets	$ 0	$ 0
Napo | Equipment | Minimum
Goodwill
Estimated useful lives	3 years
Napo | Equipment | Maximum
Goodwill
Estimated useful lives	10 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Leases (Details) - USD ($)	Aug. 31, 2020	Mar. 31, 2021
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Monthly base rents		$ 38,000
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Monthly base rents		41,000
Office space sub lease
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sub lease rent	$ 15,000
Operating lease - right-of-use asset		0
Operating leases liabilities, current portion		$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Aug. 28, 2018
Disaggregation of Product Revenue
Practical Expedients, not disclose the value of unsatisfied performance obligations	true
Warrants to purchase (in shares)			9,580
Mytesi
Disaggregation of Product Revenue
Product revenue	$ 729,000	$ 835,000
Mytesi | Specialty Pharmacies
Disaggregation of Product Revenue
Product revenue	479,000	0
Neonorm
Disaggregation of Product Revenue
Product revenue	$ 33,000	$ 34,000

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Revenue Recognition - Collaboration Revenue (Details) - USD ($) $ in Thousands	Sep. 03, 2020	Sep. 24, 2018	Mar. 31, 2021	Mar. 31, 2020
Collaboration Revenue
License agreement term (in years)	2 years 6 months
Collaboration revenue			$ 0	$ 0
Knight
Collaboration Revenue
License agreement term (in years)		15 years
Transfer price receivable upon achievement of certain regulatory and sales milestones		$ 18,000

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Liabilities Measured on a Recurring Basis (Details) - USD ($)	Mar. 31, 2021	Jan. 13, 2021	Dec. 31, 2020	Jul. 23, 2019
Fair value of liabilities measured on a recurring basis
Warrant liability	$ 12,000		$ 179,000	$ 4,300,000
Fair value	6,452,000		0
Total fair value	6,464,000		179,000
Level 3
Fair value of liabilities measured on a recurring basis
Warrant liability	12,000		179,000
Total fair value	6,464,000		$ 179,000
Streeterville Note
Fair value of liabilities measured on a recurring basis
Fair value	6,452,000	$ 6,000,000
Streeterville Note | Level 3
Fair value of liabilities measured on a recurring basis
Fair value	$ 6,452

Fair Value Measurements - Estim

Fair Value Measurements - Estimated fair value of Level 3 (Details) - Level 3 - Recurring $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Warrant liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning fair value of Level 3 liability	$ 179
Additions	1,462
Exercises	(1,776)
Change in fair value	147
Ending fair value of level 3 liability	12
Streeterville Note
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Additions	6,000
Change in fair value	452
Ending fair value of level 3 liability	$ 6,452

Fair Value Measurements - Est_2

Fair Value Measurements - Estimated Fair Value of Warrant Liability (Details)	Jan. 08, 2021shares	Jul. 21, 2020USD ($)shares	Jan. 31, 2021USD ($)shares	May 31, 2020$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / shares	Apr. 30, 2020$ / shares	Jul. 23, 2019$ / shares
Series A Warrants
Fair Value Assumptions and Methodology for Assets and Liabilities
Change in fair value					$ 0
Series A Warrants | Stock price
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability | $ / shares					1.80	0.82
Series A Warrants | Strike price
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability | $ / shares					787.50	787.50
Series A Warrants | Expected life
Fair Value Assumptions and Methodology for Assets and Liabilities
Weighted-average expected term (years)					1 year 1 month 28 days	1 year 4 months 28 days
Series A Warrants | Volatility
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability					184	148
Series A Warrants | Risk free rate
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability					0.16	0.13
Series 3 warrants
Fair Value Assumptions and Methodology for Assets and Liabilities
Weighted-average expected term (years)				5 years
Number of warrants purchase common stock exchanged | shares	406,250			4,005,062
Warrants exercised | shares		8,456,352			620,750
Warrants conversion | shares				1
Aggregate fair value of the common stocks issued by the exercise of Warrants		$ 6,100,000			$ 1,800,000
Series 3 warrants | Stock price
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability | $ / shares				0.05		0.82
Series 3 warrants | Strike price
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability | $ / shares				0.44		0
Series 3 warrants | Expected life
Fair Value Assumptions and Methodology for Assets and Liabilities
Weighted-average expected term (years)				5 years 6 months		4 years 10 months 21 days
Series 3 warrants | Volatility
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability				141		142
Series 3 warrants | Risk free rate
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability				0.34		0.36
Underwriter Warrants | Stock price
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability | $ / shares					1.80	0.82	2.50
Underwriter Warrants | Strike price
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability | $ / shares					52.50	52.50	0.45
Underwriter Warrants | Expected life
Fair Value Assumptions and Methodology for Assets and Liabilities
Weighted-average expected term (years)					2 years 6 months	2 years 9 months 4 days	4 years 3 months
Underwriter Warrants | Volatility
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability					169	156	141
Underwriter Warrants | Risk free rate
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability					0.35	0.17	0.29
2019 Bridge Note Warrants
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrants exercised | shares	406,250
2019 Bridge Note Warrants | Strike price
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability | $ / shares								2
2019 Bridge Note Warrants | Expected life
Fair Value Assumptions and Methodology for Assets and Liabilities
Weighted-average expected term (years)								4 years 9 months 18 days
2019 Bridge Note Warrants | Volatility
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability								145.84
2019 Bridge Note Warrants | Risk free rate
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability								1.76
Warrant liability | Recurring | Level 3
Fair Value Assumptions and Methodology for Assets and Liabilities
Fair value of warrant					$ 12,000	$ 179,000
Change in fair value					147,000
Warrant liability | Series A Warrants
Fair Value Assumptions and Methodology for Assets and Liabilities
Fair value of warrant					0	$ 0
Warrant liability						0
Warrant liability | Series 3 warrants
Fair Value Assumptions and Methodology for Assets and Liabilities
Fair value of warrant					0	$ 175,000
Change in fair value					$ 139,000
Number of warrants purchase common stock exchanged | shares			406,250
Warrants exercised | shares					620,750
Warrants conversion | shares					1
Aggregate fair value of the common stocks issued by the exercise of Warrants			$ 1,500,000		$ 1,800,000
Warrant liability | Underwriter Warrants
Fair Value Assumptions and Methodology for Assets and Liabilities
Fair value of warrant					12,000	$ 4,000
Change in fair value					$ 8,000
Warrant liability | 2019 Bridge Note Warrants
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrants exercised | shares			406,250

Fair Value Measurements - Stree

Fair Value Measurements - Streeterville Note (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Jan. 13, 2021	Dec. 31, 2020
Fair value of liabilities measured on a recurring basis
Fair value	$ 6,452		$ 0
Streeterville Note
Fair value of liabilities measured on a recurring basis
Fair value	$ 6,452	$ 6,000

Fair Value Measurements - Quant

Fair Value Measurements - Quantitative information about the significant unobservable inputs (Details) - Level 3	3 Months Ended
	Mar. 31, 2021USD ($)
Risk Adjusted Discount Rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Probability (as a percent)	6.56
Risk Adjusted Discount Rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Probability (as a percent)	22
Risk Adjusted Discount Rate | Weighted average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Probability (as a percent)	21.09
Sale Proceeds | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Amount of comparable TDPRV	$ 67,500,000
Fair value increase (decrease)	(954,000)
Sale Proceeds | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Amount of comparable TDPRV	350,000,000
Fair value increase (decrease)	7,300,000
Sale Proceeds | Weighted average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Amount of comparable TDPRV	$ 100,000,000
Timing of Cash Flows | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Probability (as a percent)	0.39
Fair value increase (decrease)	$ (211,000)
Timing of Cash Flows | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Probability (as a percent)	39.78
Fair value increase (decrease)	$ 2,000,000

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Value Option - Hybrid Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value Measurements
Fair value	$ 6,452	$ 0
Unpaid Principal Balance	6,000
Fair Value Over (Under) Unpaid Prepaid Balance	$ 452

Balance Sheet Components - Inve

Balance Sheet Components - Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory, Gross [Abstract]
Raw Material	$ 790	$ 1,321
Work in Process	1,478	1,026
Finished Goods	553	435
Inventory	$ 2,821	$ 2,782

Balance Sheet Components - Prop

Balance Sheet Components - Property and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Land, Property and Equipment
Total property and equipment at cost	$ 948,000		$ 942,000
Accumulated depreciation	(274,000)		(265,000)
Property and equipment, net	674,000		677,000
Depreciation and amortization expense	431,000	$ 432,000
Depreciation and amortization expense	9,000	$ 10,000
Land
Land, Property and Equipment
Total property and equipment at cost	396,000		396,000
Lab equipment
Land, Property and Equipment
Total property and equipment at cost	424,000		418,000
Clinical equipment
Land, Property and Equipment
Total property and equipment at cost	65,000		65,000
Software
Land, Property and Equipment
Total property and equipment at cost	$ 63,000		$ 63,000

Balance Sheet Components - Inta

Balance Sheet Components - Intangible assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Intangible assets
Impairment	$ 0	$ 0
Finite-lived intangible assets, net	19,116,000
Total intangible assets, net	23,916,000		$ 24,337,000
Amortization expense	422,000	$ 422,000
Developed technology
Intangible assets
Total intangible assets	25,000,000		25,000,000
Accumulated amortization	(6,111,000)		(5,694,000)
Finite-lived intangible assets, net	18,889,000		19,306,000
In process research and development
Intangible assets
Total intangible assets	4,800,000		4,800,000
Finite-lived intangible assets, net	4,800,000		4,800,000
Trademarks
Intangible assets
Total intangible assets	300,000		300,000
Accumulated amortization	(73,000)		(69,000)
Finite-lived intangible assets, net	$ 227,000		$ 231,000

Balance Sheet Components - Esti

Balance Sheet Components - Estimated future amortization expense (Details) $ in Thousands	Mar. 31, 2021USD ($)
Balance Sheet Components
2021	$ 1,265
2022	1,687
2023	1,687
2024	1,687
2025	1,687
Thereafter	11,103
Finite-lived intangible assets, net	$ 19,116

Related Party Transactions - Ma

Related Party Transactions - Management Services Agreement (Details) - Sagard Capital Partners, L.P. - USD ($)	Sep. 01, 2020	Mar. 31, 2018	Mar. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Consulting and management advisory services fees		$ 450,000
Maximum aggregate payments for consulting and management advisory services received		$ 1,400,000
Issuance of common stock in exchange for services (in shares)	2,289,474
Accrued consulting and management fees	$ 1,100,000
Management fee incurred			$ 0	$ 112,500
Payable amount			$ 0	$ 0

Related Party Transactions - Le

Related Party Transactions - Letter of Credit (Details) - USD ($)	Mar. 24, 2020	Aug. 28, 2018	Oct. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Mar. 18, 2019
Related party Transactions
Standby letter of credit received as collateral		$ 475,000
Principal amount					$ 350,000		$ 5,100,000
Letter of credit | Dr. A. Conte
Related party Transactions
Principal amount	$ 475,000
Consideration	10,000
Expenses reimbursable				$ 0		$ 0
Payment of additional consideration			$ 7,000	0	$ 0
Payable amount				$ 0		$ 0
Letter of credit | Maximum | Dr. A. Conte
Related party Transactions
Expenses reimbursable	7,500
Payable amount	$ 7,500

Commitments and Contingencies -

Commitments and Contingencies - Commitments (Details)	Sep. 03, 2020kg	Aug. 31, 2020USD ($)ft²	Aug. 28, 2018USD ($)ft²shares	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Commitments and Contingencies
Monthly base rent for first twelve months			$ 38,000
Monthly base rent for subsequent twelve months			40,000
Monthly base rent for final months			41,000
Standby letter of credit received as collateral			$ 475,000
Term			5 years
Warrants to purchase (in shares) | shares			9,580
Fair value of warrants included in stockholders equity			$ 494,000
Lease liabilities				$ 30,000
License agreement term (in years)	2 years 6 months
Agreement extension term	2 years
Minimum
Commitments and Contingencies
Lease expense under non-cancelable operating lease				38,000
General and administrative expense
Commitments and Contingencies
Lease expense under non-cancelable operating lease				45,000	$ 191,000
Office lease extension agreement
Commitments and Contingencies
Area (in square feet) | ft²			6,311
Office space sub lease
Commitments and Contingencies
Area (in square feet) | ft²		5,263
Sub lease rent		$ 15,000
Manufacturing and Supply Agreement with Glenmark Life Sciences Limited [Member]
Commitments and Contingencies
License termination term option	12 months
License termination activated upon written notice of material breach of Agreement	90 days
Manufacturing and Supply Agreement with Glenmark Life Sciences Limited [Member] | Minimum
Commitments and Contingencies
Number of kilograms of crofelemer per year per agreement | kg	300
Master Services Agreement With Integrium LLC, 2019
Commitments and Contingencies
Lease liabilities				86,000
Master Services Agreement With Integrium LLC, 2020
Commitments and Contingencies
Lease liabilities				$ 11,800,000

Commitments and Contingencies_2

Commitments and Contingencies - Master Services Agreement and Angel Pond Agreement (Details) $ in Millions	Oct. 05, 2020USD ($)
2020 MSA | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Consideration payable on achievement of milestones	$ 12.4

Commitments and Contingencies_3

Commitments and Contingencies - Asset Transfer and Transition Commitment Update (Details) $ in Millions	Sep. 25, 2017USD ($)
Commitments and Contingencies
Percentage of amount received to be paid to Glenmark	25.00%
Maximum amount to be received by Glenmark	$ 7
Payments made to date to Glenmark	$ 0

Commitments and Contingencies_4

Commitments and Contingencies - Revenue Sharing Commitment Update and Legal Proceedings (Details) - USD ($) $ in Millions	Aug. 02, 2019	Dec. 14, 2017	Mar. 31, 2021
Long-term Purchase Commitment [Line Items]
Payments made to date to SEED			$ 0
Damages awarded	$ 2.6
SEED
Long-term Purchase Commitment [Line Items]
Percentage of revenue sharing commitment		15.00%
Percentage of revenue sharing commitment after first million dollars of revenue		20.00%

Commitments and Contingencies_5

Commitments and Contingencies - Settlement of Underwriter Fee (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Aug. 31, 2018	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Aug. 28, 2018
Number of pre-funded warrants issued		406,250	22,048,278
Convertible preferred stock						9,580
Underwriter
Underwriters settlement fee	$ 387,000
Payments of underwriters settlement fee			$ 185,000	$ 202,000
Number of pre-funded warrants issued					1,096
Convertible preferred stock			100,780
Exercise price (in dollars per share)			$ 2.50
Issuance of common stock (In shares)			100,000
Amount of shares issued			$ 45,000

Debt - Notes Payable (Details)

Debt - Notes Payable (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Oct. 31, 2019
Notes payable
Principal amount			$ 500,000
Notes payable, net of discount			$ 150,000
Notes payable - non-current, net	$ 24,230,000	$ 12,421,000
Notes payable - current, net	1,431,000	3,789,000
Notes payable
Notes payable
Principal amount	46,950,000	33,892,000
Less: unamortized discount and debt issuance costs	(21,289,000)	(17,682,000)
Notes payable, net of discount	25,661,000	16,210,000
Notes payable - non-current, net	24,230,000	12,421,000
Notes payable - current, net	1,431,000	3,789,000
Royalty Interest | Notes payable
Notes payable
Principal amount	40,000,000	30,000,000
Streeterville Note | Notes payable
Notes payable
Principal amount	6,452,000
Tempesta Note Payable
Notes payable
Principal amount				$ 550,000
Tempesta Note Payable | Notes payable
Notes payable
Principal amount	400,000	450,000
Oasis Secured Borrowing | Notes payable
Notes payable
Principal amount		1,822,000
2019 Exchange Note 2 | Notes payable
Notes payable
Principal amount		1,525,000
Insurance Premium Financing
Notes payable
Notes payable, net of discount	0	95,000
Insurance Premium Financing | Notes payable
Notes payable
Principal amount		$ 95,000
Umbrella Insurance Financing | Notes payable
Notes payable
Principal amount	$ 98,000

Debt - Notes Payable - Future M

Debt - Notes Payable - Future Maturities (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Years ended March 31,
Notes payable, net of discount			$ 150,000
Notes payable
Years ended March 31,
Less: unamortized discount and debt issuance costs	$ (21,289,000)	$ (17,682,000)
Notes payable, net of discount	25,661,000	$ 16,210,000
Future maturities of the notes payable not designated at FVO
Years ended March 31,
2022	1,431,000
2023	6,398,000
2024	15,851,000
2025	7,080,000
2026	8,150,000
2027	1,588,000
Total	40,498,000
Less: unamortized discount and debt issuance costs	(21,289,000)
Notes payable, net of discount	$ 19,209,000

Debt - Sale of Future Royalty I

Debt - Sale of Future Royalty Interest (Details) - USD ($)

Mar. 08, 2021

Dec. 22, 2020

Dec. 10, 2020

Nov. 13, 2020

Oct. 08, 2020

Jul. 10, 2020

Nov. 30, 2020

Oct. 31, 2020

Mar. 31, 2020

Mar. 31, 2021

Jan. 13, 2021

Dec. 31, 2020

Debt Instrument [Line Items]

Percentage of net sales

10.00%

Percentage of worldwide revenues

10.00%

Royalty discount rate

105.00%

Tempesta Note Payable

Debt Instrument [Line Items]

Carrying value of notes

$ 400,000

$ 450,000

Streeterville Note

Debt Instrument [Line Items]

Aggregate purchase price

$ 6,000,000

Beginning on March 2021

Debt Instrument [Line Items]

Increase in Royalty Repayment, Percent

5.00%

Purchase Agreement

Debt Instrument [Line Items]

Aggregate purchase price

$ 5,000,000

March 2021 Purchase Agreement

Debt Instrument [Line Items]

Royalty interest

$ 500,000

Payments for Royalties

$ 283,000

Royalty payments due

$ 0

$ 6,000,000

Percentage of net sales

10.00%

10.00%

Percentage of worldwide revenues

10.00%

10.00%

Carrying value of notes

$ 5,000,000

Interest expense

62,000

Percentage of royalties collected from licenses

50.00%

Shares issued to Iliad in exchange of Royalty Interest (in shares)

1,314,974

Royalty Instrument, Debt Instrument Carrying Value

0

March 2021 Purchase Agreement | Beginning on September 4, 2020

Debt Instrument [Line Items]

Minimum monthly royalty repayment amount

25,000

March 2021 Purchase Agreement | Beginning on March 4, 2021

Debt Instrument [Line Items]

Minimum monthly royalty repayment amount

$ 44,000

March 2021 Purchase Agreement | Beginning on March 2021

Debt Instrument [Line Items]

Royalty interest

$ 10,000,000

Royalty discount

$ 5,000,000

Royalty discount rate

19.36%

19.36%

Increase in Royalty Repayment, Percent

10.00%

Royalty Instrument, Debt Instrument Carrying Value

$ 600,000

March 2021 Purchase Agreement | Beginning On April 2021

Debt Instrument [Line Items]

Minimum monthly royalty repayment amount

250,000

March 2021 Purchase Agreement | Beginning On October 2021

Debt Instrument [Line Items]

Minimum monthly royalty repayment amount

400,000

October 2020 Purchase Agreement

Debt Instrument [Line Items]

Royalty interest

$ 12,000,000

Aggregate purchase price

$ 6,000,000

Percentage of net sales

10.00%

Minimum Volume Weighted Average Price

$ 0.3035

$ 0.3035

Carrying value of notes

$ 7,300,000

6,300,000

Interest expense

$ 1,100,000

Royalty discount rate

45.42%

45.42%

Royalty Instrument, Debt Instrument Carrying Value

$ 6,000,000

October 2020 Purchase Agreement | Beginning On October 2020

Debt Instrument [Line Items]

Minimum monthly royalty repayment amount

$ 750,000

October 2020 Purchase Agreement | Beginning On April 2021

Debt Instrument [Line Items]

Minimum monthly royalty repayment amount

$ 250,000

October 2020 Purchase Agreement | Beginning On October 2021

Debt Instrument [Line Items]

Minimum monthly royalty repayment amount

400,000

October 2020 Purchase Agreement | Beginning On April 2022

Debt Instrument [Line Items]

Minimum monthly royalty repayment amount

600,000

October 2020 Purchase Agreement | Beginning On October 2022

Debt Instrument [Line Items]

Minimum monthly royalty repayment amount

750,000

December 2020 Purchase Agreement

Debt Instrument [Line Items]

Royalty interest

$ 12,000,000

12,000,000

Aggregate purchase price

$ 6,000,000

$ 6,000,000

Percentage of net sales

10.00%

Percentage of worldwide revenues

10.00%

Minimum monthly royalty repayment amount

$ 750,000

Carrying value of notes

$ 6,300,000

$ 6,000,000

Interest expense

$ 664,000

Royalty discount rate

23.70%

34.51%

23.70%

Royalty Instrument, Debt Instrument Carrying Value

$ 6,000,000

Debt - Streeterville Note (Deta

Debt - Streeterville Note (Details)	Jan. 13, 2021USD ($)	Jul. 01, 2020	Jan. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Oct. 31, 2019USD ($)shares	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)	Mar. 18, 2019USD ($)
Debt
Principal amount				$ 350,000			$ 350,000		$ 5,100,000
Proceeds from issuance of notes payable, net of issuance costs of $50						$ 10,975,000	350,000
Long-term Debt, Gross						6,000,000
Convertible Notes Payable Gross				500,000			500,000
Maximum aggregate redemption amount				500,000
Principal less discount				$ 500,000			500,000
Loss on extinguishment of debt			$ (753,000)			753,000
Cash proceeds						10,975,000	$ 350,000
Fair value						6,452,000		$ 0
Streeterville Note
Debt
Principal amount	$ 6,200,000
Proceeds from issuance of notes payable, net of issuance costs of $50						$ 6,000,000
Debt Instrument, Term	4 years
Percentage of Return Bonus Payable		1
Percentage of Reduction in Return Bonus			1
Interest rate (as a percent)	3.25%
Term for Initiation of Human Trials			6 months
Percentage of Outstanding Balance Payable the Company Elects to Prepay						112.50
Capped percentage of aggregate default	25.00%
Cash proceeds						$ 6,000,000
Transaction expense						25,000
Fair value						6,500,000
Net increase in the Fair value recorded as loss						$ 452,000
Streeterville Note | Maximum
Debt
Percentage of Gross Proceeds Received from Return Bonus						18
Interest rate (as a percent)	18.00%
Percentage of default effect	15.00%
Streeterville Note | Minimum
Debt
Interest rate (as a percent)						1.00%
Percentage of default effect	5.00%
Tempesta Note Payable
Debt
Principal amount					$ 550,000
Interest rate (as a percent)					2.50%
Convertible Notes Payable Gross					$ 550,000
Principal less discount					$ 550,000
Common stock issued in exchange of debt | shares					40,000
Carrying value of notes						$ 400,000		$ 450,000
Accounts Receivable Purchase Agreement | Streeterville Note
Debt
Interest rate (as a percent)	25.00%

Debt - 2019 Tempesta Notes (Det

Debt - 2019 Tempesta Notes (Details) - USD ($)	1 Months Ended
	Oct. 31, 2019	Mar. 31, 2020	Mar. 18, 2019
Debt Instrument [Line Items]
Principal amount		$ 350,000	$ 5,100,000
Principal amount		$ 500,000
Tempesta Note Payable
Debt Instrument [Line Items]
Cash received in the settlement	$ 50,000
Principal amount	$ 550,000
Common stock issued in exchange of debt	40,000
Interest rate (as a percent)	2.50%
Semi-annual principal and interest payments	$ 50,000
Principal amount	$ 550,000

Debt - Umbrella Insurance Finan

Debt - Umbrella Insurance Financing and Insurance Premium Financing (Details) - USD ($)	1 Months Ended
	Mar. 31, 2021	May 31, 2020	Dec. 31, 2020	Mar. 31, 2020	Mar. 18, 2019
Short-term Debt [Line Items]
Principal amount				$ 350,000	$ 5,100,000
Financing balance	$ 6,000,000
Outstanding balance				$ 150,000
Insurance Premium Financing
Short-term Debt [Line Items]
Principal amount		$ 873,000
Debt term		9 months
Interest rate (as a percent)		4.15%
Outstanding balance	0		$ 95,000
Umbrella Insurance Financing
Short-term Debt [Line Items]
Principal amount	98,000
Unpaid balance	115,000
Interest expense	$ 2,000
Debt term	10 months
Interest rate (as a percent)	4.60%
Financing balance	$ 98,000

Debt - Oasis Secured Borrowing

Debt - Oasis Secured Borrowing (Details) - USD ($)	Mar. 08, 2021	Jan. 13, 2021	Feb. 28, 2021	Dec. 31, 2020	Nov. 30, 2020	Oct. 31, 2020	Sep. 30, 2020	Aug. 31, 2020	Jun. 30, 2020	May 31, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 18, 2019
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Accounts Receivable, Net, Current				$ 2,098,000							$ 2,098,000	$ 5,897,000
Debt Instrument, Face Amount													$ 350,000	$ 5,100,000
Streeterville Note
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Interest rate (as a percent)		3.25%
Debt Instrument, Face Amount		$ 6,200,000
Oasis Capital | Oasis Secured Note - Tranche1
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Transaction fee										$ 25,000,000
Cash proceeds										1,000,000
Accounts receivable gross										2,800,000
Accumulated chargebacks and discounts on accounts receivable										1,100,000
Accounts receivable derecognized										1,700,000
Purchase price										1,200,000
Principal amount										1,000,000
Short Term Debt, Gross										1,200,000
Discount on debt										$ 175,000
Effective interest rate										147.90%
Oasis Capital | Oasis Secured Note Tranche 2
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Proceeds from receivables, Gross									$ 1,200,000
Accounts Receivable, Net, Current									1,700,000
Accounts receivable gross									2,800,000
Accumulated chargebacks and discounts on accounts receivable									1,100,000
Threshold price							$ 1,400,000
Principal amount									1,200,000
Short Term Debt, Gross									1,400,000
Discount on debt									$ 156,000
Effective interest rate									77.70%
Oasis Capital | Oasis Secured Note Tranche 3
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Proceeds from receivables, Gross								$ 1,300,000
Accounts Receivable, Net, Current								1,900,000
Accounts receivable gross								3,100,000
Accumulated chargebacks and discounts on accounts receivable								1,200,000
Threshold price						$ 1,500,000
Principal amount								1,300,000
Short Term Debt, Gross								1,500,000
Discount on debt								$ 177,000
Interest rate (as a percent)								125.60%
Oasis Capital | Oasis Secured Note Tranche 4
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Proceeds from receivables, Gross							985,000
Accounts Receivable, Net, Current							1,400,000
Accounts receivable gross							2,300,000
Accumulated chargebacks and discounts on accounts receivable							920,000
Threshold price					$ 1,100,000
Principal amount							1,100,000
Discount on debt							$ 132,000
Effective interest rate							98.40%
Oasis Capital | Oasis Secured Note Tranche 5
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Proceeds from receivables, Gross						895,000
Accounts Receivable, Net, Current						1,200,000
Accounts receivable gross						2,100,000
Accumulated chargebacks and discounts on accounts receivable						955,000
Threshold price				1,000,000
Principal amount						895,000
Short Term Debt, Gross						1,000,000
Discount on debt						$ 120,000
Effective interest rate						90.20%
Oasis Capital | Oasis Secured Note Tranche 6
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Proceeds from receivables, Gross				1,600,000
Accounts Receivable, Net, Current				2,200,000							2,200,000
Accounts receivable gross				3,800,000							3,800,000
Accumulated chargebacks and discounts on accounts receivable				1,600,000							1,600,000
Threshold price			$ 1,800,000	1,800,000							1,800,000
Principal amount				1,600,000							1,600,000
Short Term Debt, Gross				1,800,000							1,800,000
Discount on debt				$ 213,000							$ 213,000
Effective interest rate				128.40%							128.40%
Beginning on March 2021
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Shortfall restoration period	30 days
Accounts Receivable Purchase Agreement | Streeterville Note
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Transaction fee		$ 25,000,000
Interest rate (as a percent)		25.00%
Accounts Receivable Purchase Agreement | Oasis Capital
Convertible Promissory Notes and Common Stock Warrants [Line Items]
First purchase price (in percent)										37.50%
Subsequent purchase price (in percent)										42.50%
Face amount of purchased account multiplier										0.0545
Overage amount return period										5 days
Shortfall restoration period										30 days
Additional accounts receivable (in percent)										25.00%
Agreement renewal term										1 year
Non renewal notice period before expiration										30 days
Notice period for termination Of agreement										60 days
Transaction fee										$ 25,000,000
Additional transaction fee										$ 5,000,000
Purchase Agreement
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Threshold price	$ 10,000,000

Debt - 2019 Exchange Notes (Det

Debt - 2019 Exchange Notes (Details)	1 Months Ended				3 Months Ended
	Jan. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)shares	Sep. 30, 2020USD ($)$ / sharesshares	May 31, 2019USD ($)item	Mar. 31, 2021USD ($)shares	Mar. 31, 2020USD ($)	Mar. 18, 2019USD ($)
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Principal amount						$ 350,000	$ 5,100,000
Gains (Losses) on Extinguishment of Debt	$ 753,000				$ (753,000)
Convertible Notes Payable Gross						$ 500,000
Loss on extinguishment of debt	(753,000)				$ 753,000
Series D perpetual preferred stock
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Gains (Losses) on Extinguishment of Debt		$ (1,300,000)
Shares issued (in shares) | shares			842,500
Preferred stock dividend rate (as a percent)			8.00%
Preferred stock dividend payable in arrears			24 months
Fair Value of Stock, Inception			$ 6,400,000
Preferred Stock Redemption Price | $ / shares			$ 8
Shares issued on conversion | shares		15,889,871
Shares converted | shares		859,348
Loss on extinguishment of debt		$ 1,300,000
Outstanding | shares		0			0
Series D perpetual preferred stock | Minimum
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Effective interest rate			12.00%
Series D perpetual preferred stock | Maximum
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Effective interest rate			15.00%
Global amendment agreement
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Increase in principal debt (in percent)			5.00%
Increase in principal debt			$ 2,600,000
Incremental value of cash flows			228,000
December 2020 Purchase Agreement
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Principal amount		$ 1,000,000
Exchange Notes
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Number of Napo convertible notes | item				2
2019 Exchange Note 1
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Common stock issued in exchange of debt | shares		20,221,724
Convertible debt payable		$ 0
Debt Conversion, Converted Instrument, Shares Issued | shares		20,221,724
Gains (Losses) on Extinguishment of Debt		$ (560,000)
Share issued for principal and interest payment | shares		20,221,724
Loss on extinguishment of debt		$ 560,000
2019 Exchange Note 2
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Principal amount	$ 1,800,000	$ 1,000,000		$ 2,300,000
Interest rate (as a percent)		10.00%		10.00%
Common stock issued in exchange of debt | shares	1,413,606	1,250,000
Convertible debt payable		$ 1,400,000			$ 0
Principal amount of exchange note		$ 5,000,000
Debt Conversion, Converted Instrument, Shares Issued | shares	1,413,606	1,250,000
Share issued for principal and interest payment | shares	1,413,606	1,250,000
2019 Exchange Note 2 | Series D perpetual preferred stock
Convertible Promissory Notes and Common Stock Warrants [Line Items]
Convertible debt payable			$ 0

Warrants - Warrants outstanding

Warrants - Warrants outstanding and exercisable (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Warrants
Warrants outstanding, beginning balance	7,205,454	19,421,892
Issuances	406,250	22,048,278
Exercises	(6,021,350)	(34,264,393)
Expirations and cancelations		(323)
Warrants outstanding, ending balance	1,590,354	7,205,454

Warrants - Ladenburg Warrants (

Warrants - Ladenburg Warrants (Details)

Jan. 08, 2021shares

Jul. 21, 2020USD ($)shares

Jul. 23, 2019USD ($)$ / sharesshares

May 31, 2020USD ($)$ / sharesitemshares

Feb. 29, 2020shares

Mar. 31, 2019USD ($)$ / sharesshares

Mar. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)$ / sharesshares

Apr. 30, 2020USD ($)$ / sharesshares

Dec. 31, 2019shares

Oct. 31, 2018$ / sharesshares

Aug. 28, 2018shares

Warrants

Warrants exercisable

2,781,250

208,022

Warrants to purchase (in shares)

9,580

Fair value of warrants | $

$ 4,300,000

$ 12,000

$ 179,000

Warrant liability | $

$ 12,000

$ 179,000

Warrants outstanding

1,590,354

7,205,454

19,421,892

Series A Warrants | Stock price

Warrants

Warrants - Measurement input | $ / shares

1.80

0.82

Series A Warrants | Strike price

Warrants

Warrants - Measurement input | $ / shares

787.50

787.50

Series A Warrants | Expected life

Warrants

Term of warrant

1 year 1 month 28 days

1 year 4 months 28 days

Series A Warrants | Volatility

Warrants

Warrants - Measurement input

184

148

Series A Warrants | Risk free rate

Warrants

Warrants - Measurement input

0.16

0.13

Series 3 warrants

Warrants

Warrants to purchase (in shares)

8,670,852

Exercise price (in dollars per share) | $ / shares

$ 0.53

Warrants exercisable period

6 months

Term of warrant

5 years

Contingent settlement methods | item

2

Warrants conversion

1

Warrant liability | $

$ 3,700,000

Warrants exercised

8,456,352

620,750

Number of warrants purchase common stock exchanged

406,250

4,005,062

Warrants outstanding

0

214,500

Aggregate fair value of the common stocks issued by the exercise of Warrants | $

$ 6,100,000

$ 1,800,000

Series 3 warrants | Stock price

Warrants

Warrants - Measurement input | $ / shares

0.05

0.82

Series 3 warrants | Strike price

Warrants

Warrants - Measurement input | $ / shares

0.44

0

Series 3 warrants | Expected life

Warrants

Term of warrant

5 years 6 months

4 years 10 months 21 days

Series 3 warrants | Volatility

Warrants

Warrants - Measurement input

141

142

Series 3 warrants | Risk free rate

Warrants

Warrants - Measurement input

0.34

0.36

Underwriter Warrants

Warrants

Warrants to purchase (in shares)

100,780

17,142

Exercise price (in dollars per share) | $ / shares

$ 2.50

$ 52.50

Warrant liability | $

$ 32,000

Underwriter Warrants | Stock price

Warrants

Warrants - Measurement input | $ / shares

1.80

0.82

2.50

Underwriter Warrants | Strike price

Warrants

Warrants - Measurement input | $ / shares

52.50

52.50

0.45

Underwriter Warrants | Expected life

Warrants

Term of warrant

2 years 6 months

2 years 9 months 4 days

4 years 3 months

Underwriter Warrants | Volatility

Warrants

Warrants - Measurement input

169

156

141

Underwriter Warrants | Risk free rate

Warrants

Warrants - Measurement input

0.35

0.17

0.29

March 2019 LOC Warrants

Warrants

Warrants exercisable

45,750

Fair value of warrants | $

$ 71,000

2019 Bridge Note Warrants

Warrants

Warrants exercised

406,250

Warrants outstanding

571,875

1,903,125

2019 Bridge Note Warrants | Stock price

Warrants

Warrant liability | $

$ 1.73

2019 Bridge Note Warrants | Strike price

Warrants

Warrants - Measurement input | $ / shares

2

2019 Bridge Note Warrants | Expected life

Warrants

Term of warrant

4 years 9 months 18 days

2019 Bridge Note Warrants | Volatility

Warrants

Warrants - Measurement input

145.84

2019 Bridge Note Warrants | Risk free rate

Warrants

Warrants - Measurement input

1.76

Securities Purchase Agreement | March 2019 Ladenburg Warrants

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Shares issued (in shares)

19,019

Warrants

Warrants to purchase (in shares)

761

Exercise price (in dollars per share) | $ / shares

$ 17.50

Warrants - Measurement input | $ / shares

17.50

Warrant liability | $

$ 13,000

Securities Purchase Agreement | March 2019 Ladenburg Warrants | Strike price

Warrants

Warrants - Measurement input | $ / shares

18.90

Securities Purchase Agreement | March 2019 Ladenburg Warrants | Expected life

Warrants

Term of warrant

5 years

Securities Purchase Agreement | March 2019 Ladenburg Warrants | Volatility

Warrants

Warrants - Measurement input

146

Securities Purchase Agreement | March 2019 Ladenburg Warrants | Risk free rate

Warrants

Warrants - Measurement input

2.21

Warrants - 2019 Bridge Note War

Warrants - 2019 Bridge Note Warrants (Details)	Jan. 08, 2021shares	Mar. 23, 2020USD ($)$ / sharesshares	Mar. 05, 2020USD ($)$ / sharesshares	Jul. 23, 2019USD ($)$ / sharesshares	Jun. 26, 2019USD ($)	Mar. 18, 2019USD ($)	Jan. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)$ / sharesshares	May 31, 2020USD ($)$ / sharesshares	Mar. 31, 2020USD ($)$ / shares	Feb. 29, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Jul. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2021USD ($)shares	Mar. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Jul. 21, 2020shares	Apr. 30, 2020$ / shares	Mar. 22, 2020$ / shares	Mar. 04, 2020$ / shares	Jan. 31, 2020$ / shares	Dec. 31, 2019shares	Aug. 31, 2019$ / shares	May 31, 2019USD ($)
Debt
Debt Instrument, Face Amount | $						$ 5,100,000				$ 350,000					$ 350,000
Number Of Promissory Notes Issued | $					21	21
Fair value of warrants | $				$ 4,300,000				$ 179,000						$ 12,000		$ 179,000
Warrants exercisable				2,781,250							208,022
Loss on extinguishment of debt | $							$ (753,000)							$ 753,000
Warrants outstanding								7,205,454						1,590,354		7,205,454						19,421,892
Number of shares issued for preferred stock converted													500
Aggregate purchase price of warrants | $								$ 179,000						$ 12,000		$ 179,000
Proceeds from issuance of warrants | $		$ 653,000
Class of Warrant or Right, Number of Securities Exercisable				2,781,250							208,022
Series B convertible preferred stock
Debt
Units issued													10,787
Class A units | Underwritten Public Offering
Debt
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right													1
Units issued													2,886,500
Unit Price | $ / shares													$ 2
Number of warrants converted for each share													1
Class B units
Debt
Units issued													10,787
Issuance costs | $													$ 1,600,000			$ 1,600,000
Class B units | Underwritten Public Offering
Debt
Units issued													10,787
Unit Price | $ / shares													$ 1,000
Class B units | Underwritten Public Offering | Series B convertible preferred stock
Debt
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				500
Number of shares in exchange for each unit													1
Number of warrants converted for each share				500
2019 Bridge Note Warrants
Debt
Warrants outstanding								1,903,125						571,875		1,903,125
Warrants exercised	406,250
2019 Bridge Note Warrants | Stock price
Debt
Aggregate purchase price of warrants | $				$ 1.73
2019 Bridge Note Warrants | Strike price
Debt
Warrant liability | $ / shares				2
2019 Bridge Note Warrants | Expected life
Debt
Term of warrant				4 years 9 months 18 days
2019 Bridge Note Warrants | Volatility
Debt
Warrant liability				145.84
2019 Bridge Note Warrants | Risk free rate
Debt
Warrant liability				1.76
Series 1 warrants
Debt
Warrants exercisable											208,022
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right														1,392,175
Warrants issued												8,280,000			8,280,000
Issuance of warrants | $													$ 5
Impact of modification | $												$ 522,000
Warrant Exercise Inducement Offer, Warrants To Purchase Common Stock Issued									4,572,040
Warrants outstanding								1,078,365						436,190		1,078,365
Impact of modification previously reported | $															$ 6,000
Number of warrants converted for each share														1,392,175
Term of warrant													5 years
Exercise price (in dollars per share) | $ / shares		$ 0.5227								$ 2	$ 0.6920	$ 1.40	$ 2		$ 2						$ 2		$ 2
Proceeds from issuance of warrants | $											$ 144,000			$ 682,000
Class of Warrant or Right, Number of Securities Exercisable											208,022
Debt Conversion, Converted Instrument, Shares Issued											208,022
Series 1 warrants | Stock price
Debt
Warrant liability | $ / shares													1.73
Series 1 warrants | Strike price
Debt
Warrant liability | $ / shares													2
Series 1 warrants | Expected life
Debt
Warrant liability													5
Series 1 warrants | Volatility
Debt
Warrant liability													109.25
Series 1 warrants | Risk free rate
Debt
Warrant liability													1.83
Series 1 warrants | Class A units
Debt
Common stock issued and issuable													2,886,500
Warrants issued													2,886,500
Series 1 warrants | Class A units | Underwritten Public Offering
Debt
Number of shares in exchange for each unit													1
Series 1 warrants | Class B units
Debt
Units issued													10,787
Common stock issued and issuable													5,393,500
Series 1 warrants | Class B units | Underwritten Public Offering
Debt
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right													500
Number of shares in exchange for each unit													500
Number of shares issued for preferred stock converted													500
Number of warrants converted for each share													500
Series 2 warrants
Debt
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right														1,427,175
Warrants issued													8,280,000
Issuance of warrants | $													$ 5,000,000
Impact of modification | $		$ 65,000
Impact of modification previously reported | $														$ 6,000
Number of warrants converted for each share														1,427,175
Term of warrant													5 years
Exercise price (in dollars per share) | $ / shares		$ 0.5227	$ 0.6050										$ 2						$ 2	$ 2
Proceeds from issuance of warrants | $			$ 55,000											$ 700,000
Net proceeds from issuance of warrants | $		$ 628,000
Issuance costs | $		$ 25,000
Debt Conversion, Converted Instrument, Shares Issued		90,940	90,940
Fair Value Adjustment of Warrants | $		$ 65,000
Warrants exercised		1,250,000	90,940											8,280,000
Series 2 warrants | Exercise Agreement
Debt
Exercise price (in dollars per share) | $ / shares										$ 2					$ 2
Proceeds from issuance of warrants | $										$ 653,000
Series 2 warrants | Stock price
Debt
Warrant liability | $ / shares													1.73
Series 2 warrants | Strike price
Debt
Warrant liability | $ / shares													2
Series 2 warrants | Expected life
Debt
Warrant liability | $													5
Series 2 warrants | Risk free rate
Debt
Warrant liability													1.83
Series 2 warrants | Underwritten Public Offering
Debt
Number of shares in exchange for each unit													1
Series 2 warrants | Class A units
Debt
Units issued													2,886,500
Common stock issued and issuable													2,886,500
Series 2 warrants | Class B units
Debt
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right													500
Units issued													10,787
Common stock issued and issuable													5,393,500
Number of warrants converted for each share													500
Series 2 warrants | Class B units | Underwritten Public Offering
Debt
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right													500
Number of shares in exchange for each unit													500
Number of shares issued for preferred stock converted													500
Number of warrants converted for each share													500
Series 3 warrants
Debt
Warrant Exercise Inducement Offer, Warrants To Purchase Common Stock Exchanged	406,250								4,005,062
Warrants outstanding								214,500						0		214,500
Term of warrant									5 years
Exercise price (in dollars per share) | $ / shares									$ 0.53
Aggregate purchase price of warrants | $									$ 3,700,000
Warrants exercised														620,750			8,456,352
Series 3 warrants | Stock price
Debt
Warrant liability | $ / shares								0.82	0.05							0.82
Series 3 warrants | Strike price
Debt
Warrant liability | $ / shares								0	0.44							0
Series 3 warrants | Expected life
Debt
Term of warrant								4 years 10 months 21 days	5 years 6 months							4 years 10 months 21 days
Series 3 warrants | Volatility
Debt
Warrant liability								142	141							142
Series 3 warrants | Risk free rate
Debt
Warrant liability								0.36	0.34							0.36
Modification of Certain 2019 Bridge Note Warrants [Member]
Debt
Impact of modification previously reported | $											$ 7,000
Exercise price (in dollars per share) | $ / shares											$ 0.692										$ 2
Proceeds from issuance of warrants | $											$ 173,000
Debt Conversion, Converted Instrument, Shares Issued											250,000
Warrants exercised											250,000
Modification of the 2019 Bridge Note Warrants and Inducement Offer
Debt
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right														1,331,250
Warrant Exercise Inducement Offer, Warrants To Purchase Common Stock Exchanged									93,750
Warrant Exercise Inducement Offer, Warrants To Purchase Common Stock Issued									93,750
Number of warrants converted for each share														1,331,250
Exercise price (in dollars per share) | $ / shares									$ 0.49									$ 2
Proceeds from issuance of warrants | $														$ 652,000
Fair Value Adjustment of Warrants | $									$ 166,000
May 2020 Modification of the July 2019 Series 1 Warrants and Inducement Offer
Debt
Warrant Exercise Inducement Offer, Warrants To Purchase Common Stock Exchanged									4,572,040
Exercise price (in dollars per share) | $ / shares									$ 0.49									1.40
Fair Value Adjustment of Warrants | $									$ 284,000
May 2020 Modification of the July 2019 Series 2 Warrants and Inducement Offer
Debt
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								878,365						401,190		878,365
Impact of modification | $									$ 406,000
Warrant Exercise Inducement Offer, Warrants To Purchase Common Stock Exchanged									4,033,562
Number of warrants converted for each share								878,365						401,190		878,365
Exercise price (in dollars per share) | $ / shares									$ 0.49									$ 2
2019 Exchange Note 2
Debt
Debt Instrument, Face Amount | $							$ 1,800,000	$ 1,000,000								$ 1,000,000								$ 2,300,000
Debt Conversion, Converted Instrument, Shares Issued							1,413,606	1,250,000

Warrants - PIPE Financing Warra

Warrants - PIPE Financing Warrants (Details)

Mar. 23, 2020USD ($)$ / shares

Mar. 05, 2020USD ($)$ / shares

Mar. 31, 2020USD ($)$ / shares

Dec. 31, 2019USD ($)$ / sharesshares

Jul. 31, 2019USD ($)$ / shares

Mar. 31, 2021USD ($)

Dec. 31, 2020USD ($)item

Dec. 31, 2019USD ($)$ / sharesshares

Jan. 31, 2021USD ($)

Mar. 22, 2020$ / shares

Mar. 04, 2020$ / shares

Aug. 28, 2018shares

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrants to purchase (in shares) | shares

9,580

Aggregate purchase price of warrants

$ 12,000

$ 179,000

Proceeds from issuance of warrants

$ 653,000

PIPE Financing Warrants, Dec 2019

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Exercise price (in dollars per share) | $ / shares

$ 0.78

$ 0.78

Warrant exercisable period after, issuance date

6 months

Term of warrant

5 years

5 years

Proceeds from issuance of warrants

$ 1,500,000

Number of securities | item

2

Issuance of common stock

$ 1,000,000

Issuance of warrants

$ 686,000

$ 465,000

PIPE Financing Warrants, Dec 2019 | Exercise Agreement

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Aggregate purchase price of warrants

$ 1,250,000

Proceeds from issuance of warrants

$ 975,000

PIPE Financing Warrants, Dec 2019 | Maximum

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrants to purchase (in shares) | shares

1,250,000

1,250,000

Aggregate purchase price of warrants

$ 1,500,000

$ 1,500,000

Series 2 warrants

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Exercise price (in dollars per share) | $ / shares

$ 0.5227

$ 0.6050

$ 2

$ 2

$ 2

Term of warrant

5 years

Proceeds from issuance of warrants

$ 55,000

$ 700,000

Issuance of warrants

$ 5,000,000

Series 2 warrants | Exercise Agreement

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Exercise price (in dollars per share) | $ / shares

$ 2

Proceeds from issuance of warrants

$ 653,000

Private placement | PIPE Financing Warrants, Dec 2019

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Unregistered shares issued | shares

2,500,000

Stock price | PIPE Financing Warrants, Dec 2019

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrant liability | $ / shares

0.62

0.62

Stock price | Series 2 warrants

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrant liability | $ / shares

1.73

Strike price | PIPE Financing Warrants, Dec 2019

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrant liability | $ / shares

0.78

0.78

Strike price | Series 2 warrants

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrant liability | $ / shares

2

Expected life | PIPE Financing Warrants, Dec 2019

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrant liability

5

5

Expected life | Series 2 warrants

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrant liability

5

Volatility | PIPE Financing Warrants, Dec 2019

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrant liability

143

143

Risk free rate | PIPE Financing Warrants, Dec 2019

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrant liability

2.42

2.42

Risk free rate | Series 2 warrants

Convertible Promissory Notes and Common Stock Warrants [Line Items]

Warrant liability

1.83

Preferred Stock (Details)

Preferred Stock (Details) - $ / shares	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2018
Class of Stock [Line Items]
Shares Authorized	1,021,165
Series A
Class of Stock [Line Items]
Shares Authorized				5,524,926
Outstanding			5,524,926
Series B convertible preferred stock
Class of Stock [Line Items]
Shares Authorized		0
Outstanding		0
Series B-2 convertible preferred stock
Class of Stock [Line Items]
Shares Authorized	10,165
Outstanding	0	0
Series C perpetual preferred stock
Class of Stock [Line Items]
Shares Authorized	1,011,000	1,011,000
Issued	0	0
Outstanding	0	0
Liquidation Preference per Share	$ 8	$ 8

Preferred Stock - Series A Rede

Preferred Stock - Series A Redeemable Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Sep. 30, 2020	Mar. 31, 2018	Mar. 31, 2021	Dec. 31, 2020	Oct. 31, 2020	Jul. 31, 2019
Number of shares issued for each convertible preferred stock						500
Carrying amount in excess of fair value amount				$ 2.5
Series C perpetual preferred stock
Shares issued (in shares)	842,500
Series D perpetual preferred stock
Shares issued (in shares)	842,500
Convertible preferred stock, shares outstanding			0	0
Series A
Convertible preferred stock, shares outstanding				0
Sagard Capital Partners, L.P. | Series A convertible participating preferred stock
Number of shares issued for each convertible preferred stock		473,565
Effective conversion price		$ 194.25
Maximum period from date of issuance		1 year
Iliad | Series C perpetual preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001			$ 0.0001
Gross proceeds from the issuance of common stock	$ 2.3
Number of shares issued for each convertible preferred stock	842,500
Second Amendment to Note Purchase Agreement and Notes | Sagard Capital Partners, L.P. | Series A convertible participating preferred stock | Private placement
Gross proceeds from the issuance of common stock		$ 9.2
Amount of shares issued		$ 9

Preferred Stock - Series B and

Preferred Stock - Series B and B-1 Convertible Preferred Stock (Details)	Mar. 23, 2020USD ($)$ / shares	Mar. 05, 2020USD ($)$ / shares	Dec. 31, 2020USD ($)shares	Oct. 31, 2020shares	Mar. 31, 2020USD ($)$ / sharesshares	Feb. 29, 2020USD ($)$ / shares	Jan. 31, 2020$ / sharesshares	Dec. 31, 2019$ / shares	Jul. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2021USD ($)shares	Mar. 31, 2020USD ($)$ / shares	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)$ / sharesshares	Mar. 22, 2020$ / shares	Mar. 04, 2020$ / shares	Sep. 30, 2019$ / shares	Aug. 31, 2019$ / shares	Jul. 23, 2019shares	Aug. 28, 2018shares
Number of shares issued for each convertible preferred stock									500
Value of shares issued on conversion | $													$ 153.90
Warrants and Rights Outstanding | $			$ 179,000							$ 12,000		$ 179,000
Proceeds from Issuance of Warrants | $	$ 653,000
Series B convertible preferred stock inducement expense | $											$ 1,647,000
Number of securities issued on conversion																			9,580
Series B convertible preferred stock
Units issued									10,787
Stated or par value | $ / shares									$ 1,000
Beneficial Conversion Feature | $									$ 4,200,000
Deemed dividend | $									4,200,000
Shares converted													8,816
Preferred stock, shares outstanding			0									0
Series B-2 convertible preferred stock
Shares converted			6,559	975			2,631
Value of shares issued on conversion | $													$ 153.90
Conversion Price (in dollars per share) | $ / shares								$ 0.81					$ 0.81
Conversion ratio								190					190
Shares issued on conversion			1,246,210	500,186			499,890
Preferred stock, shares outstanding			0							0		0
Common Stock | Series B convertible preferred stock
Shares issued on conversion													4,408,000
Series 1 warrants
Number of warrants converted for each share										1,392,175
Gross proceeds | $									$ 3,300,000
Exercise price (in dollars per share) | $ / shares	$ 0.5227				$ 2	$ 0.6920	$ 2		$ 2		$ 2					$ 1.40	$ 2
Proceeds from Issuance of Warrants | $						$ 144,000				$ 682,000
Warrant exercise agreement					1,250,000
Series 2 warrants
Number of warrants converted for each share										1,427,175
Gross proceeds | $									$ 3,300,000
Issuance costs | $	$ 25,000
Exercise price (in dollars per share) | $ / shares	$ 0.5227	$ 0.6050							$ 2					$ 2	$ 2
Proceeds from Issuance of Warrants | $		$ 55,000								$ 700,000
Class A units | Series 1 warrants
Common stock issued and issuable									2,886,500
Class A units | Series 2 warrants
Units issued									2,886,500
Common stock issued and issuable									2,886,500
Class B units
Units issued									10,787
Stated or par value | $ / shares									$ 1,000
Gross proceeds | $									$ 10,800,000
Issuance costs | $									$ 1,600,000			$ 1,600,000
Class B units | Series 1 warrants
Units issued									10,787
Common stock issued and issuable									5,393,500
Class B units | Series 2 warrants
Units issued									10,787
Number of warrants converted for each share									500
Common stock issued and issuable									5,393,500
Underwritten Public Offering | Series 2 warrants
Number of shares in exchange for each unit									1
Underwritten Public Offering | Class A units
Units issued									2,886,500
Public offering price | $ / shares									$ 2
Number of warrants converted for each share									1
Underwritten Public Offering | Class A units | Series 1 warrants
Number of shares in exchange for each unit									1
Underwritten Public Offering | Class B units
Units issued									10,787
Public offering price | $ / shares									$ 1,000
Underwritten Public Offering | Class B units | Series B convertible preferred stock
Number of shares in exchange for each unit									1
Number of warrants converted for each share																		500
Underwritten Public Offering | Class B units | Series 1 warrants
Number of shares in exchange for each unit									500
Number of warrants converted for each share									500
Number of shares issued for each convertible preferred stock									500
Underwritten Public Offering | Class B units | Series 2 warrants
Number of shares in exchange for each unit									500
Number of warrants converted for each share									500
Number of shares issued for each convertible preferred stock									500
Exercise Agreement | Series 2 warrants
Exercise price (in dollars per share) | $ / shares					$ 2						2
Proceeds from Issuance of Warrants | $					$ 653,000
Exercise Agreement | Series 2 warrants | Series B-2 convertible preferred stock
Exercise price (in dollars per share) | $ / shares					$ 0.4456						$ 0.4456

Preferred Stock - Series B-2 Co

Preferred Stock - Series B-2 Convertible Preferred Stock (Details)	1 Months Ended				12 Months Ended
	Dec. 31, 2020shares	Oct. 31, 2020shares	Jan. 31, 2020shares	Dec. 31, 2019$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2021shares
Value of shares issued on conversion | $					$ 153.90
Series B-2 convertible preferred stock
Number of shares for which unexercised prepaid forward contracts are exercisable				1,236,223
Shares issued in exchange of convertible preferred stock				695,127
Shares Authorized	10,165			10,165	10,165	10,165
Conversion ratio				190	190
Value of shares issued on conversion | $					$ 153.90
Conversion Price (in dollars per share) | $ / shares				$ 0.81	$ 0.81
Shares converted	6,559	975	2,631
Shares issued on conversion	1,246,210	500,186	499,890
Preferred stock, shares outstanding	0					0

Preferred Stock - Series C Conv

Preferred Stock - Series C Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
	Oct. 31, 2020	Sep. 30, 2020	Mar. 31, 2021	Dec. 31, 2020	Jul. 31, 2019	Aug. 28, 2018	Mar. 31, 2018
Number of shares issued for each convertible preferred stock					500
Number of securities issued on conversion						9,580
Carrying amount in excess of fair value amount				$ 2,500
Warrants and Rights Outstanding			$ 12	$ 179
Series A
Preferred stock, shares outstanding		5,524,926
Series C perpetual preferred stock
Preferred stock, shares outstanding			0	0
Carrying value
Percentage of cumulative stock dividends eligible to receive			10.00%
Number of consecutive months			24 months
Fair value of preferred stock			$ 4,700
Iliad | Series C perpetual preferred stock
Number of shares issued for each convertible preferred stock		842,500
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001					$ 0.0001
Accreted value		$ 11,200
Gross proceeds from the issuance of common stock		2,300
Carrying value		$ 2,600
Percentage increase in the outstanding balance		5.00%
Exchange Agreement with Iliad
Shares issued on conversion	250,000			8,203,880
Exchange Agreement with Iliad | Series C perpetual preferred stock
Shares converted	285,000			573,810
Pre-funded Warrants | Exchange Agreement with Iliad
Number of securities issued on conversion	7,057,692
Pre-funded Warrants | Exchange Agreement with Iliad | Series C perpetual preferred stock
Warrants and Rights Outstanding				$ 1

Stockholders' Equity (Details)

Stockholders' Equity (Details)	Dec. 22, 2020	Mar. 31, 2021Voteshares	Dec. 31, 2020shares
Stockholders' Equity
Number of voting rights entitled for each share of common stock held | Vote		1
Shares of common stock reserved for issuance
Options issued and outstanding		4,449,398	4,456,748
Options available for grant under stock option plans		6,355,104	596,597
RSUs awards issued and outstanding		5,613	5,613
Warrants issued and outstanding		1,590,354	7,205,454
Total		12,571,361	12,379,304
Minimum
Stockholders' Equity
Reverse stock split ratio	0.5
Maximum
Stockholders' Equity
Reverse stock split ratio	0.05
Inducement options issued and outstanding
Shares of common stock reserved for issuance
Options issued and outstanding		170,892	114,892
Blank check preferred stock
Stockholders' Equity
Common stock, shares authorized		4,475,074
Common Stock
Stockholders' Equity
Common stock, shares authorized		204,475,074
Common Stock | Common stock - voting
Stockholders' Equity
Common stock, shares authorized		150,000,000	150,000,000
Common Stock | Common stock - non-voting
Stockholders' Equity
Common stock, shares authorized		50,000,000	50,000,000
Convertible non-voting common stock
Stockholders' Equity
Reverse stock split ratio		1

Stockholders' Equity - Transact

Stockholders' Equity - Transactions with Oasis Capital and Underwritten Public Offering (Details)	Jan. 13, 2021USD ($)$ / sharesshares	Oct. 06, 2020USD ($)$ / sharesshares	Oct. 05, 2020USD ($)shares	Mar. 23, 2020USD ($)$ / shares	Mar. 05, 2020USD ($)$ / shares	Apr. 30, 2020USD ($)shares	Mar. 31, 2020USD ($)D$ / sharesshares	Feb. 29, 2020USD ($)$ / shares	Feb. 28, 2021USD ($)shares	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)$ / sharesshares	May 15, 2021shares	Dec. 31, 2020USD ($)	Apr. 15, 2020USD ($)	Mar. 24, 2020USD ($)	Mar. 22, 2020$ / shares	Mar. 04, 2020$ / shares	Jan. 31, 2020$ / shares	Dec. 31, 2019USD ($)	Sep. 30, 2019$ / shares	Aug. 31, 2019$ / shares	Jul. 31, 2019$ / shares	Aug. 28, 2018shares
Stockholders’ equity							$ 6,233,000			$ 31,891,000	$ 6,233,000		$ 17,202,000						$ 10,673,000
Number of securities issued on conversion | shares																							9,580
Common stock, shares issued | shares												9,411,705
Proceeds from issuance of warrants				$ 653,000
PoC Capital, LLC
Issuance of common stock (In shares) | shares		1,333,333
Share Price | $ / shares		$ 0.30
Common stock par value (in dollars per share) | $ / shares		$ 0.0001
At The Market Offering
Issuance of common stock (In shares) | shares			3,814,925						2,009,554
Amount of shares issued										5,365,000
Issuance costs			$ 40,000						$ 311,000	311,000	52,000
Sale of worth of shares			$ 1,300,000						$ 5,400,000
Series B convertible preferred stock
Stockholders’ equity							$ 476,000				$ 476,000								$ 476,000
Series 1 warrants
Exercise price (in dollars per share) | $ / shares				$ 0.5227			$ 2	$ 0.6920			$ 2							$ 2		$ 1.40	$ 2	$ 2
Proceeds from issuance of warrants								$ 144,000		682,000
Series 2 warrants
Exercise price (in dollars per share) | $ / shares				$ 0.5227	$ 0.6050											$ 2	$ 2					$ 2
Proceeds from issuance of warrants					$ 55,000					$ 700,000
Net proceeds from issuance of warrants				$ 628,000
Issuance costs				$ 25,000
PIPE Financing Warrants, March 2020 | Private placement
Issuance of common stock (In shares) | shares											1,714,283
Proceeds from issuance of warrants											$ 720,000
Net proceeds from issuance of warrants											668,000
Securities Purchase Agreement | Registered Direct Offering
Issuance of common stock (In shares) | shares	4,437,870
Share Price | $ / shares	$ 3.38
Net proceeds	$ 1,600,000
Proceeds from issuance of warrants	$ 15,000,000
Common stock par value (in dollars per share) | $ / shares	$ 0.0001
Equity Line of Credit
Gross proceeds from issuance						$ 22,627
Issuance of common stock (In shares) | shares						52,000
Amount of shares issued							$ 200,000
Term of equity purchase agreement							36 months
Shares issued in settlement of commitment fee | shares						68,807
Fair value of equity issued						$ 33,027
Equity Line of Credit | Maximum
Aggregate amount of put option on any put date or clearing date							$ 500,000				500,000
Aggregate amount of equity purchase agreement							$ 2,000,000				$ 2,000,000
Napo | PoC Capital, LLC
Amount of shares issued		$ 400,000
Option 1 Put | Equity Line of Credit
Issuance of common stock (In shares) | shares							200,000
Percentage of average trading volume							20.00%
Trading days | D							10
Share Price | $ / shares							$ 0.436				$ 0.436
Option 2 Puts | Equity Line of Credit
Percentage of average trading volume							10.00%
Share Price | $ / shares							$ 0.436				$ 0.436
Option 1 and Option 2 Puts | Equity Line of Credit
Stockholders’ equity														$ 0
Derivative Asset, Noncurrent															$ 0

Stock Based Compensation - Summ

Stock Based Compensation - Summary of Stock Incentive Plans (Details) - USD ($)	Jun. 16, 2020	May 12, 2015	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Mar. 31, 2021	Dec. 31, 2020
Stock Based Compensation
Option outstanding			4,449,398		4,456,748	4,449,398	4,456,748
Options available for grant under stock option plans			6,355,104		596,597	6,355,104	596,597
Shares Available for Grant
Beginning balance (in shares)			596,597
Ending balance (in shares)			6,355,104		596,597
Stock Options Outstanding
Beginning balance (in shares)			4,456,748
Options exercised (in shares)			0		0
Ending balance (in shares)			4,449,398		4,456,748
RSUs Outstanding
Beginning balance (in shares)			5,613
Ending balance (in shares)			5,613		5,613
Weighted Average Stock Option Exercise Price
Beginning balance (in dollars per share)			$ 4.23
Options granted (in dollars per share)			1.92
Options cancelled (in dollars per share)			10.68
Ending balance (in dollars per share)			$ 4.16		$ 4.23
Options vested, exercisable and expected to vest
Options exercised (in shares)			0		0
Weighted average grant date fair value of stock options granted (in dollars per share)			$ 1.76	$ 0.41
Number of options vested (in shares)			383,419	333,926
Weighted average fair value of options vested on grant date			$ 1.65	$ 2.38
Common Stock, Capital Shares Reserved for Future Issuance						12,571,361	12,379,304
Inducement options issued and outstanding
Stock Based Compensation
Option outstanding			170,892		114,892	170,892	114,892
Stock Options Outstanding
Beginning balance (in shares)			114,892
Ending balance (in shares)			170,892		114,892
Stock options and RSUs
Stock Based Compensation
Option outstanding			4,620,216		4,571,566	4,620,216	4,571,566
Options available for grant under stock option plans			6,355,104		596,597	6,355,104	596,597
Shares Available for Grant
Beginning balance (in shares)			596,597
Additional shares authorized (in shares)			5,807,157
Options granted (in shares)			(70,000)
Options cancelled (in shares)			21,350
Ending balance (in shares)			6,355,104		596,597
Stock Options Outstanding
Beginning balance (in shares)			4,571,566
Options granted (in shares)			70,000
Options cancelled (in shares)			(21,350)
Ending balance (in shares)			4,620,216		4,571,566
RSUs Outstanding
Beginning balance (in shares)			5,613
Ending balance (in shares)			5,613		5,613
Weighted Average Remaining Contractual Life (Years)
Weighted Average Remaining Contractual Life (Years)			8 years 6 months 4 days		8 years 8 months 16 days
Options vested, exercisable and expected to vest
Options vested and exercisable (in shares)						2,623,013
Options vested and exercisable (in dollars per share)						$ 6.35
Options vested and exercisable (in years)			8 years 4 months 21 days
Options vested and expected to vest (in shares)						4,400,382
Options vested and expected to vest (in dollars per share)						$ 4.31
Options vested and expected to vest (in years)			8 years 5 months 27 days
Aggregate Intrinsic Value ,outstanding						$ 1,808,000	$ 364,000
Aggregate Intrinsic Value, Exercisable						686,000
Aggregate Intrinsic Value, Vested and expected to vest						$ 1,655,000
2013 Plan
Stock Based Compensation
Option shares outstanding						384	384
2013 Plan | Stock options
Stock Options Outstanding
Options granted (in shares)			0
2014 Plan
Stock Based Compensation
Incentive stock option term		P10Y
2014 Plan | Stock options
Stock Based Compensation
Increase in share reserve based on outstanding number of shares (as a percent)		2.00%
2014 Plan
Stock Based Compensation
Option outstanding			4,449,014		4,456,364	4,449,014	4,456,364
Options available for grant under stock option plans			6,025,922		211,415	6,025,922	211,415
Shares Available for Grant
Beginning balance (in shares)			211,415
Ending balance (in shares)			6,025,922		211,415
Stock Options Outstanding
Beginning balance (in shares)			4,456,364
Ending balance (in shares)			4,449,014		4,456,364
2020 New Employee Inducement Award Plan
Stock Based Compensation
Incentive stock option term	P10Y
Option outstanding			170,818			170,818
Options available for grant under stock option plans	500,000		329,182			329,182
Shares Available for Grant
Ending balance (in shares)	500,000		329,182
Stock Options Outstanding
Ending balance (in shares)			170,818
Common Stock
Options vested, exercisable and expected to vest
Share Price						$ 1.80
Participants Voting Power More than Ten Percent | 2014 Plan
Stock Based Compensation
Incentive stock option term		P5Y
Participants Voting Power More than Ten Percent | 2020 New Employee Inducement Award Plan
Stock Based Compensation
Incentive stock option term	P5Y

Stock Based Compensation - Stoc

Stock Based Compensation - Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock Based Compensation
Total stock-based compensation expense	$ 634	$ 760
Estimated grant-date fair value of stock options calculated using the Black-Scholes option-pricing model
Expected term (years)	5 years	5 years
Research and development expense
Stock Based Compensation
Total stock-based compensation expense	$ 164	$ 202
Sales and marketing expense
Stock Based Compensation
Total stock-based compensation expense	52	56
General and administrative expense
Stock Based Compensation
Total stock-based compensation expense	418	$ 502
Stock options and RSUs
Stock Based Compensation
Unrecognized stock-based compensation expense	$ 2,200
Expected weighted average period to be recognized	1 year 1 month 17 days
Employee stock options
Estimated grant-date fair value of stock options calculated using the Black-Scholes option-pricing model
Volatility (as a percent)		150.10%
Risk-free interest rate (as a percent)		0.50%
Minimum | Employee stock options
Estimated grant-date fair value of stock options calculated using the Black-Scholes option-pricing model
Volatility (as a percent)	163.80%
Risk-free interest rate (as a percent)	0.50%
Maximum | Employee stock options
Estimated grant-date fair value of stock options calculated using the Black-Scholes option-pricing model
Volatility (as a percent)	164.00%
Risk-free interest rate (as a percent)	0.90%

Stock Based Compensation - 401(

Stock Based Compensation - 401(k) Plan (Details)	3 Months Ended
	Mar. 31, 2021USD ($)
Stock Based Compensation
Employer contributions to the plan	$ 0

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Calculation of basic and diluted net loss per common share
Net loss attributable to common shareholders (basic and diluted)	$ (12,009)	$ (8,416)
Shares used to compute net loss per common share, basic and diluted	125,416,228	15,141,906
Net loss per share attributable to common stockholders, basic and diluted	$ (0.10)	$ (0.56)

Net Loss Per Share - Excluded F

Net Loss Per Share - Excluded From Calculation (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	May 15, 2021
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)	6,216,257	28,464,913
Common stock, shares issued			9,411,705
Options issued and outstanding
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)	4,449,398	4,508,021
Inducement options issued and outstanding
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)	170,892	74
Restricted stock units issued and outstanding
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)	5,613	5,613
Warrants issued and outstanding
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)	1,590,354	17,622,930
Series A convertible preferred stock
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)		473,565
Series B convertible preferred stock
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)		4,423,250
Series B-2 convertible preferred stock
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)		1,431,460

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)segment	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)
Segment Information
Number of reportable segments | segment	2
Segment net loss	$ (12,009)	$ (7,936)
Segment assets	68,713		$ 42,843
Less: investment in subsidiary	(29,241)		(29,241)
Less: Intercompany loan	(49,162)		(41,877)
Human Health
Segment Information
Segment net loss	(3,941)	(3,200)
Segment assets	37,064		34,201
Animal Health
Segment Information
Segment net loss	(8,068)	(4,736)
Segment assets	110,052		79,760
Product revenue
Segment Information
Revenue from external customers	1,241	869
Product revenue | Human Health
Segment Information
Revenue from external customers	1,208	835
Product revenue | Animal Health
Segment Information
Revenue from external customers	33	$ 34
Operating Segments
Segment Information
Segment assets	$ 147,116		$ 113,961

Subsequent Events (Details)

Subsequent Events (Details)

Apr. 29, 2021USD ($)$ / sharesshares

Apr. 13, 2021USD ($)shares

Apr. 07, 2021$ / sharesshares

Apr. 06, 2021USD ($)ft²$ / shares

Oct. 05, 2020USD ($)shares

Jul. 23, 2019shares

Aug. 28, 2018USD ($)ft²

Apr. 30, 2020USD ($)shares

Feb. 29, 2020shares

Feb. 28, 2021USD ($)shares

Mar. 31, 2021USD ($)

Mar. 31, 2020USD ($)

Aug. 31, 2020ft²

May 31, 2020$ / shares

Dec. 31, 2019$ / shares

Subsequent Events.

Monthly base rent for first twelve months

$ 38,000

Monthly base rent for subsequent twelve months

40,000

Monthly base rent for final months

$ 41,000

Warrants exercisable | shares

2,781,250

208,022

Equity Line of Credit

Purchase Agreements

Shares issued (in shares) | shares

52,000

Proceeds from Issuance of Common Stock

$ 22,627

Series 3 warrants

Subsequent Events.

Exercise price (in dollars per share) | $ / shares

$ 0.53

PIPE Financing Warrants, Dec 2019

Subsequent Events.

Exercise price (in dollars per share) | $ / shares

$ 0.78

At The Market Offering

Purchase Agreements

Shares issued (in shares) | shares

3,814,925

2,009,554

Payments of Stock Issuance Costs

$ 40,000

$ 311,000

$ 311,000

$ 52,000

Office lease extension agreement

Subsequent Events.

Area (in square feet) | ft²

6,311

Office space sub lease

Subsequent Events.

Area (in square feet) | ft²

5,263

Subsequent event

Subsequent Events.

Monthly base rent for first twelve months

$ 42,000

Monthly base rent for next twelve months

43,000

Monthly base rent for final months

$ 45,000

Subsequent event | Securities Purchase Agreement

Subsequent Events.

Strike price (in dollars per share) | $ / shares

$ 1.41

Purchase Agreements

Shares issued (in shares) | shares

7,647,000

Common stock par value (in dollars per share) | $ / shares

$ 0.0001

Share issue price (in dollars per share) | $ / shares

$ 1.41

Proceeds from Issuance of Common Stock

$ 10,800,000

Payments of Stock Issuance Costs

$ 995,000

Subsequent event | Equity Line of Credit

Subsequent Events.

Strike price (in dollars per share) | $ / shares

$ 3

$ 0.436

Threshold Price | $ / shares

$ 3.45

0.5014

Warrants exercisable | shares

100,000

Exercise price (in dollars per share) | $ / shares

$ 1.87

Purchase Agreements

Share issue price (in dollars per share) | $ / shares

$ 3

$ 0.436

Subsequent event | Iliad

Royalty Transaction

Repayment of royalty

$ 3,000,000

Consideration for royalty

$ 0

Purchase Agreements

Shares issued (in shares) | shares

1,764,705

Subsequent event | Office space sub lease

Subsequent Events.

Area (in square feet) | ft²

10,526